BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-14. [PMID: 16702586 DOI: 10.7326/0003-4819-144-10-200605160-00004] [Cited by in Crossref: 1443] [Cited by in F6Publishing: 1368] [Article Influence: 90.2] [Reference Citation Analysis]
Number Citing Articles
1 Shiffman ML, Long AG, James A, Alexander P. My treatment approach to chronic hepatitis C virus. Mayo Clin Proc 2014;89:934-42. [PMID: 24867397 DOI: 10.1016/j.mayocp.2014.04.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
2 Bonacini M, Kim Y, Pitney C, McKoin L, Tran M, Landis C. Wirelessly Observed Therapy to Optimize Adherence and Target Interventions for Oral Hepatitis C Treatment: Observational Pilot Study. J Med Internet Res 2020;22:e15532. [PMID: 32352385 DOI: 10.2196/15532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Novo-Veleiro I, Alvela-Suárez L, Chamorro AJ, González-Sarmiento R, Laso FJ, Marcos M. Alcoholic liver disease and hepatitis C virus infection. World J Gastroenterol 2016; 22(4): 1411-1420 [PMID: 26819510 DOI: 10.3748/wjg.v22.i4.1411] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
4 Monnet E, Ramée C, Minello A, Jooste V, Carel D, Di Martino V. Socioeconomic context, distance to primary care and detection of hepatitis C: a French population-based study. Soc Sci Med 2008;66:1046-56. [PMID: 18164525 DOI: 10.1016/j.socscimed.2007.11.044] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
5 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Ma Y, Huang Z, Jian Z, Wei X. The association between hepatitis C virus infection and renal cell cancer, prostate cancer, and bladder cancer: a systematic review and meta-analysis. Sci Rep 2021;11:10833. [PMID: 34035396 DOI: 10.1038/s41598-021-90404-2] [Reference Citation Analysis]
7 Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, Taylor MW, Belle SH, Di Bisceglie AM, Aurora R, Tavis JE. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol. 2007;81:8211-8224. [PMID: 17522222 DOI: 10.1128/jvi.00487-07] [Cited by in Crossref: 92] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
8 Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med. 2012;157:817-822. [PMID: 22910836 DOI: 10.7326/0003-4819-157-9-201211060-00529] [Cited by in Crossref: 216] [Cited by in F6Publishing: 188] [Article Influence: 24.0] [Reference Citation Analysis]
9 Mishra P, Jensen DM. Hepatitis C: current and future therapies. Mt Sinai J Med 2008;75:405-14. [PMID: 18729159 DOI: 10.1002/msj.20060] [Reference Citation Analysis]
10 Vicknasingam B, Narayanan S, Navaratnam V. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia. Drug Alcohol Rev 2009;28:447-54. [PMID: 19594801 DOI: 10.1111/j.1465-3362.2009.00087.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
11 Motayo BO, Akpa OM, Ezeani I, Faneye AO, Udo UA, Onoja B. Seroprevalence rates of hepatitis C virus (HCV) antibody and hepatitis B virus surface antigen (HBsAG) in blood donors in a Southwestern Nigerian city. J Immunoassay Immunochem 2015;36:91-9. [PMID: 24628383 DOI: 10.1080/15321819.2014.899256] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
12 Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology. 2006;44:1675-1684. [PMID: 17133499 DOI: 10.1002/hep.21440] [Cited by in Crossref: 117] [Cited by in F6Publishing: 97] [Article Influence: 7.8] [Reference Citation Analysis]
13 Fu Y, Xia W, Wang Y, Tian L, Pybus OG, Lu L, Nelson K. The seroprevalence of hepatitis C virus (HCV) among 559,890 first-time volunteer blood donors in China reflects regional heterogeneity in HCV prevalence and changes in blood donor recruitment models. Transfusion 2010;50:1505-11. [PMID: 20456675 DOI: 10.1111/j.1537-2995.2010.02616.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
14 Zuure FR, Bouman J, Martens M, Vanhommerig JW, Urbanus AT, Davidovich U, van Houdt R, Speksnijder AG, Weegink CJ, van den Hoek A. Screening for hepatitis B and C in first-generation Egyptian migrants living in the Netherlands. Liver Int. 2013;33:727-738. [PMID: 23448397 DOI: 10.1111/liv.12131] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
15 Nguyen GC, Thuluvath PJ. Racial disparity in liver disease: Biological, cultural, or socioeconomic factors. Hepatology. 2008;47:1058-1066. [PMID: 18302296 DOI: 10.1002/hep.22223] [Cited by in Crossref: 100] [Cited by in F6Publishing: 91] [Article Influence: 7.1] [Reference Citation Analysis]
16 Hernandez B, Hasson NK, Cheung R. Hepatitis C Performance Measure on Hepatitis A and B Vaccination: Missed Opportunities? Am J Gastroenterol 2009;104:1961-7. [DOI: 10.1038/ajg.2009.252] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
17 Sharma M, Al Kaabi S, John AK, Al Dweik N, Ullah Wani H, Babu Thandassary R, Derbala MF, Al Ejji K, Sultan K, Pasic F, Al Mohannadi M, Yacoub R, Butt MT, Singh R. Screening for hepatitis C in average and high-risk populations of Qatar using rapid point-of-care testing. United European Gastroenterol J 2015;3:364-70. [PMID: 26279845 DOI: 10.1177/2050640615580725] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
18 Endres CJ, Moss AM, Govindarajan R, Choi DS, Unadkat JD. The role of nucleoside transporters in the erythrocyte disposition and oral absorption of ribavirin in the wild-type and equilibrative nucleoside transporter 1-/- mice. J Pharmacol Exp Ther 2009;331:287-96. [PMID: 19602549 DOI: 10.1124/jpet.109.153130] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
19 Tang L, Ward H, Kattakuzhy S, Wilson E, Kottilil S. Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection. Expert Rev Gastroenterol Hepatol 2016;10:21-36. [PMID: 26558305 DOI: 10.1586/17474124.2016.1119042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
20 Wei L, Lok AS. Impact of new hepatitis C treatments in different regions of the world. Gastroenterology 2014; 146: 1145-50. e1-4. [PMID: 24662488 DOI: 10.1053/j.gastro.2014.03.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
21 Kang I, Wang L, Hsu S, Lee C, Lee Y, Wu Y, Yueh A, Wang J, Hsu T, Chao Y, Chern J. Design and efficient synthesis of novel arylthiourea derivatives as potent hepatitis C virus inhibitors. Bioorganic & Medicinal Chemistry Letters 2009;19:6063-8. [DOI: 10.1016/j.bmcl.2009.09.037] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
22 Harzke AJ, Baillargeon JG, Goodman KJ, Pruitt SL. Liver cancer mortality among male prison inmates in Texas, 1992-2003. Prev Med 2009;48:588-92. [PMID: 19289141 DOI: 10.1016/j.ypmed.2009.03.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
23 Khera L, Paul C, Kaul R. Hepatitis C Virus E1 protein promotes cell migration and invasion by modulating cellular metastasis suppressor Nm23-H1. Virology 2017;506:110-20. [PMID: 28376369 DOI: 10.1016/j.virol.2017.03.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
24 Choi JH, Sohn W, Cho YK. The effect of moderate alcohol drinking in nonalcoholic fatty liver disease. Clin Mol Hepatol 2020;26:662-9. [PMID: 32971586 DOI: 10.3350/cmh.2020.0163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
25 Mitra D, Davis KL, Beam C, Medjedovic J, Rustgi V. Treatment Patterns and Adherence among Patients with Chronic Hepatitis C Virus in a US Managed Care Population. Value in Health 2010;13:479-86. [DOI: 10.1111/j.1524-4733.2009.00691.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
26 Jadoul M, Bieber BA, Martin P, Akiba T, Nwankwo C, Arduino JM, Goodkin DA, Pisoni RL. Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney Int 2019;95:939-47. [PMID: 30904068 DOI: 10.1016/j.kint.2018.11.038] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 18.0] [Reference Citation Analysis]
27 Mahajan R, Xing J, Liu SJ, Ly KN, Moorman AC, Rupp L, Xu F, Holmberg SD; Chronic Hepatitis Cohort Study (CHeCS) Investigators. Mortality among persons in care with hepatitis C virus infection: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010. Clin Infect Dis. 2014;58:1055-1061. [PMID: 24523214 DOI: 10.1093/cid/ciu077] [Cited by in Crossref: 86] [Cited by in F6Publishing: 80] [Article Influence: 10.8] [Reference Citation Analysis]
28 Norton BL, Southern WN, Steinman M, Smith BD, Deluca J, Rosner Z, Litwin AH. No Differences in Achieving Hepatitis C Virus Care Milestones Between Patients Identified by Birth Cohort or Risk-Based Screening. Clin Gastroenterol Hepatol 2016;14:1356-60. [PMID: 27108792 DOI: 10.1016/j.cgh.2016.04.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
29 Kanwal F, Hoang T, Kramer J, Chrusciel T, El-Serag H, Dominitz JA, Asch SM. The performance of process measures in hepatitis C. Am J Gastroenterol 2012;107:1512-21. [PMID: 22777337 DOI: 10.1038/ajg.2012.201] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
30 Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, Sneller M, Kohli A, Barrett L, Proschan M, Herrmann E, Shivakumar B, Gu W, Kwan R, Teferi G, Talwani R, Silk R, Kotb C, Wroblewski S, Fishbein D, Dewar R, Highbarger H, Zhang X, Kleiner D, Wood BJ, Chavez J, Symonds WT, Subramanian M, McHutchison J, Polis MA, Fauci AS, Masur H, Kottilil S. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013;310:804-11. [PMID: 23982366 DOI: 10.1001/jama.2013.109309] [Cited by in Crossref: 211] [Cited by in F6Publishing: 215] [Article Influence: 23.4] [Reference Citation Analysis]
31 Iqbal T, Mahale P, Turturro F, Kyvernitakis A, Torres HA. Prevalence and association of hepatitis C virus infection with different types of lymphoma. Int J Cancer 2016;138:1035-7. [PMID: 26356141 DOI: 10.1002/ijc.29845] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
32 Linton SL, Celentano DD, Kirk GD, Mehta SH. The longitudinal association between homelessness, injection drug use, and injection-related risk behavior among persons with a history of injection drug use in Baltimore, MD. Drug Alcohol Depend 2013;132:457-65. [PMID: 23578590 DOI: 10.1016/j.drugalcdep.2013.03.009] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 7.2] [Reference Citation Analysis]
33 El-Serag H, Lok AS, Thomas DL. The dawn of a new era: transforming our domestic response to hepatitis B & C. Gastroenterology 2010;138:1225-30, 1230.e1-3. [PMID: 20176024 DOI: 10.1053/j.gastro.2010.02.034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
34 Perumalswami PV, Factor SH, Kapelusznik L, Friedman SL, Pan CQ, Chang C, Di Clemente F, Dieterich DT. Hepatitis Outreach Network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities. J Hepatol. 2013;58:890-897. [PMID: 23333446 DOI: 10.1016/j.jhep.2013.01.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.9] [Reference Citation Analysis]
35 Punzalan CS, Bukong TN, Szabo G. Alcoholic hepatitis and HCV interactions in the modulation of liver disease. J Viral Hepat. 2015;22:769-776. [PMID: 25754333 DOI: 10.1111/jvh.12399] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
36 Jackson CB, Varon J, Ho A, Marks KM, Talal AH, Kreek MJ. Identification of substance use and dependence among patients with viral hepatitis. Dig Liver Dis 2010;42:650-6. [PMID: 20418192 DOI: 10.1016/j.dld.2010.03.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
37 Geboy AG, Mahajan S, Daly AP, Sewell CF, Fleming IC, Cha HA, Perez IE, Cole CA, Ayodele AA, Fishbein DA. High Hepatitis C Infection Rate Among Baby Boomers in an Urban Primary Care Clinic: Results from the HepTLC Initiative. Public Health Rep 2016;131 Suppl 2:49-56. [PMID: 27168662 DOI: 10.1177/00333549161310S209] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
38 Mahmud S, Akbarzadeh V, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses. Sci Rep. 2018;8:150. [PMID: 29317673 DOI: 10.1038/s41598-017-18296-9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 13.3] [Reference Citation Analysis]
39 Sarkar M, Watt KD, Terrault N, Berenguer M. Outcomes in liver transplantation: Does sex matter? J Hepatol. 2015;62:946-955. [PMID: 25433162 DOI: 10.1016/j.jhep.2014.11.023] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 5.1] [Reference Citation Analysis]
40 Dávalos Moscol M. Indications for treatment in chronic HCV infection. Annals of Hepatology 2010;9:S49-53. [DOI: 10.1016/s1665-2681(19)31724-7] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
41 Yee LJ, Im K, Borg B, Yang H, Liang TJ; Virahep-C Study. Interleukin-6 haplotypes and the response to therapy of chronic hepatitis C virus infection. Genes Immun 2009;10:365-72. [PMID: 19387461 DOI: 10.1038/gene.2009.26] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
42 Shrivastava S, Bhanja Chowdhury J, Steele R, Ray R, Ray RB. Hepatitis C virus upregulates Beclin1 for induction of autophagy and activates mTOR signaling. J Virol. 2012;86:8705-8712. [PMID: 22674982 DOI: 10.1128/jvi.00616-12] [Cited by in Crossref: 114] [Cited by in F6Publishing: 78] [Article Influence: 11.4] [Reference Citation Analysis]
43 Weiderpass E, Pukkala E. Time trends in socioeconomic differences in incidence rates of cancers of gastro-intestinal tract in Finland. BMC Gastroenterol 2006;6:41. [PMID: 17144908 DOI: 10.1186/1471-230X-6-41] [Cited by in Crossref: 61] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
44 Yu X, Sainz B Jr, Petukhov PA, Uprichard SL. Identification of hepatitis C virus inhibitors targeting different aspects of infection using a cell-based assay. Antimicrob Agents Chemother 2012;56:6109-20. [PMID: 22948883 DOI: 10.1128/AAC.01413-12] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
45 Liu L, Wang H, Chen Y, Rustveld L, Liu G, Du XL. Splenic marginal zone lymphoma: a population-based study on the 2001–2008 incidence and survival in the United States. Leukemia & Lymphoma 2013;54:1380-6. [DOI: 10.3109/10428194.2012.743655] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
46 Birerdinc A, Afendy A, Stepanova M, Younossi I, Baranova A, Younossi ZM. Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C). Brain Behav 2012;2:525-31. [PMID: 23139898 DOI: 10.1002/brb3.72] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
47 Valway S, Jenison S, Keller N, Vega-Hernandez J, Hubbard McCree D. Risk assessment and screening for sexually transmitted infections, HIV, and hepatitis virus among long-distance truck drivers in New Mexico, 2004-2006. Am J Public Health 2009;99:2063-8. [PMID: 19762674 DOI: 10.2105/AJPH.2008.145383] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
48 García-Alonso FJ, Bonillo-Cambrodón D, Bermejo A, García-Martínez J, Hernández-Tejero M, Valer López Fando P, Piqueras B, Bermejo F. Acceptance, yield and feasibility of attaching HCV birth cohort screening to colorectal cancer screening in Spain. Dig Liver Dis 2016;48:1237-42. [PMID: 27481585 DOI: 10.1016/j.dld.2016.06.034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
49 Volk ML, Choi H, Warren GJW, Sonnenday CJ, Marrero JA, Heisler M. Geographic Variation in Organ Availability Is Responsible for Disparities in Liver Transplantation between Hispanics and Caucasians. American Journal of Transplantation 2009;9:2113-8. [DOI: 10.1111/j.1600-6143.2009.02744.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.0] [Reference Citation Analysis]
50 Uhanova J, Tate RB, Tataryn DJ, Minuk GY. A population-based study of the epidemiology of hepatitis C in a North American population. J Hepatol. 2012;57:736-742. [PMID: 22668641 DOI: 10.1016/j.jhep.2012.05.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
51 Adams MH, Lovejoy TI, Turk DC, Dobscha SK, Hauser P, Morasco BJ. Pain-related anxiety mediates the relationship between depressive symptoms and pain interference in veterans with hepatitis C. Gen Hosp Psychiatry 2015;37:533-7. [PMID: 26265311 DOI: 10.1016/j.genhosppsych.2015.07.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
52 Maithel SK, Kneuertz PJ, Kooby DA, Scoggins CR, Weber SM, Martin RC 2nd, McMasters KM, Cho CS, Winslow ER, Wood WC, Staley CA 3rd. Importance of low preoperative platelet count in selecting patients for resection of hepatocellular carcinoma: a multi-institutional analysis. J Am Coll Surg. 2011;212:638-648; discussion 648-650. [PMID: 21463803 DOI: 10.1016/j.jamcollsurg.2011.01.004] [Cited by in Crossref: 82] [Cited by in F6Publishing: 72] [Article Influence: 7.5] [Reference Citation Analysis]
53 Abughali N, Maxwell JR, Kamath AS, Nwankwo U, Mhanna MJ. Interventions using electronic medical records improve follow up of infants born to hepatitis C virus infected mothers. Pediatr Infect Dis J 2014;33:376-80. [PMID: 24401869 DOI: 10.1097/INF.0000000000000129] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
54 Beckman AL, Bilinski A, Boyko R, Camp GM, Wall AT, Lim JK, Wang EA, Bruce RD, Gonsalves GS. New Hepatitis C Drugs Are Very Costly And Unavailable To Many State Prisoners. Health Affairs 2016;35:1893-901. [DOI: 10.1377/hlthaff.2016.0296] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 7.2] [Reference Citation Analysis]
55 Prasad MR, Honegger JR. Hepatitis C virus in pregnancy. Am J Perinatol 2013;30:149-59. [PMID: 23389935 DOI: 10.1055/s-0033-1334459] [Cited by in Crossref: 71] [Cited by in F6Publishing: 62] [Article Influence: 7.9] [Reference Citation Analysis]
56 Basnayake SK, Easterbrook PJ. Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature. J Viral Hepat 2016;23:545-59. [PMID: 27028545 DOI: 10.1111/jvh.12519] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
57 Rustagi T, Zarookian EI, Qasba O, Diez LF. Chronic hepatitis C as a risk factor for colorectal adenoma. Int J Colorectal Dis 2014;29:75-80. [PMID: 23982424 DOI: 10.1007/s00384-013-1763-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
58 Suryaprasad A, Byrd KK, Redd JT, Perdue DG, Manos MM, McMahon BJ. Mortality caused by chronic liver disease among American Indians and Alaska Natives in the United States, 1999-2009. Am J Public Health 2014;104 Suppl 3:S350-8. [PMID: 24754616 DOI: 10.2105/AJPH.2013.301645] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
59 Wang CC, Krantz E, Klarquist J, Krows M, McBride L, Scott EP, Shaw-Stiffel T, Weston SJ, Thiede H, Wald A. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis. 2007;196:1474-1482. [PMID: 18008226 DOI: 10.1086/522608] [Cited by in Crossref: 129] [Cited by in F6Publishing: 126] [Article Influence: 8.6] [Reference Citation Analysis]
60 Mackesy-Amiti ME, Boodram B, Williams C, Ouellet LJ, Broz D. Sexual risk behavior associated with transition to injection among young non-injecting heroin users. AIDS Behav 2013;17:2459-66. [PMID: 23065126 DOI: 10.1007/s10461-012-0335-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
61 Sung H, Siegel RL, Rosenberg PS, Jemal A. Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. Lancet Public Health. 2019;4:e137-e147. [PMID: 30733056 DOI: 10.1016/s2468-2667(18)30267-6] [Cited by in Crossref: 150] [Cited by in F6Publishing: 89] [Article Influence: 50.0] [Reference Citation Analysis]
62 Fenoglio L, Serraino C, Castagna E, Cardellicchio A, Pomero F, Grosso M, Senore C. Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases. World J Gastroenterol 2013; 19(21): 3207-3216 [PMID: 23745022 DOI: 10.3748/wjg.v19.i21.3207] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
63 Alpers CE, Kowalewska J. Emerging Paradigms in the Renal Pathology of Viral Diseases. CJASN 2007;2:S6-S12. [DOI: 10.2215/cjn.00280107] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
64 Drezner K, Bornschlegel K, McGibbon E, Balter S. Enhanced chronic hepatitis C surveillance in New York City, April 2009-January 2011. Public Health Rep 2013;128:510-8. [PMID: 24179262 DOI: 10.1177/003335491312800610] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
65 Wu AH, Khalili M. The birth and potential death of IL28B genotyping for hepatitis C therapy. Per Med 2015;12:55-7. [PMID: 29754535 DOI: 10.2217/pme.14.60] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
66 Simon TG, Bonilla H, Yan P, Chung RT, Butt AA. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. Hepatology. 2016;64:47-57. [PMID: 26891205 DOI: 10.1002/hep.28506] [Cited by in Crossref: 94] [Cited by in F6Publishing: 90] [Article Influence: 15.7] [Reference Citation Analysis]
67 Osna NA, Bardag-Gorce F, White RL, Weinman SA, Donohue TM Jr, Kharbanda KK. Ethanol and hepatitis C virus suppress peptide-MHC class I presentation in hepatocytes by altering proteasome function. Alcohol Clin Exp Res 2012;36:2028-35. [PMID: 22551112 DOI: 10.1111/j.1530-0277.2012.01813.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
68 Roose RJ, Cockerham-Colas L, Soloway I, Batchelder A, Litwin AH. Reducing barriers to hepatitis C treatment among drug users: an integrated hepatitis C peer education and support program. J Health Care Poor Underserved 2014;25:652-62. [PMID: 24858874 DOI: 10.1353/hpu.2014.0096] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
69 Maaroufi A, Vince A, Himatt SM, Mohamed R, Fung J, Opare-Sem O, Workneh A, Njouom R, Al Ghazzawi I, Abdulla M, Kaliaskarova KS, Owusu-Ofori S, Abdelmageed MK, Adda D, Akin O, Al Baqali A, Al Dweik N, Al Ejji K, Al Kaabi S, Al Naamani K, Al Qamish J, Al Sadadi M, Al Salman J, AlBadri M, Al-Busafi SA, Al-Romaihi HE, Ampofo W, Antonov K, Anyaike C, Arome F, Bane A, Blach S, Borodo MM, Brandon SM, Bright B, Butt MT, Cardenas I, Chan HLY, Chen CJ, Chen DS, Chen PJ, Chien RN, Chuang WL, Cuellar D, Derbala M, Elbardiny AA, Estes C, Farag E, Gamkrelidze I, Garcia V, Genov J, Ghandour Z, Ghuloom M, Gomez B, Gunter J, Habeeb J, Hajelssedig O, Hamoudi W, Hrstic I, Hu CC, Huang CF, Hui YT, Jahis R, Jelev D, John AK, Kamel Y, Kao JH, Khamis J, Khattabi H, Khoudri I, Konysbekova A, Kotzev I, Lai MS, Lao WC, Layden J, Lee MH, Lesi O, Li M, Lo A, Loo CK, Lukšić B, Malu AO, Mateva L, Mitova R, Morović M, Murphy K, Mustapha B, Nde H, Nersesov A, Ngige E, Njoya O, Nonković D, Obekpa S, Oguche S, Okolo EE, Omede O, Omuemu C, Ondoa P, Phillips RO, Prokopenko YN, Razavi H, Razavi-Shearer D, Redae B, Reic T, Rinke de Wit T, Rios C, Robbins S, Roberts LR, Sanad SJ, Schmelzer JD, Sharma M, Simonova M, Su TH, Sultan K, Tan SS, Tchernev K, Tsang OTY, Tsang S, Tzeuton C, Ugoeze S, Uzochukwu B, Vi R, Wani HU, Wong VWS, Yacoub R, Yesmembetov KI, Youbi M, Yuen MF, Razavi-Shearer K. Historical epidemiology of hepatitis C virus in select countries-volume 4. J Viral Hepat 2017;24 Suppl 2:8-24. [PMID: 29105285 DOI: 10.1111/jvh.12762] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
70 Gallay PA. Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agents. Immunol Res 2012;52:200-10. [PMID: 22169996 DOI: 10.1007/s12026-011-8263-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
71 Gong J, Eley T, He B, Arora V, Philip T, Jiang H, Easter J, Humphreys WG, Iyer RA, Li W. Characterization of ADME properties of [(14)C]asunaprevir (BMS-650032) in humans. Xenobiotica 2016;46:52-64. [PMID: 26153443 DOI: 10.3109/00498254.2015.1048487] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
72 Norton BL, Voils CI, Timberlake SH, Hecker EJ, Goswami ND, Huffman KM, Landgraf A, Naggie S, Stout JE. Community-based HCV screening: knowledge and attitudes in a high risk urban population. BMC Infect Dis 2014;14:74. [PMID: 24512462 DOI: 10.1186/1471-2334-14-74] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
73 Patwardhan VR, Curry MP. Reappraisal of the hepatitis C virus-positive donor in solid organ transplantation. Curr Opin Organ Transplant. 2015;20:267-275. [PMID: 25944236 DOI: 10.1097/mot.0000000000000191] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
74 Durham DP, Skrip LA, Bruce RD, Vilarinho S, Elbasha EH, Galvani AP, Townsend JP. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States. Clin Infect Dis. 2016;62:298-304. [PMID: 26628566 DOI: 10.1093/cid/civ894] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
75 Ganova-raeva LM, Dimitrova ZE, Campo DS, Lin Y, Ramachandran S, Xia G, Honisch C, Cantor CR, Khudyakov YE. Detection of Hepatitis C Virus Transmission by Use of DNA Mass Spectrometry. The Journal of Infectious Diseases 2013;207:999-1006. [DOI: 10.1093/infdis/jis938] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
76 Shah HA, Heathcote J, Feld JJ. A Canadian screening program for hepatitis C: is now the time? CMAJ 2013;185:1325-8. [PMID: 24082023 DOI: 10.1503/cmaj.121872] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
77 Falade-Nwulia O, Irvin R, McAdams-Mahmoud A, Mehta SH, Niculescu A, Lasola J, Baker D, Eppel A, Chaulk P, Page KR, Sulkowski M, Thomas D. Senior Center-Based Hepatitis C Screening in Baltimore. Open Forum Infect Dis 2016;3:ofv217. [PMID: 26885546 DOI: 10.1093/ofid/ofv217] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
78 Pinchoff J, Drobnik A, Bornschlegel K, Braunstein S, Chan C, Varma JK, Fuld J. Deaths Among People With Hepatitis C in New York City, 2000-2011. Clinical Infectious Diseases 2014;58:1047-54. [DOI: 10.1093/cid/ciu075] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
79 Henderson WA, Shankar R, Gill JM, Kim KH, Ghany MG, Skanderson M, Butt AA. Hepatitis C progressing to hepatocellular carcinoma: the HCV dialysis patient in dilemma. J Viral Hepat 2010;17:59-64. [PMID: 19566787 DOI: 10.1111/j.1365-2893.2009.01151.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
80 Mir HM, Stepanova M, Afendy M, Kugelmas M, Younossi ZM. African americans are less likely to have clearance of hepatitis C virus infection: the findings from recent U.S. population data. J Clin Gastroenterol 2012;46:e62-5. [PMID: 22178959 DOI: 10.1097/MCG.0b013e318238352b] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
81 Blessman DJ. Chronic hepatitis C in the Hispanic/Latino population living in the United States: a literature review. Gastroenterol Nurs 2008;31:17-25; quiz 26-7. [PMID: 18300820 DOI: 10.1097/01.SGA.0000310931.64854.5f] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
82 Anderson ES, Pfeil SK, Deering LJ, Todorovic T, Lippert S, White DA. High-impact hepatitis C virus testing for injection drug users in an urban ED. Am J Emerg Med. 2016;34:1108-1111. [PMID: 27037135 DOI: 10.1016/j.ajem.2016.03.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
83 Melia MT, Muir AJ, McCone J, Shiffman ML, King JW, Herrine SK, Galler GW, Bloomer JR, Nunes FA, Brown KA. Racial differences in hepatitis C treatment eligibility. Hepatology. 2011;54:70-78. [PMID: 21488082 DOI: 10.1002/hep.24358] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.7] [Reference Citation Analysis]
84 Martin-Thormeyer EM, Paul RH. Drug abuse and hepatitis C infection as comorbid features of HIV associated neurocognitive disorder: neurocognitive and neuroimaging features. Neuropsychol Rev 2009;19:215-31. [PMID: 19468837 DOI: 10.1007/s11065-009-9101-6] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 4.5] [Reference Citation Analysis]
85 Jewett A, Al-Tayyib AA, Ginnett L, Smith BD. Successful Integration of Hepatitis C Virus Point-of-Care Tests into the Denver Metro Health Clinic. AIDS Res Treat 2013;2013:528904. [PMID: 24455220 DOI: 10.1155/2013/528904] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
86 Sterling RK, Smith PG, Brunt EM. Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse. J Clin Gastroenterol. 2013;47:182-187. [PMID: 23059409 DOI: 10.1097/mcg.0b013e318264181d] [Cited by in Crossref: 53] [Cited by in F6Publishing: 24] [Article Influence: 5.9] [Reference Citation Analysis]
87 Wang TC, Cominelli F, Fleischer DE, Gordon JM, Glickman RM, Limsui D, Mcquaid KR, Montrose M, Pasricha PJ, Powell DW, Rowe WA, Sandborn WJ, Todisco A. AGA Institute Future Trends Committee Report: The Future of Gastroenterology Training Programs in the United States. Gastroenterology 2008;135:1764-1789.e2. [DOI: 10.1053/j.gastro.2008.09.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
88 Lansky A, Finlayson T, Johnson C, Holtzman D, Wejnert C, Mitsch A, Gust D, Chen R, Mizuno Y, Crepaz N. Estimating the number of persons who inject drugs in the united states by meta-analysis to calculate national rates of HIV and hepatitis C virus infections. PLoS One 2014;9:e97596. [PMID: 24840662 DOI: 10.1371/journal.pone.0097596] [Cited by in Crossref: 157] [Cited by in F6Publishing: 148] [Article Influence: 19.6] [Reference Citation Analysis]
89 Shapshak P, Somboonwit C, Drumright LN, Frost SD, Commins D, Tellinghuisen TL, Scott WK, Duncan R, McCoy C, Page JB, Giunta B, Fernandez F, Singer E, Levine A, Minagar A, Oluwadara O, Kotila T, Chiappelli F, Sinnott JT. Molecular and contextual markers of hepatitis C virus and drug abuse. Mol Diagn Ther 2009;13:153-79. [PMID: 19650670 DOI: 10.2165/01250444-200913030-00002] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
90 Gaglio PJ, Moss N, McGaw C, Reinus J. Direct-acting antiviral therapy for hepatitis C: attitudes regarding future use. Dig Dis Sci 2011;56:1509-15. [PMID: 21336604 DOI: 10.1007/s10620-011-1604-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
91 Cooper EN, Dodson C, Stopka TJ, Riley ED, Garfein RS, Bluthenthal RN. Pharmacy participation in non-prescription syringe sales in Los Angeles and San Francisco counties, 2007. J Urban Health 2010;87:543-52. [PMID: 20549568 DOI: 10.1007/s11524-010-9483-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
92 Panetta JD, Gilani N. Interferon-induced retinopathy and its risk in patients with diabetes and hypertension undergoing treatment for chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2009;30:597-602. [PMID: 19549263 DOI: 10.1111/j.1365-2036.2009.04071.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
93 Sapra S, Chang E, Broder MS, L'Italien G. Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study. BMC Health Serv Res 2014;14:429. [PMID: 25249187 DOI: 10.1186/1472-6963-14-429] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
94 Tanaka J, Koyama T, Mizui M, Uchida S, Katayama K, Matsuo J, Akita T, Nakashima A, Miyakawa Y, Yoshizawa H. Total Numbers of Undiagnosed Carriers of Hepatitis C and B Viruses in Japan Estimated by Age- and Area-Specific Prevalence on the National Scale. Intervirology 2011;54:185-95. [DOI: 10.1159/000324525] [Cited by in Crossref: 114] [Cited by in F6Publishing: 94] [Article Influence: 10.4] [Reference Citation Analysis]
95 Sinit RB, Dorer RK, Flores JP, Aboulafia DM. Rare Causes of Isolated and Progressive Splenic Lesions: Challenges in Differential Diagnosis, Evaluation, and Treatment of Primary Splenic Lymphomas. Clin Med Insights Blood Disord 2020;13:1179545X20926188. [PMID: 32565679 DOI: 10.1177/1179545X20926188] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
96 Mindikoglu AL, Miller RR. Hepatitis C in the elderly: epidemiology, natural history, and treatment. Clin Gastroenterol Hepatol. 2009;7:128-34; quiz 124. [PMID: 19084480 DOI: 10.1016/j.cgh.2008.07.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
97 Chen Q, Ayer T, Bethea E, Kanwal F, Wang X, Roberts M, Zhuo Y, Fagiuoli S, Petersen J, Chhatwal J. Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. BMJ Open. 2019;9:e026726. [PMID: 31189677 DOI: 10.1136/bmjopen-2018-026726] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
98 Dong C, Yoon YH, Chen CM, Yi HY. Heavy alcohol use and premature death from hepatocellular carcinoma in the United States, 1999-2006. J Stud Alcohol Drugs 2011;72:892-902. [PMID: 22051203 DOI: 10.15288/jsad.2011.72.892] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
99 Arora SS, Axley P, Ahmed Z, Satapathy SK, Wong R, Kuo YF, Singal AK. Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals - a retrospective cohort study. Transpl Int. 2019;32:854-864. [PMID: 30866110 DOI: 10.1111/tri.13424] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
100 Patel YA, Yao J, Proeschold-Bell RJ, Niedzwiecki D, Goacher E, Muir AJ. Reduced Alcohol Use Is Sustained in Patients Provided Alcohol-Related Counseling During Direct-Acting Antiviral Therapy for Hepatitis C. Dig Dis Sci 2021;66:2956-63. [PMID: 32968965 DOI: 10.1007/s10620-020-06616-5] [Reference Citation Analysis]
101 Liebman HA. Viral-Associated Immune Thrombocytopenic Purpura. Hematology 2008;2008:212-8. [DOI: 10.1182/asheducation-2008.1.212] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 3.0] [Reference Citation Analysis]
102 Bashir MR, Horowitz JM, Kamel IR, Arif-Tiwari H, Asrani SK, Chernyak V, Goldstein A, Grajo JR, Hindman NM, Kamaya A, McNamara MM, Porter KK, Solnes LB, Srivastava PK, Zaheer A, Carucci LR; Expert Panel on Gastrointestinal Imaging. ACR Appropriateness Criteria® Chronic Liver Disease. J Am Coll Radiol 2020;17:S70-80. [PMID: 32370979 DOI: 10.1016/j.jacr.2020.01.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
103 Salemi JL, Spooner KK, Mejia de Grubb MC, Aggarwal A, Matas JL, Salihu HM. National trends of hepatitis B and C during pregnancy across sociodemographic, behavioral, and clinical factors, United States, 1998-2011. J Med Virol 2017;89:1025-32. [PMID: 27805270 DOI: 10.1002/jmv.24725] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
104 Bornschlegel K, Berger M, Garg RK, Punsalang A, McKinney CM, Gwynn RC, Thorpe LE. Prevalence of hepatitis C infection in New York City, 2004. J Urban Health 2009;86:909-17. [PMID: 19672718 DOI: 10.1007/s11524-009-9396-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
105 Khleif AA, Rodriguez N, Brown D, Escobar MA. Multiple Comorbid Conditions among Middle-Aged and Elderly Hemophilia Patients: Prevalence Estimates and Implications for Future Care. J Aging Res 2011;2011:985703. [PMID: 21912745 DOI: 10.4061/2011/985703] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
106 Wu A, Burrowes S, Zisman E, Brown TT, Bagchi S. Association of hepatitis C infection and acute coronary syndrome: A case-control study. Medicine (Baltimore) 2021;100:e26033. [PMID: 34032724 DOI: 10.1097/MD.0000000000026033] [Reference Citation Analysis]
107 Gunewardene R, Lampe L, Ilchef R. Prevalence of hepatitis C in two inpatient psychiatry populations. Australas Psychiatry 2010;18:330-4. [PMID: 20645899 DOI: 10.3109/10398561003763273] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
108 Chapman LE, Sullivent EE, Grohskopf LA, Beltrami EM, Perz JF, Kretsinger K, Panlilio AL, Thompson ND, Ehrenberg RL, Gensheimer KF, Duchin JS, Kilmarx PH, Hunt RC. Postexposure interventions to prevent infection with HBV, HCV, or HIV, and tetanus in people wounded during bombings and other mass casualty events--United States, 2008: recommendations of the Centers for Disease Control and Prevention and Disaster Medicine and Public Health Preparedness. Disaster Med Public Health Prep 2008;2:150-65. [PMID: 18677271 DOI: 10.1097/DMP.0b013e318187ac66] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
109 Cheung R, Mannalithara A, Singh G. Utilization and Antiviral Therapy in Patients with Chronic Hepatitis C: Analysis of Ambulatory Care Visits in the US. Dig Dis Sci 2010;55:1744-51. [DOI: 10.1007/s10620-010-1147-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
110 Kwo PY, Badshah MB. Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature. Curr Gastroenterol Rep 2015;17:462. [PMID: 26342813 DOI: 10.1007/s11894-015-0462-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
111 Yeh MM, Daniel HD, Torbenson M. Hepatitis C-associated hepatocellular carcinomas in non-cirrhotic livers. Mod Pathol. 2010;23:276-283. [PMID: 19935643 DOI: 10.1038/modpathol.2009.174] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
112 El Garf A, Shaheen N, Gaber W, Sobhy N. Prevalence and impact of chronic hepatitis C virus infection on the clinical manifestations and disease activity among patients suffering from systemic lupus erythematosus. The Egyptian Rheumatologist 2013;35:9-14. [DOI: 10.1016/j.ejr.2012.09.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
113 Kelly EM, Dodge JL, Bacchetti P, Sarkar M, French AL, Tien PC, Glesby MJ, Golub ET, Augenbraun M, Plankey M, Peters MG. Moderate Alcohol Use Is Not Associated With Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women: A Prospective Cohort Study. Clin Infect Dis. 2017;65:2050-2056. [PMID: 29020382 DOI: 10.1093/cid/cix716] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
114 Ephraim R, Donko I, Sakyi SA, Ampong J, Agbodjakey H. Seroprevalence and risk factors of Hepatitis B and Hepatitis C infections among pregnant women in the Asante Akim North Municipality of the Ashanti region, Ghana; a cross sectional study. Afr Health Sci 2015;15:709-13. [PMID: 26957956 DOI: 10.4314/ahs.v15i3.2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
115 Bichoupan K, Martel-Laferriere V, Sachs D, Ng M, Schonfeld EA, Pappas A, Crismale J, Stivala A, Khaitova V, Gardenier D. Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology. 2014;60:1187-1195. [PMID: 25065814 DOI: 10.1002/hep.27340] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
116 Lawitz E, Rodriguez-Torres M, Muir AJ, Kieffer TL, McNair L, Khunvichai A, McHutchison JG. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol. 2008;49:163-169. [PMID: 18486984 DOI: 10.1016/j.jhep.2008.03.027] [Cited by in Crossref: 96] [Cited by in F6Publishing: 80] [Article Influence: 6.9] [Reference Citation Analysis]
117 Faustini A, Colais P, Fabrizi E, Bargagli AM, Davoli M, Di Lallo D, Di Napoli A, Pezzotti P, Sorge C, Grillo R, Maresca C, Recchia O, Perucci CA; HCV laboratory surveillance Lazio-Region Group. Hepatic and extra-hepatic sequelae, and prevalence of viral hepatitis C infection estimated from routine data in at-risk groups. BMC Infect Dis 2010;10:97. [PMID: 20403169 DOI: 10.1186/1471-2334-10-97] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
118 Chapko MK, Dufour DR, Hatia RI, Drobeniuc J, Ward JW, Teo CG. Cost-effectiveness of strategies for testing current hepatitis C virus infection. Hepatology. 2015;62:1396-1404. [PMID: 26126725 DOI: 10.1002/hep.27966] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
119 Kim B, Ahn HJ, Choi MH, Park Y. Retrospective analysis on the diagnostic performances and signal-to-cut-off ratios of the Elecsys Anti-HCV II assay. J Clin Lab Anal 2018;32. [PMID: 28187227 DOI: 10.1002/jcla.22165] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
120 Younossi ZM, McCullough AJ. Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver Int. 2009;29 Suppl 2:3-12. [PMID: 19187068 DOI: 10.1111/j.1478-3231.2008.01949.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
121 Zalesak M, Francis K, Gedeon A, Gillis J, Hvidsten K, Kidder P, Li H, Martyn D, Orne L, Smith A, Kwong A. Current and future disease progression of the chronic HCV population in the United States. PLoS One. 2013;8:e63959. [PMID: 23704962 DOI: 10.1371/journal.pone.0063959] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
122 Chhatwal J, Chen Q, Aggarwal R. Estimation of Hepatitis C Disease Burden and Budget Impact of Treatment Using Health Economic Modeling. Infect Dis Clin North Am 2018;32:461-80. [PMID: 29778266 DOI: 10.1016/j.idc.2018.02.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
123 Beste LA, Straits-Troster K, Zickmund S, Larson M, Chapko M, Dominitz JA. Specialty care and education associated with greater disease-specific knowledge but not satisfaction with care for chronic hepatitis C. Aliment Pharmacol Ther 2009;30:275-82. [PMID: 19438425 DOI: 10.1111/j.1365-2036.2009.04036.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
124 Kozlowski HN, Sindhwani S, Chan WCW. The Impact of Patient Characteristics on Diagnostic Test Performance. Small Methods 2022;:e2101233. [PMID: 34994108 DOI: 10.1002/smtd.202101233] [Reference Citation Analysis]
125 Charlebois A, Lee L, Cooper E, Mason K, Powis J. Factors associated with HCV antiviral treatment uptake among participants of a community-based HCV programme for marginalized patients. J Viral Hepat. 2012;19:836-842. [PMID: 23121361 DOI: 10.1111/j.1365-2893.2012.01648.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
126 Perzynski AT, McCormick R, Webster NJ, Blixen CE, Kanuch S, Thomas CL, Mullen KD, Dawson NV. Psychosocial correlates of alcohol use and reduction for individuals with hepatitis C. J Stud Alcohol Drugs 2011;72:787-98. [PMID: 21906506 DOI: 10.15288/jsad.2011.72.787] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
127 Skolnik AA, Noska A, Yakovchenko V, Tsai J, Jones N, Gifford AL, McInnes DK. Experiences with interferon-free hepatitis C therapies: addressing barriers to adherence and optimizing treatment outcomes. BMC Health Serv Res 2019;19:91. [PMID: 30709352 DOI: 10.1186/s12913-019-3904-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
128 Shah BB, Wong JB. The Economics of Hepatitis C Virus. Clinics in Liver Disease 2006;10:717-34. [DOI: 10.1016/j.cld.2006.08.026] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
129 Rein DB, Borton J, Liffmann DK, Wittenborn JS. The burden of hepatitis C to the United States Medicare system in 2009: Descriptive and economic characteristics: Rein et al. Hepatology 2016;63:1135-44. [DOI: 10.1002/hep.28430] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
130 Lee CK, Jonas MM. Hepatitis C: Issues in Children. Gastroenterol Clin North Am 2015;44:901-9. [PMID: 26600227 DOI: 10.1016/j.gtc.2015.07.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
131 Jain MK, Zoellner C. Role of ribavirin in HCV treatment response: now and in the future. Expert Opin Pharmacother. 2010;11:673-683. [PMID: 20163278 DOI: 10.1517/14656560903580001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
132 Crist RC, Vickers-Smith R, Kember RL, Rentsch CT, Xu H, Edelman EJ, Hartwell EE, Kampman KM, Kranzler HR. Analysis of genetic and clinical factors associated with buprenorphine response. Drug Alcohol Depend 2021;227:109013. [PMID: 34488071 DOI: 10.1016/j.drugalcdep.2021.109013] [Reference Citation Analysis]
133 Edlin BR. Hepatitis C screening: getting it right. Hepatology 2013;57:1644-50. [PMID: 23239521 DOI: 10.1002/hep.26194] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
134 Gish RG, Meanwell NA. The NS5A replication complex inhibitors: difference makers? Clin Liver Dis 2011;15:627-39. [PMID: 21867941 DOI: 10.1016/j.cld.2011.05.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
135 Harzke AJ. Regional and global summary estimates of antibody to hepatitis C virus prevalence in detainee populations: seeing the forest and the trees? Hepatology 2013;58:1197-9. [PMID: 23696103 DOI: 10.1002/hep.26474] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
136 Brogan AJ, Talbird SE, Thompson JR, Miller JD, Rubin J, Deniz B. Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C. PLoS One 2014;9:e90295. [PMID: 24603445 DOI: 10.1371/journal.pone.0090295] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
137 Owens CM, Brasher BB, Polemeropoulos A, Rhodin MH, McAllister N, Peng X, Wang C, Ying L, Cao H, Lawitz E, Poordad F, Rondon J, Box TD, Zeuzem S, Buggisch P, Lin K, Qiu YL, Jiang L, Colvin R, Or YS. Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239. Antimicrob Agents Chemother 2016;60:6207-15. [PMID: 27503640 DOI: 10.1128/AAC.00808-16] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
138 Proeschold-Bell RJ, Evon DM, Makarushka C, Wong JB, Datta SK, Yao J, Patkar AA, Mannelli P, Hodge T, Naggie S, Wilder JM, Fried MW, Niedzwiecki D, Muir AJ. The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial. Contemp Clin Trials 2018;72:73-85. [PMID: 30006024 DOI: 10.1016/j.cct.2018.07.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
139 Mohammad A, Carey JJ, Storan E, Scarry M, Coughlan RJ, Lee JM. Prevalence of fibromyalgia among patients with chronic hepatitis C infection: relationship to viral characteristics and quality of life. J Clin Gastroenterol. 2012;46:407-412. [PMID: 22499073 DOI: 10.1097/mcg.0b013e3182485528] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
140 Ortiz AP, Soto-Salgado M, Calo WA, Tortolero-Luna G, Pérez CM, Romero CJ, Pérez J, Figueroa-Vallés N, Suárez E. Incidence and mortality rates of selected infection-related cancers in Puerto Rico and in the United States. Infect Agent Cancer 2010;5:10. [PMID: 20470399 DOI: 10.1186/1750-9378-5-10] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
141 Melchardt T, Weiss L, Greil R, Egle A. Viral infections and their management in patients with chronic lymphocytic leukemia. Leukemia & Lymphoma 2013;54:1602-13. [DOI: 10.3109/10428194.2012.755178] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
142 Mishra P, DeVoss A, Pai R, Hart J, Jensen DM. Marked flare in hepatic aminotransferases during treatment with pegylated interferon for chronic hepatitis C, genotype 2: a case report. Dig Dis Sci 2009;54:1369-72. [PMID: 18770036 DOI: 10.1007/s10620-008-0476-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
143 Phillips B, Cai R, Delaney W, Du Z, Ji M, Jin H, Lee J, Li J, Niedziela-Majka A, Mish M, Pyun HJ, Saugier J, Tirunagari N, Wang J, Yang H, Wu Q, Sheng C, Zonte C. Highly potent HCV NS4B inhibitors with activity against multiple genotypes. J Med Chem 2014;57:2161-6. [PMID: 24512292 DOI: 10.1021/jm401646w] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
144 Chappell CA, Krans EE. Hepatitis C virus among pregnant women and children in the USA: an emerging epidemic. Future Virology 2018;13:855-62. [DOI: 10.2217/fvl-2018-0147] [Reference Citation Analysis]
145 Buffington J, Murray PJ, Schlanger K, Shih L, Badsgard T, Hennessy RR, Wood R, Weisfuse IB, Gunn RA. Low prevalence of hepatitis C virus antibody in men who have sex with men who do not inject drugs. Public Health Rep 2007;122 Suppl 2:63-7. [PMID: 17542456 DOI: 10.1177/00333549071220S212] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
146 Pereira LM, Martelli CM, Moreira RC, Merchan-Hamman E, Stein AT, Cardoso MR, Figueiredo GM, Montarroyos UR, Braga C, Turchi MD. Prevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study. BMC Infect Dis. 2013;13:60. [PMID: 23374914 DOI: 10.1186/1471-2334-13-60] [Cited by in Crossref: 92] [Cited by in F6Publishing: 94] [Article Influence: 10.2] [Reference Citation Analysis]
147 Brunner N, Bruggmann P. Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination. J Prev Med Public Health 2021;54:251-8. [PMID: 34370938 DOI: 10.3961/jpmph.21.151] [Reference Citation Analysis]
148 Honorato Castro AC, França EG, de Paula LF, Soares MM, Goulart LR, Madurro JM, Brito-madurro AG. Preparation of genosensor for detection of specific DNA sequence of the hepatitis B virus. Applied Surface Science 2014;314:273-9. [DOI: 10.1016/j.apsusc.2014.06.084] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
149 Kwo PY, Badshah MB. New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease. Curr Opin Organ Transplant. 2015;20:235-241. [PMID: 25944238 DOI: 10.1097/mot.0000000000000198] [Cited by in Crossref: 47] [Cited by in F6Publishing: 14] [Article Influence: 6.7] [Reference Citation Analysis]
150 Wise M, Finelli L, Sorvillo F. Prognostic factors associated with hepatitis C disease: a case-control study utilizing U.S. multiple-cause-of-death data. Public Health Rep 2010;125:414-22. [PMID: 20433036 DOI: 10.1177/003335491012500310] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
151 Gardenier D, Neushotz LA, O'connor-moore N. Medical/Psychiatric Comanagement by Nurse Practitioners in Chronic Hepatitis C Treatment: A Case Study. Archives of Psychiatric Nursing 2007;21:87-90. [DOI: 10.1016/j.apnu.2006.11.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
152 Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013;57:2164-2170. [PMID: 23280550 DOI: 10.1002/hep.26218] [Cited by in Crossref: 307] [Cited by in F6Publishing: 293] [Article Influence: 34.1] [Reference Citation Analysis]
153 Hall EW, Rosenberg ES, Sullivan PS. Estimates of state-level chronic hepatitis C virus infection, stratified by race and sex, United States, 2010. BMC Infect Dis 2018;18:224. [PMID: 29769036 DOI: 10.1186/s12879-018-3133-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
154 Louie KS, St Laurent S, Forssen UM, Mundy LM, Pimenta JM. The high comorbidity burden of the hepatitis C virus infected population in the United States. BMC Infect Dis 2012;12:86. [PMID: 22494445 DOI: 10.1186/1471-2334-12-86] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 5.6] [Reference Citation Analysis]
155 Winetsky D, Zucker J, Slowikowski J, Scherer M, Verna EC, Gordon P. Preliminary Screening Results Outside the 1945-1965 Birth Cohort: A Forgotten Population for Hepatitis C? Open Forum Infect Dis 2019;6:ofz178. [PMID: 31123691 DOI: 10.1093/ofid/ofz178] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
156 Huynh T, Hu KQ. Excellent Safety and Sustained Virologic Response to Direct-Acting Antivirals Treatment in HCV-Infected Geriatric Patients: A Real-World Data. Dig Dis Sci 2021;66:1327-34. [PMID: 32405981 DOI: 10.1007/s10620-020-06286-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
157 Zibbell JE, Hart-Malloy R, Barry J, Fan L, Flanigan C. Risk factors for HCV infection among young adults in rural New York who inject prescription opioid analgesics. Am J Public Health 2014;104:2226-32. [PMID: 25211717 DOI: 10.2105/AJPH.2014.302142] [Cited by in Crossref: 71] [Cited by in F6Publishing: 48] [Article Influence: 8.9] [Reference Citation Analysis]
158 Younossi ZM, Stepanova M, Schwarz KB, Wirth S, Rosenthal P, Gonzalez-Peralta R, Murray K, Henry L, Hunt S. Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin. J Viral Hepat. 2018;25:354-362. [PMID: 29193603 DOI: 10.1111/jvh.12830] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
159 Hagan LM, Yang Z, Ehteshami M, Schinazi RF. All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. J Viral Hepat. 2013;20:847-857. [PMID: 24304454 DOI: 10.1111/jvh.12111] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 4.9] [Reference Citation Analysis]
160 Melkonian SC, Jim MA, Reilley B, Erdrich J, Berkowitz Z, Wiggins CL, Haverkamp D, White MC. Incidence of primary liver cancer in American Indians and Alaska Natives, US, 1999-2009. Cancer Causes Control 2018;29:833-44. [PMID: 30030669 DOI: 10.1007/s10552-018-1059-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
161 Wu T, Konyn PG, Cattaneo AW, Saab S. New Face of Hepatitis C. Dig Dis Sci 2019;64:1782-8. [PMID: 30756208 DOI: 10.1007/s10620-019-05511-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
162 Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91. [PMID: 19224838 DOI: 10.1200/JCO.2008.20.7753] [Cited by in Crossref: 1121] [Cited by in F6Publishing: 613] [Article Influence: 86.2] [Reference Citation Analysis]
163 Pappas N, Lee DH. Hepatitis C and the hand surgeon: what you should know. J Hand Surg Am 2012;37:1711-3; quiz 1714. [PMID: 22503652 DOI: 10.1016/j.jhsa.2012.02.043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
164 Jordan AE, Des Jarlais DC, Arasteh K, McKnight C, Nash D, Perlman DC. Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006-2013. Drug Alcohol Depend 2015;152:194-200. [PMID: 25891230 DOI: 10.1016/j.drugalcdep.2015.03.039] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 5.1] [Reference Citation Analysis]
165 Falade-Nwulia O, Mehta SH, Lasola J, Latkin C, Niculescu A, O'Connor C, Chaulk P, Ghanem K, Page KR, Sulkowski MS, Thomas DL. Public health clinic-based hepatitis C testing and linkage to care in Baltimore. J Viral Hepat. 2016;23:366-374. [PMID: 26840570 DOI: 10.1111/jvh.12507] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 6.5] [Reference Citation Analysis]
166 Gayam V, Tiongson B, Mandal AK, Garlapati P, Pan C, Mohanty S. Real-world study of hepatitis C treatment with direct-acting antivirals in patients with drug abuse and opioid agonist therapy. Scand J Gastroenterol 2019;54:646-55. [PMID: 31120776 DOI: 10.1080/00365521.2019.1617893] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
167 Bacchetti P, Boylan R, Astemborski J, Shen H, Mehta SH, Thomas DL, Terrault NA, Monto A. Progression of biopsy-measured liver fibrosis in untreated patients with hepatitis C infection: non-Markov multistate model analysis. PLoS One 2011;6:e20104. [PMID: 21637766 DOI: 10.1371/journal.pone.0020104] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
168 Seem DL, Lee I, Umscheid CA, Kuehnert MJ; United States Public Health Service. PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation. Public Health Rep 2013;128:247-343. [PMID: 23814319 DOI: 10.1177/003335491312800403] [Cited by in Crossref: 158] [Cited by in F6Publishing: 127] [Article Influence: 17.6] [Reference Citation Analysis]
169 Pichetshote N, Groessl E, Yee H, Ho SB. Optimizing the dose and duration of therapy for chronic hepatitis C. Gut Liver 2009;3:1-13. [PMID: 20479894 DOI: 10.5009/gnl.2009.3.1.1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
170 Tapp H, Ludden T, Shade L, Thomas J, Mohanan S, Leonard M. Electronic medical record alert activation increase hepatitis C and HIV screening rates in primary care practices within a large healthcare system. Prev Med Rep 2020;17:101036. [PMID: 31970042 DOI: 10.1016/j.pmedr.2019.101036] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
171 Mueller MR, Instone S. Beyond the informed consent procedure: continuing consent in human research. Cien Saude Colet 2008;13:381-9. [PMID: 18813554 DOI: 10.1590/s1413-81232008000200013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
172 Adler H, Lambert JS. Daclatasvir for the treatment of hepatitis C virus infection. Expert Rev Gastroenterol Hepatol. 2014;8:725-738. [PMID: 24882552 DOI: 10.1586/17474124.2014.925798] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
173 Zuchowski JL, Hamilton AB, Pyne JM, Clark JA, Naik AD, Smith DL, Kanwal F. Qualitative analysis of patient-centered decision attributes associated with initiating hepatitis C treatment. BMC Gastroenterol 2015;15:124. [PMID: 26429337 DOI: 10.1186/s12876-015-0356-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
174 Strehlow AJ, Robertson MJ, Zerger S, Rongey C, Arangua L, Farrell E, O'Sullivan A, Gelberg L. Hepatitis C among clients of health care for the homeless primary care clinics. J Health Care Poor Underserved 2012;23:811-33. [PMID: 22643626 DOI: 10.1353/hpu.2012.0047] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
175 Donnelly JP, Franco RA, Wang HE, Galbraith JW. Emergency Department Screening for Hepatitis C Virus: Geographic Reach and Spatial Clustering in Central Alabama. Clin Infect Dis 2016;62:613-6. [PMID: 26611776 DOI: 10.1093/cid/civ984] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
176 Mahajan R, Liu SJ, Klevens RM, Holmberg SD. Indications for testing among reported cases of HCV infection from enhanced hepatitis surveillance sites in the United States, 2004-2010. Am J Public Health 2013;103:1445-9. [PMID: 23763404 DOI: 10.2105/AJPH.2013.301211] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
177 Backus LI, Belperio PS, Loomis TP, Mole LA. Impact of race/ethnicity and gender on HCV screening and prevalence among U.S. veterans in Department of Veterans Affairs Care. Am J Public Health 2014;104 Suppl 4:S555-61. [PMID: 25100421 DOI: 10.2105/AJPH.2014.302090] [Cited by in Crossref: 40] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
178 Backus LI, Gavrilov S, Loomis TP, Halloran JP, Phillips BR, Belperio PS, Mole LA. Clinical Case Registries: simultaneous local and national disease registries for population quality management. J Am Med Inform Assoc. 2009;16:775-783. [PMID: 19717794 DOI: 10.1197/jamia.m3203] [Cited by in Crossref: 79] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
179 Saab S, Virabhak S, Parisé H, Johnson S, Wang A, Misurski D, Gonzalez YS, Juday T. Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States. Adv Ther 2016;33:1316-30. [PMID: 27342742 DOI: 10.1007/s12325-016-0362-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
180 Sears DM, Cohen DC, Ackerman K, Ma JE, Song J. Birth cohort screening for chronic hepatitis during colonoscopy appointments. Am J Gastroenterol. 2013;108:981-989. [PMID: 23511461 DOI: 10.1038/ajg.2013.50] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
181 McCown MF, Rajyaguru S, Le Pogam S, Ali S, Jiang WR, Kang H, Symons J, Cammack N, Najera I. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 2008;52:1604-12. [PMID: 18285474 DOI: 10.1128/AAC.01317-07] [Cited by in Crossref: 134] [Cited by in F6Publishing: 61] [Article Influence: 9.6] [Reference Citation Analysis]
182 Hom JK, Witt C, Johnson CC, Viner K. Demographic, risk factor, and provider characteristics associated with confirmatory hepatitis C testing. Ann Epidemiol 2016;26:157-9. [PMID: 26733081 DOI: 10.1016/j.annepidem.2015.11.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
183 Nikoo N, Javidanbardan S, Akm M, Hakobyan S, Nikoo M, Kwan C, Song M, Vogel M, Somers J, Krausz M. Hepatitis C prevalence and associated risk factors among individuals who are homeless and diagnosed with mental illness: At Home/Chez Soi Study, Vancouver, BC. European Journal of Public Health 2019;29:242-7. [DOI: 10.1093/eurpub/cky142] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
184 Tracy D, Hahn JA, Fuller Lewis C, Evans J, Briceño A, Morris MD, Lum PJ, Page K. Higher risk of incident hepatitis C virus among young women who inject drugs compared with young men in association with sexual relationships: a prospective analysis from the UFO Study cohort. BMJ Open 2014;4:e004988. [PMID: 24875490 DOI: 10.1136/bmjopen-2014-004988] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
185 Chirikov VV, Marx SE, Manthena SR, Strezewski JP, Saab S. Development of a Comprehensive Dataset of Hepatitis C Patients and Examination of Disease Epidemiology in the United States, 2013–2016. Adv Ther 2018;35:1087-102. [DOI: 10.1007/s12325-018-0721-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
186 Beckwith CG, Kurth AE, Bazerman L, Solomon L, Patry E, Rich JD, Kuo I. Survey of US Correctional Institutions for Routine HCV Testing. Am J Public Health 2015;105:68-71. [PMID: 25393180 DOI: 10.2105/AJPH.2014.302071] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
187 Mohanty A, Erqou S, Mcginnis KA, Vanasse G, Freiberg MS, Sherman KE, Butt AA. Therapy for Hepatitis C Virus Infection Increases Survival of Patients With Pretreatment Anemia. Clinical Gastroenterology and Hepatology 2013;11:741-747.e3. [DOI: 10.1016/j.cgh.2013.01.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
188 El-Serag HB, Alsarraj A, Richardson P, Davila JA, Kramer JR, Durfee J, Kanwal F. Hepatocellular carcinoma screening practices in the Department of Veterans Affairs: findings from a national facility survey. Dig Dis Sci 2013;58:3117-26. [PMID: 23868438 DOI: 10.1007/s10620-013-2794-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
189 Venook AP, Papandreou C, Furuse J, Ladrón de Guevara L. The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective. The Oncologist 2010;15:5-13. [DOI: 10.1634/theoncologist.2010-s4-05] [Cited by in Crossref: 575] [Cited by in F6Publishing: 343] [Article Influence: 47.9] [Reference Citation Analysis]
190 Kanwal F, Lok AS, El-Serag HB. CDC and USPSTF 2012 recommendations for screening for hepatitis C virus infection: overview and take-home messages. Clin Gastroenterol Hepatol 2013;11:200-3. [PMID: 23432900 DOI: 10.1016/j.cgh.2013.01.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
191 Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med. 2012;156:279-290. [PMID: 22351713 DOI: 10.1059/0003-4819-156-4-201202210-00005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
192 Lam B, Henry L, Younossi Z. Sofosbuvir (Sovaldi) for the treatment of hepatitis C. Expert Rev Clin Pharmacol 2014;7:555-66. [PMID: 24918162 DOI: 10.1586/17512433.2014.928196] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
193 Mitchell DG, Navarro VJ, Herrine SK, Bergin D, Parker L, Frangos A, Mccue P, Rubin R. Compensated hepatitis C: unenhanced MR imaging correlated with pathologic grading and staging. Abdom Imaging 2008;33:58-64. [DOI: 10.1007/s00261-007-9203-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
194 Cartwright EJ, Rentsch C, Rimland D. Hepatitis C virus screening practices and seropositivity among US veterans born during 1945 - 1965. BMC Res Notes 2014;7:449. [PMID: 25023159 DOI: 10.1186/1756-0500-7-449] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
195 Tyson GL, Duan Z, Kramer JR, Davila JA, Richardson PA, El-Serag HB. Level of α-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9:989-994. [PMID: 21820396 DOI: 10.1016/j.cgh.2011.07.026] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
196 Rossaro L, Torruellas C, Dhaliwal S, Botros J, Clark G, Li CS, Minoletti MM. Clinical outcomes of hepatitis C treated with pegylated interferon and ribavirin via telemedicine consultation in Northern California. Dig Dis Sci 2013;58:3620-5. [PMID: 24154637 DOI: 10.1007/s10620-013-2810-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
197 Gordon CE, Balk EM, Becker BN, Crooks PA, Jaber BL, Johnson CA, Michael MA, Pereira BJ, Uhlig K, Levin A. KDOQI US commentary on the KDIGO clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in CKD. Am J Kidney Dis. 2008;52:811-825. [PMID: 18971009 DOI: 10.1053/j.ajkd.2008.08.005] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
198 Abara WE, Moorman AC, Zhong Y, Collier MG, Rupp LB, Gordon SC, Boscarino JA, Schmidt MA, Trinacty CM, Holmberg SD, for the Checs Investigators. The Predictive Value of International Classification of Disease Codes for Chronic Hepatitis C Virus Infection Surveillance: The Utility and Limitations of Electronic Health Records. Population Health Management 2018;21:110-5. [DOI: 10.1089/pop.2017.0004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
199 Mahale P, Sturgis EM, Tweardy DJ, Ariza-Heredia EJ, Torres HA. Association Between Hepatitis C Virus and Head and Neck Cancers. J Natl Cancer Inst 2016;108. [PMID: 27075854 DOI: 10.1093/jnci/djw035] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 6.5] [Reference Citation Analysis]
200 Kretzer IF, do Livramento A, da Cunha J, Gonçalves S, Tosin I, Spada C, Treitinger A. Hepatitis C worldwide and in Brazil: silent epidemic--data on disease including incidence, transmission, prevention, and treatment. ScientificWorldJournal. 2014;2014:827849. [PMID: 25013871 DOI: 10.1155/2014/827849] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
201 Nguyen GC, Segev DL, Thuluvath PJ. Nationwide increase in hospitalizations and hepatitis C among inpatients with cirrhosis and sequelae of portal hypertension. Clin Gastroenterol Hepatol. 2007;5:1092-1099. [PMID: 17625983 DOI: 10.1016/j.cgh.2007.04.027] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 4.5] [Reference Citation Analysis]
202 Wojcik GL, Thio CL, Kao WH, Latanich R, Goedert JJ, Mehta SH, Kirk GD, Peters MG, Cox AL, Kim AY, Chung RT, Thomas DL, Duggal P. Admixture analysis of spontaneous hepatitis C virus clearance in individuals of African descent. Genes Immun 2014;15:241-6. [PMID: 24622687 DOI: 10.1038/gene.2014.11] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
203 Lonardo A, Adinolfi LE, Petta S, Craxì A, Loria P. Hepatitis C and diabetes: the inevitable coincidence? Expert Rev Anti Infect Ther. 2009;7:293-308. [PMID: 19344243 DOI: 10.1586/eri.09.3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 3.6] [Reference Citation Analysis]
204 Young AM, Crosby RA, Oser CB, Leukefeld CG, Stephens DB, Havens JR. Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia. J Med Virol 2012;84:1376-87. [PMID: 22825816 DOI: 10.1002/jmv.23252] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
205 Ramcharran D, Wahed AS, Conjeevaram HS, Evans RW, Wang T, Belle SH, Yee LJ. Serum lipids and their associations with viral levels and liver disease severity in a treatment-naïve chronic hepatitis C type 1-infected cohort. J Viral Hepat. 2011;18:e144-e152. [PMID: 21070504 DOI: 10.1111/j.1365-2893.2010.01394.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
206 Butt AA, McGinnis K, Skanderson M, Justice AC. A comparison of treatment eligibility for hepatitis C virus in HCV-monoinfected versus HCV/HIV-coinfected persons in electronically retrieved cohort of HCV-infected veterans. AIDS Res Hum Retroviruses 2011;27:973-9. [PMID: 21338329 DOI: 10.1089/AID.2011.0004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
207 Simon TG, Butt AA. Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes. World J Gastroenterol 2015; 21(27): 8293-8303 [PMID: 26217081 DOI: 10.3748/wjg.v21.i27.8293] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
208 Pergam SA, Hawes SE, Gardella CM, Wang CC. HCV and pregnancy: is now the time for universal testing? Future Virology 2008;3:1-5. [DOI: 10.2217/17460794.3.1.1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
209 Chou R, Carson S, Chan BKS. Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials. Journal of Viral Hepatitis 2008;15:551-70. [DOI: 10.1111/j.1365-2893.2008.00984.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
210 Tran HA, Reeves GE, Ianna EA, Leembruggen N. Thyroid Function Outcomes after Pegylated Interferon-α and Ribavirin Therapy - For Chronic Hepatitis C. Endocrine Practice 2010;16:934-9. [DOI: 10.4158/ep10036.or] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
211 Tseng CH, Muo CH, Hsu CY, Kao CH. Increased Risk of intracerebral hemorrhage among patients with hepatitis C virus infection. Medicine (Baltimore). 2015;94:e2132. [PMID: 26579831 DOI: 10.1097/md.0000000000002132] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
212 Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis. 2012;55 Suppl 1:S10-S15. [PMID: 22715208 DOI: 10.1093/cid/cis361] [Cited by in Crossref: 185] [Cited by in F6Publishing: 182] [Article Influence: 18.5] [Reference Citation Analysis]
213 Rowe IA, Parker R, Armstrong MJ, Houlihan DD, Mutimer DJ. Hepatitis A virus vaccination in persons with hepatitis C virus infection: consequences of quality measure implementation. Hepatology 2012;56:501-6. [PMID: 22371026 DOI: 10.1002/hep.25683] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
214 Kwan JW, Cronkite RC, Yiu A, Goldstein MK, Kazis L, Cheung RC. The impact of chronic hepatitis C and co-morbid illnesses on health-related quality of life. Qual Life Res 2008;17:715-24. [PMID: 18427949 DOI: 10.1007/s11136-008-9344-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
215 Gicquelais RE, Foxman B, Coyle J, Eisenberg MC. Hepatitis C transmission in young people who inject drugs: Insights using a dynamic model informed by state public health surveillance. Epidemics 2019;27:86-95. [PMID: 30930214 DOI: 10.1016/j.epidem.2019.02.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
216 Davis GL, Alter MJ, El–serag H, Poynard T, Jennings LW. Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression. Gastroenterology 2010;138:513-521.e6. [DOI: 10.1053/j.gastro.2009.09.067] [Cited by in Crossref: 649] [Cited by in F6Publishing: 613] [Article Influence: 54.1] [Reference Citation Analysis]
217 Deshpande R, Stepanova M, Golabi P, Brown K, Younossi ZM. Prevalence, mortality and healthcare utilization among Medicare beneficiaries with Hepatitis C in Haemodialysis units. J Viral Hepat 2019;26:1293-300. [PMID: 31294521 DOI: 10.1111/jvh.13173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
218 Frederick T, Burian P, Terrault N, Cohen M, Augenbraun M, Young M, Seaberg E, Justman J, Levine AM, Mack WJ, Kovacs A. Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women's Interagency HIV Study (WIHS). AIDS Patient Care STDS 2009;23:915-23. [PMID: 19877800 DOI: 10.1089/apc.2009.0111] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
219 Kabiri M, Jazwinski AB, Roberts MS, Schaefer AJ, Chhatwal J. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med 2014;161:170-80. [PMID: 25089861 DOI: 10.7326/M14-0095] [Cited by in Crossref: 107] [Cited by in F6Publishing: 58] [Article Influence: 13.4] [Reference Citation Analysis]
220 Mazzarelli C, Considine A, Childs K, Carey I, Manini MA, Suddle A, Dusheiko G, Agarwal K, Cannon MD. Efficacy and Tolerability of Direct-Acting Antivirals for Hepatitis C in Older Adults. J Am Geriatr Soc 2018;66:1339-45. [PMID: 29799112 DOI: 10.1111/jgs.15392] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
221 Kim AY. Management algorithm for genotype 1 hepatitis C virus. F1000Prime Rep 2013;5:24. [PMID: 23864931 DOI: 10.12703/P5-24] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
222 Sherif ZA, Nouraie M, Begum R, Afsari A, Shokrani B, Lee E, Laiyemo AO, Brim H, Ashktorab H. Factors influencing treatment outcome in hepatitis C virus minority patients at an inner-city hospital: A STROBE-complaint article. Medicine (Baltimore) 2020;99:e19505. [PMID: 32243366 DOI: 10.1097/MD.0000000000019505] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
223 Saab S, Jackson C, Nieto J, Francois F. Hepatitis C in African Americans. Am J Gastroenterol 2014;109:1576-84; quiz 1575, 1585. [PMID: 25178700 DOI: 10.1038/ajg.2014.243] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
224 O'Brien SF, Fan W, Xi G, Yi QL, Goldman M, Fearon MA, Infante-Rivard C, Chiavetta JA, Willems B, Pi D, Fast M, Delage G. Declining hepatitis C rates in first-time blood donors: insight from surveillance and case-control risk factor studies. Transfusion 2008;48:902-9. [PMID: 18208409 DOI: 10.1111/j.1537-2995.2007.01618.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
225 Shiffman ML, Gunn NT. Management and Treatment of Chronic HBV and HCV Co-Infection and the Impact of Anti-Viral Therapy. Curr Hepatology Rep 2017;16:169-77. [DOI: 10.1007/s11901-017-0352-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
226 El‐serag HB. Epidemiology of Hepatocellular Carcinoma. In: Arias IM, Alter HJ, Boyer JL, Cohen DE, Shafritz DA, Thorgeirsson SS, Wolkoff AW, editors. The Liver. Wiley; 2020. pp. 758-72. [DOI: 10.1002/9781119436812.ch59] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
227 Searson G, Engelson ES, Carriero D, Kotler DP. Treatment of chronic hepatitis C virus infection in the United States: some remaining obstacles. Liver Int. 2014;34:668-671. [PMID: 24418358 DOI: 10.1111/liv.12467] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
228 Trigg A, Chan E, Kitchen H, Willgoss T, Ho KF, Pierson R, Scott J. Psychometric Validation of the Hepatitis C Symptom and Impact Questionnaire (HCV-SIQv4) in a Diverse Sample of Adults with Chronic Hepatitis C Virus Infection Treated with an Interferon-free Simeprevir-containing Regimen. J Health Econ Outcomes Res 2019;6:1-19. [PMID: 32685576 DOI: 10.36469/9675] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
229 Foran JM. Hepatitis C in the rituximab era. Blood. 2010;116:5081-5082. [PMID: 21148335 DOI: 10.1182/blood-2010-09-307827] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
230 Momin BR, Pinheiro PS, Carreira H, Li C, Weir HK. Liver cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study. Cancer 2017;123 Suppl 24:5059-78. [PMID: 29205306 DOI: 10.1002/cncr.30820] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
231 Mukhtar NA, Ness EM, Jhaveri M, Fix OK, Hart M, Dale C, Pratt C, Kowdley KV. Epidemiologic features of a large hepatitis C cohort evaluated in a major health system in the western United States. Ann Hepatol 2019;18:360-5. [PMID: 31053542 DOI: 10.1016/j.aohep.2018.12.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
232 Mir HM, Birerdinc A, Younossi ZM. Monoclonal and polyclonal antibodies against the HCV envelope proteins. Clin Liver Dis 2009;13:477-86. [PMID: 19628163 DOI: 10.1016/j.cld.2009.05.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
233 White DL, Thrift AP, Kanwal F, Davila J, El-Serag HB. Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. Gastroenterology. 2017;152:812-820.e5. [PMID: 27889576 DOI: 10.1053/j.gastro.2016.11.020] [Cited by in Crossref: 222] [Cited by in F6Publishing: 204] [Article Influence: 37.0] [Reference Citation Analysis]
234 Kim WR, Terrault NA, Pedersen RA, Therneau TM, Edwards E, Hindman AA, Brosgart CL. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology. 2009;137:1680-1686. [PMID: 19632234 DOI: 10.53/j.gastro.2009.07.047] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
235 Zucker DM. An intervention to prevent symptoms associated with hepatitis C: a pilot study. Applied Nursing Research 2010;23:116-20. [DOI: 10.1016/j.apnr.2008.04.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
236 Wilder JM, Muir A. Direct acting antivirals for the treatment of hepatitis C in ethnic minority populations. Expert Opin Pharmacother 2018;19:451-6. [PMID: 29488438 DOI: 10.1080/14656566.2018.1446945] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
237 Garcia-Rivera JA, Lin K, Hopkins S, Gregory MA, Wilkinson B, Gallay PA. Development of a flow cytometry live cell assay for the screening of inhibitors of hepatitis C virus (HCV) replication. Open Virol J 2012;6:97-102. [PMID: 23230455 DOI: 10.2174/1874357901206010097] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
238 Poordad F, Dieterich D. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents: Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. Journal of Viral Hepatitis 2012;19:449-64. [DOI: 10.1111/j.1365-2893.2012.01617.x] [Cited by in Crossref: 119] [Cited by in F6Publishing: 120] [Article Influence: 11.9] [Reference Citation Analysis]
239 Kang IJ, Wang LW, Yeh TK, Lee CC, Lee YC, Hsu SJ, Wu YS, Wang JC, Chao YS, Yueh A, Chern JH. Synthesis, activity, and pharmacokinetic properties of a series of conformationally-restricted thiourea analogs as novel hepatitis C virus inhibitors. Bioorg Med Chem 2010;18:6414-21. [PMID: 20675142 DOI: 10.1016/j.bmc.2010.07.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
240 Mogul D, Schwarz KB. Hepatitis C viral infection in children. Clin Liver Dis. 2012;1:77-80. [PMID: 31186854 DOI: 10.1002/cld.64] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
241 Loria A, Doyle K, Weinstein AA, Winter P, Escheik C, Price J, Wang L, Birerdinc A, Baranova A, Gerber L, Younossi ZM. Multiple Factors Predict Physical Performance in People with Chronic Liver Disease. American Journal of Physical Medicine & Rehabilitation 2014;93:470-6. [DOI: 10.1097/phm.0000000000000050] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
242 Reznik DA. Screening for Infectious Diseases in the Dental Setting. Dental Clinics of North America 2012;56:809-18. [DOI: 10.1016/j.cden.2012.07.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
243 Ridruejo E, Solano Á, Marciano S, Galdame O, Adrover R, Cocozzella D, Delettieres D, Martínez A, Gadano A, Mandό OG, Silva MO. Genetic variation in Interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin. Annals of Hepatology 2011;10:452-7. [DOI: 10.1016/s1665-2681(19)31512-1] [Cited by in Crossref: 17] [Article Influence: 1.5] [Reference Citation Analysis]
244 Wursthorn K, Manns MP, Wedemeyer H. Natural history: the importance of viral load, liver damage and HCC. Best Pract Res Clin Gastroenterol 2008;22:1063-79. [PMID: 19187867 DOI: 10.1016/j.bpg.2008.11.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
245 Klevens RM, Moorman AC. Hepatitis C virus: an overview for dental health care providers. J Am Dent Assoc. 2013;144:1340-1347. [PMID: 24282263 DOI: 10.14219/jada.archive.2013.0069] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
246 Lam JT, Jacob S. Boceprevir: a recently approved protease inhibitor for hepatitis C virus infection. Am J Health Syst Pharm 2012;69:2135-9. [PMID: 23230035 DOI: 10.2146/ajhp110500] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
247 Wertheimer AM, Polyak SJ, Leistikow R, Rosen HR. Engulfment of apoptotic cells expressing HCV proteins leads to differential chemokine expression and STAT signaling in human dendritic cells. Hepatology. 2007;45:1422-1432. [PMID: 17538964 DOI: 10.1002/hep.21637] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
248 Larney S, Mahowald MK, Scharff N, Flanigan TP, Beckwith CG, Zaller ND. Epidemiology of hepatitis C virus in Pennsylvania state prisons, 2004-2012: limitations of 1945-1965 birth cohort screening in correctional settings. Am J Public Health 2014;104:e69-74. [PMID: 24825235 DOI: 10.2105/AJPH.2014.301943] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
249 Al-tayyib AA, Thiede H, Burt RD, Koester S. Unmet Health Care Needs and Hepatitis C Infection Among Persons Who Inject Drugs in Denver and Seattle, 2009. Prev Sci 2015;16:330-40. [DOI: 10.1007/s11121-014-0500-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
250 Silasi M, Cardenas I, Kwon JY, Racicot K, Aldo P, Mor G. Viral infections during pregnancy. Am J Reprod Immunol 2015;73:199-213. [PMID: 25582523 DOI: 10.1111/aji.12355] [Cited by in Crossref: 196] [Cited by in F6Publishing: 177] [Article Influence: 28.0] [Reference Citation Analysis]
251 Rosen HR, Weston SJ, Im K, Yang H, Burton JR, Erlich H, Klarquist J, Belle SH; Virahep-C Study Group. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology 2007;46:350-8. [DOI: 10.1002/hep.21714] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
252 Vergara C, Thio CL, Johnson E, Kral AH, O'Brien TR, Goedert JJ, Mangia A, Piazzolla V, Mehta SH, Kirk GD, Kim AY, Lauer GM, Chung RT, Cox AL, Peters MG, Khakoo SI, Alric L, Cramp ME, Donfield SM, Edlin BR, Busch MP, Alexander G, Rosen HR, Murphy EL, Latanich R, Wojcik GL, Taub MA, Valencia A, Thomas DL, Duggal P. Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. Gastroenterology 2019;156:1496-1507.e7. [PMID: 30593799 DOI: 10.1053/j.gastro.2018.12.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
253 Wu S, Wu F, Hong R, He J. Incidence analyses and space-time cluster detection of hepatitis C in Fujian Province of China from 2006 to 2010. PLoS One 2012;7:e40872. [PMID: 22829893 DOI: 10.1371/journal.pone.0040872] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
254 Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology. 2008;48:1420-1429. [PMID: 18671304 DOI: 10.1002/hep.22486] [Cited by in Crossref: 191] [Cited by in F6Publishing: 178] [Article Influence: 13.6] [Reference Citation Analysis]
255 Nappi A, Perrella A, Bellopede P, Lanza A, Izzi A, Spatarella M, Sbreglia C. Safety of new DAAs for chronic HCV infection in a real life experience: role of a surveillance network based on clinician and hospital pharmacist. Infect Agent Cancer 2017;12:12. [PMID: 28191032 DOI: 10.1186/s13027-017-0119-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
256 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065] [Cited by in Crossref: 365] [Cited by in F6Publishing: 367] [Article Influence: 91.3] [Reference Citation Analysis]
257 Ompad DC, Galea S, Marshall G, Fuller CM, Weiss L, Beard JR, Chan C, Edwards V, Vlahov D. Sampling and recruitment in multilevel studies among marginalized urban populations: the IMPACT studies. J Urban Health 2008;85:268-80. [PMID: 18214686 DOI: 10.1007/s11524-008-9256-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
258 Falade-Nwulia O, McAdams-Mahmoud A, Irvin R, Niculescu A, Page KR, Mix M, Thomas DL, Sulkowski MS, Mehta SH. Primary Care Providers Knowledge, Attitude and Practices Related to Hepatitis C Screening and Treatment in the Oral Direct Acting Antiviral Agents Era. J Community Med Health Educ. 2016;6:pii: 481. [PMID: 28083156 DOI: 10.4172/2161-0711.1000481] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
259 O'Brien SF, Xi G, Yi QL, Goldman M. Understanding non-disclosure of deferrable risk: a study of blood donors with a history of intravenous drug use. Transfus Med 2010;20:15-21. [PMID: 19793079 DOI: 10.1111/j.1365-3148.2009.00969.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
260 Valdiserri R, Khalsa J, Dan C, Holmberg S, Zibbell J, Holtzman D, Lubran R, Compton W. Confronting the emerging epidemic of HCV infection among young injection drug users. Am J Public Health 2014;104:816-21. [PMID: 24625174 DOI: 10.2105/AJPH.2013.301812] [Cited by in Crossref: 65] [Cited by in F6Publishing: 36] [Article Influence: 8.1] [Reference Citation Analysis]
261 Narciso-Schiavon JL, Schiavon LL, Carvalho-Filho RJ, Cardoso JR, Freire FC, Sampaio JP, Bordin JO, Soares MA, Silva AE, Ferraz ML. Anti-HCV reactive blood donors: clinical and epidemiological factors associated with false-reactive results. Eur J Gastroenterol Hepatol 2008;20:1071-6. [PMID: 19047838 DOI: 10.1097/MEG.0b013e328303e1d6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
262 Carrion AF, Martin P. Viral hepatitis in the elderly. Am J Gastroenterol. 2012;107:691-697. [PMID: 22290404 DOI: 10.1038/ajg.2012.7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
263 Kemmer N, Safdar K, Kaiser T, Zacharias V, Neff GW. Impact of geographic location on access to liver transplantation among ethnic minorities. Transplantation. 2008;85:166-170. [PMID: 18212619 DOI: 10.1097/tp.0b013e31816223f8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
264 Calore BL, Cheung RC, Giori NJ. Prevalence of hepatitis C virus infection in the veteran population undergoing total joint arthroplasty. J Arthroplasty 2012;27:1772-6. [PMID: 22770853 DOI: 10.1016/j.arth.2012.05.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
265 Casey LC, Lee WM. Hepatitis C virus therapy update 2013. Curr Opin Gastroenterol. 2013;29:243-249. [PMID: 23563981 DOI: 10.1097/mog.0b013e32835ff972] [Cited by in Crossref: 9] [Cited by in F6Publishing: 28] [Article Influence: 1.0] [Reference Citation Analysis]
266 Ly KN, Xing J, Klevens RM, Jiles RB, Holmberg SD. Causes of death and characteristics of decedents with viral hepatitis, United States, 2010. Clin Infect Dis. 2014;58:40-49. [PMID: 24065331 DOI: 10.1093/cid/cit642] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 6.0] [Reference Citation Analysis]
267 Joseph AM. Treatment of rheumatoid arthritis in patients with concomitant chronic hepatitis C infection. Ther Adv Musculoskelet Dis 2012;4:35-40. [PMID: 22870493 DOI: 10.1177/1759720X11424459] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
268 Narciso-Schiavon JL, Schiavon LL, Carvalho-Filho RJ, Freire FC, Cardoso JR, Bordin JO, Silva AE, Ferraz ML. Anti-hepatitis C virus-positive blood donors: are women any different? Transfus Med. 2008;18:175-183. [PMID: 18598280 DOI: 10.1111/j.1365-3148.2008.00859.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
269 Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012;62:118-128. [PMID: 22281605 DOI: 10.3322/caac.20141] [Cited by in Crossref: 435] [Cited by in F6Publishing: 421] [Article Influence: 43.5] [Reference Citation Analysis]
270 Patel RC, Vellozzi C, Smith BD. Results of Hepatitis C Birth-Cohort Testing and Linkage to Care in Selected U.S. Sites, 2012-2014. Public Health Rep 2016;131 Suppl 2:12-9. [PMID: 27168656 DOI: 10.1177/00333549161310S203] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 5.6] [Reference Citation Analysis]
271 Maier MM, Zhou XH, Chapko M, Leipertz SL, Wang X, Beste LA. Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort. Dig Dis Sci 2018;63:1454-62. [PMID: 29453610 DOI: 10.1007/s10620-018-4956-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
272 Vachon ML, Dieterich DT. A great time to invest in baby Boomer's hepatitis C! Hepatology 2012;56:1575-7. [PMID: 23038650 DOI: 10.1002/hep.25898] [Reference Citation Analysis]
273 Singh R, Kaul R, Kaul A, Khan K. A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol 2007; 13(12): 1770-1787 [PMID: 17465466 DOI: 10.3748/wjg.v13.i12.1770] [Cited by in CrossRef: 138] [Cited by in F6Publishing: 135] [Article Influence: 9.2] [Reference Citation Analysis]
274 Nag A, Robotham JM, Tang H. Suppression of viral RNA binding and the assembly of infectious hepatitis C virus particles in vitro by cyclophilin inhibitors. J Virol. 2012;86:12616-12624. [PMID: 22973029 DOI: 10.1128/jvi.01351-12] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
275 Baugh J, Gallay P. Cyclophilin involvement in the replication of hepatitis C virus and other viruses. Biol Chem 2012;393:579-87. [PMID: 22944661 DOI: 10.1515/hsz-2012-0151] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
276 Jorgensen CM, Carnes CA. Lessons Learned From Exploratory Research About Viral Hepatitis. Health Promotion Practice 2013;14:364-9. [DOI: 10.1177/1524839912455643] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
277 Clifford DB, Vaida F, Kao YT, Franklin DR, Letendre SL, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, Grant I, Heaton RK; CHARTER Group. Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people. Neurology 2015;84:241-50. [PMID: 25503616 DOI: 10.1212/WNL.0000000000001156] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
278 Jindal N, Goyal LD, Singh C. Sociodemographic features associated with Hepatitis C Virus (HCV) in pregnant females: A tertiary care centre study from Malwa region of Punjab (North India). J Family Med Prim Care 2021;10:2679-83. [PMID: 34568154 DOI: 10.4103/jfmpc.jfmpc_2372_20] [Reference Citation Analysis]
279 Mansueto P, Seidita A, Vitale G, Gangemi S, Iaria C, Cascio A. Vitamin D Deficiency in HIV Infection: Not Only a Bone Disorder. Biomed Res Int 2015;2015:735615. [PMID: 26000302 DOI: 10.1155/2015/735615] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 6.4] [Reference Citation Analysis]
280 Lassmann B, Arumugaswami V, Chew KW, Lewis MJ. A new system to measure and compare hepatitis C virus replication capacity using full-length, replication competent viruses. J Virol Methods 2013;194:82-8. [PMID: 23973740 DOI: 10.1016/j.jviromet.2013.08.009] [Reference Citation Analysis]
281 Moore KJ, Gauri A, Koru-Sengul T. Prevalence and sociodemographic disparities of Hepatitis C in Baby Boomers and the US adult population. J Infect Public Health. 2019;12:32-36. [PMID: 30170837 DOI: 10.1016/j.jiph.2018.08.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
282 Tohme RA, Xing J, Liao Y, Holmberg SD. Hepatitis C testing, infection, and linkage to care among racial and ethnic minorities in the United States, 2009-2010. Am J Public Health 2013;103:112-9. [PMID: 23153151 DOI: 10.2105/AJPH.2012.300858] [Cited by in Crossref: 48] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
283 Minter S, Willner I, Shirai K. Ipilimumab-induced hepatitis C viral suppression. J Clin Oncol. 2013;31:e307-e308. [PMID: 23690418 DOI: 10.1200/jco.2012.46.5831] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
284 Alam I, Stainbrook T, Cecil B, Kistler KD. Enhanced adherence to HCV therapy with higher dose ribavirin formulation: final analyses from the ADHERE registry. Aliment Pharmacol Ther 2010;32:535-42. [PMID: 20500732 DOI: 10.1111/j.1365-2036.2010.04381.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
285 Thibault A, Brissette S, Jutras-Aswad D. Systematic review of the pharmacological treatment of alcohol use disorders in individuals infected with hepatitis C. Addict Sci Clin Pract 2015;10:6. [PMID: 25928362 DOI: 10.1186/s13722-015-0029-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
286 Pizzillo P, Almasio PL, Ferraro D, Craxì A, Di Stefano R. HCV genotypes in Sicily: Is there any evidence of a shift? J Med Virol 2009;81:1040-6. [DOI: 10.1002/jmv.21498] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
287 Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010;14:1-21, vii. [PMID: 20123436 DOI: 10.1016/j.cld.2009.11.009] [Cited by in Crossref: 276] [Cited by in F6Publishing: 239] [Article Influence: 23.0] [Reference Citation Analysis]
288 Hayman AV, Sofair AN, Manos MM, Thomas A, Terrault N, Ness GV, Stabach N, Robert M, Rumore G, Corless C, Bell B, Bialek S, Zaman A. Prevalence and predictors of hepatic steatosis in adults with newly diagnosed chronic liver disease due to hepatitis C. Medicine (Baltimore) 2009;88:302-6. [PMID: 19745689 DOI: 10.1097/MD.0b013e3181b954f4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
289 Allam SR, Krüger B, Mehrotra A, Schiano T, Schröppel B, Murphy B. The association of IL28B polymorphism and graft survival in patients with hepatitis C undergoing liver transplantation. PLoS One. 2013;8:e54854. [PMID: 23382988 DOI: 10.1371/journal.pone.0054854] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
290 Prussing C, Chan C, Pinchoff J, Kersanske L, Bornschlegel K, Balter S, Drobnik A, Fuld J. HIV and viral hepatitis co-infection in New York City, 2000-2010: prevalence and case characteristics. Epidemiol Infect 2015;143:1408-16. [PMID: 25170631 DOI: 10.1017/S0950268814002209] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
291 Chemaitelly H, Chaabna K, Abu-Raddad LJ. The Epidemiology of Hepatitis C Virus in the Fertile Crescent: Systematic Review and Meta-Analysis. PLoS One. 2015;10:e0135281. [PMID: 26296200 DOI: 10.1371/journal.pone.0135281] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 5.9] [Reference Citation Analysis]
292 Liu Y, El-Serag HB, Jiao L, Lee J, Moore D, Franco LM, Tavakoli-Tabasi S, Tsavachidis S, Kuzniarek J, Ramsey DJ. WNT signaling pathway gene polymorphisms and risk of hepatic fibrosis and inflammation in HCV-infected patients. PLoS One. 2013;8:e84407. [PMID: 24386373 DOI: 10.1371/journal.pone.0084407] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
293 Birerdinc A, Younossi ZM. Emerging therapies for hepatitis C virus. Expert Opin Emerg Drugs 2010;15:535-44. [PMID: 20629602 DOI: 10.1517/14728214.2010.502527] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
294 Malcarney MB, Horton K, Seiler N, Hastings D. Advancing the Public's Health by Scaling Innovations in Clinical Quality. Public Health Rep 2017;132:512-7. [PMID: 28595029 DOI: 10.1177/0033354917709982] [Reference Citation Analysis]
295 Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011;31:1090-1101. [PMID: 21745274 DOI: 10.1111/j.1478-3231.2011.02494.x] [Cited by in Crossref: 299] [Cited by in F6Publishing: 265] [Article Influence: 27.2] [Reference Citation Analysis]
296 North CS, Hong BA, Kerr T. Hepatitis C and substance use: new treatments and novel approaches. Curr Opin Psychiatry 2012;25:206-12. [PMID: 22395769 DOI: 10.1097/YCO.0b013e328351f85a] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
297 Appleby TC, Anderson R, Fedorova O, Pyle AM, Wang R, Liu X, Brendza KM, Somoza JR. Visualizing ATP-dependent RNA translocation by the NS3 helicase from HCV. J Mol Biol. 2011;405:1139-1153. [PMID: 21145896 DOI: 10.1016/j.jmb.2010.11.034] [Cited by in Crossref: 81] [Cited by in F6Publishing: 79] [Article Influence: 6.8] [Reference Citation Analysis]
298 Kiefer EM, Shi Q, Hoover DR, Kaplan R, Tracy R, Augenbraun M, Liu C, Nowicki M, Tien PC, Cohen M, Golub ET, Anastos K. Association of hepatitis C with markers of hemostasis in HIV-infected and uninfected women in the women's interagency HIV study (WIHS). J Acquir Immune Defic Syndr 2013;62:301-10. [PMID: 23221984 DOI: 10.1097/QAI.0b013e31827fdd61] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
299 Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013;19:850-8. [PMID: 23836235 DOI: 10.1038/nm.3184] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
300 Yang CHT, Goel A, Ahmed A. Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C. Adolesc Health Med Ther 2018;9:103-10. [PMID: 30104913 DOI: 10.2147/AHMT.S147896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
301 Boscarino JA, Sitarik A, Gordon SC, Rupp LB, Nerenz DR, Vijayadeva V, Schmidt MA, Henkle E, Lu M. Risk Factors for Hepatitis C Infection Among Vietnam Era Veterans Versus Nonveterans: Results from the Chronic Hepatitis Cohort Study (CHeCS). J Community Health 2014;39:914-21. [DOI: 10.1007/s10900-014-9863-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
302 Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med. 2012;156:279-290. [PMID: 22351713 DOI: 10.7326/0003-4819-156-4-201202210-00005] [Cited by in Crossref: 142] [Cited by in F6Publishing: 139] [Article Influence: 14.2] [Reference Citation Analysis]
303 Anbazhagan GK, Krishnamoorthy S, Thiyagarajan T. Seroprevalence of HCV and its co-infection with HBV and HIV among liver disease patients of South Tamil Nadu. World J Hepatol 2010; 2(1): 42-48 [PMID: 21160955 DOI: 10.4254/wjh.v2.i1.42] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
304 El-serag HB, Kramer J, Duan Z, Kanwal F. Epidemiology and outcomes of hepatitis C infection in elderly US Veterans. J Viral Hepat 2016;23:687-96. [DOI: 10.1111/jvh.12533] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
305 Lauffenburger JC, Mayer CL, Hawke RL, Brouwer KL, Fried MW, Farley JF. Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential. Eur J Gastroenterol Hepatol. 2014;26:1073-1082. [PMID: 25014625 DOI: 10.1097/med.00000000000152] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
306 Chandra R, Dolder NM, Dolder CR, O’Neill LW, Robinette C. Treatment of dyslipidemia with statins by primary care providers in Veterans with and without chronic Hepatitis C. Am J Health Syst Pharm. 2016;73:S30-S34. [PMID: 26896523 DOI: 10.2146/sp150030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
307 LaFleur J, Hoop R, Korner E, DuVall S, Morgan T, Pandya P, Han J, Knippenberg K, Nelson RE. Predictors of Early Discontinuation of Pegylated Interferon for Reasons Other Than Lack of Efficacy in United States Veterans With Chronic Hepatitis C. Gastroenterol Nurs 2015;38:417-28. [PMID: 26626031 DOI: 10.1097/SGA.0000000000000214] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
308 Surjadi M, Torruellas C, Ayala C, Yee HF, Khalili M. Formal patient education improves patient knowledge of hepatitis C in vulnerable populations. Dig Dis Sci. 2011;56:213-219. [PMID: 20972850 DOI: 10.1007/s10620-010-1455-3] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 3.7] [Reference Citation Analysis]
309 Salihu HM, Connell L, Salemi JL, August EM, Weldeselasse HE, Alio AP. Prevalence and temporal trends of hepatitis B, hepatitis C, and HIV/AIDS co-infection during pregnancy across the decade, 1998-2007. J Womens Health (Larchmt) 2012;21:66-72. [PMID: 22011209 DOI: 10.1089/jwh.2011.2979] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
310 Seaberg EC, Witt MD, Jacobson LP, Detels R, Rinaldo CR, Margolick JB, Young S, Phair JP, Thio CL. Spontaneous Clearance of the Hepatitis C Virus Among Men Who Have Sex With Men. Clin Infect Dis 2015;61:1381-8. [PMID: 26175521 DOI: 10.1093/cid/civ562] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
311 Eriksen MB, Jakobsen MA, Kringsholm B, Banner J, Thomsen JL, Georgsen J, Pedersen C, Christensen PB. Postmortem Detection of Hepatitis B, C, and Human Immunodeficiency Virus Genomes in Blood Samples from Drug-Related Deaths in Denmark. Journal of Forensic Sciences 2009;54:1085-8. [DOI: 10.1111/j.1556-4029.2009.01111.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
312 Thong VD, Akkarathamrongsin S, Poovorawan K, Tangkijvanich P, Poovorawan Y. Hepatitis C virus genotype 6: Virology, epidemiology, genetic variation and clinical implication. World J Gastroenterol 2014; 20(11): 2927-2940 [PMID: 24659883 DOI: 10.3748/wjg.v20.i11.2927] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
313 Boesecke C, Wedemeyer H, Rockstroh JK. Diagnosis and treatment of acute hepatitis C virus infection. Infect Dis Clin North Am 2012;26:995-1010. [PMID: 23083829 DOI: 10.1016/j.idc.2012.08.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
314 Shire AM, Sandhu DS, Kaiya JK, Oseini AM, Yang JD, Chaiteerakij R, Mettler TA, Giama NH, Roberts RO, Therneau TM. Viral hepatitis among Somali immigrants in Minnesota: association of hepatitis C with hepatocellular carcinoma. Mayo Clin Proc. 2012;87:17-24. [PMID: 22212964 DOI: 10.1016/j.mayocp.2011.08.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
315 Klevens RM, Liu S, Roberts H, Jiles RB, Holmberg SD. Estimating acute viral hepatitis infections from nationally reported cases. Am J Public Health 2014;104:482-7. [PMID: 24432918 DOI: 10.2105/AJPH.2013.301601] [Cited by in Crossref: 44] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
316 Nyberg AH, Sadikova E, Cheetham C, Chiang KM, Shi JX, Caparosa S, Younossi ZM, Nyberg LM. Increased cancer rates in patients with chronic hepatitis C. Liver Int 2020;40:685-93. [PMID: 31755208 DOI: 10.1111/liv.14305] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
317 Tran HA, Attia JR, Jones TL, Batey RG. Pegylated interferon-alpha2beta in combination with ribavirin does not aggravate thyroid dysfunction in comparison to regular interferon-alpha2beta in a hepatitis C population: meta-analysis. J Gastroenterol Hepatol. 2007;22:472-476. [PMID: 17376035 DOI: 10.1111/j.1440-1746.2006.04771.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
318 Miller L, Fluker S, Osborn M, Liu X, Strawder A. Improving Access to Hepatitis C Care for Urban, Underserved Patients Using a Primary Care-Based Hepatitis C Clinic. Journal of the National Medical Association 2012;104:244-50. [DOI: 10.1016/s0027-9684(15)30161-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
319 White DL, Tavakoli-Tabasi S, Kuzniarek J, Pascua R, Ramsey DJ, El-Serag HB. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males. Hepatology. 2012;55:759-768. [PMID: 21858849 DOI: 10.1002/hep.24618] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 4.1] [Reference Citation Analysis]
320 Tai VW, Garrido D, Price DJ, Maynard A, Pouliot JJ, Xiong Z, Seal JW, Creech KL, Kryn LH, Baughman TM, Peat AJ. Design and synthesis of spirocyclic compounds as HCV replication inhibitors by targeting viral NS4B protein. Bioorganic & Medicinal Chemistry Letters 2014;24:2288-94. [DOI: 10.1016/j.bmcl.2014.03.080] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
321 Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, Richardson P, El-Serag HB. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011;140:1182-1188.e1. [PMID: 21184757 DOI: 10.1053/j.gastro.2010.12.032] [Cited by in Crossref: 265] [Cited by in F6Publishing: 258] [Article Influence: 22.1] [Reference Citation Analysis]
322 Fabris P, Baldo V, Baldovin T, Bellotto E, Rassu M, Trivello R, Tramarin A, Tositti G, Floreani A. Changing epidemiology of HCV and HBV infections in Northern Italy: a survey in the general population. J Clin Gastroenterol. 2008;42:527-532. [PMID: 18277889 DOI: 10.1097/mcg.0b013e318030e3ab] [Cited by in Crossref: 56] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
323 Ward JW, Lok AS, Thomas DL, El-Serag HB, Kim WR. Report on a single-topic conference on “Chronic viral hepatitis--strategies to improve effectiveness of screening and treatment”. Hepatology. 2012;55:307-315. [PMID: 22105599 DOI: 10.1002/hep.24797] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
324 Marrone A, Ciotti M, Rinaldi L, Adinolfi LE, Ghany M. Hepatitis B and C virus infection and risk of haematological malignancies. J Viral Hepat 2020;27:4-12. [PMID: 31325404 DOI: 10.1111/jvh.13183] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
325 Chiba-Falek O, Linnertz C, Guyton J, Gardner SD, Roses AD, McCarthy JJ, Patel K. Pleiotropy and allelic heterogeneity in the TOMM40-APOE genomic region related to clinical and metabolic features of hepatitis C infection. Hum Genet. 2012;131:1911-1920. [PMID: 22898894 DOI: 10.1007/s00439-012-1220-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
326 El-Diwany R, Cohen VJ, Mankowski MC, Wasilewski LN, Brady JK, Snider AE, Osburn WO, Murrell B, Ray SC, Bailey JR. Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1. PLoS Pathog 2017;13:e1006235. [PMID: 28235087 DOI: 10.1371/journal.ppat.1006235] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
327 Azad T, Tashakor A, Hosseinkhani S. Split-luciferase complementary assay: applications, recent developments, and future perspectives. Anal Bioanal Chem 2014;406:5541-60. [DOI: 10.1007/s00216-014-7980-8] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
328 White DL, Richardson PA, Al-Saadi M, Fitzgerald SJ, Green L, Amaratunge C, Anand M, El-Serag HB. Dietary history and physical activity and risk of advanced liver disease in veterans with chronic hepatitis C infection. Dig Dis Sci 2011;56:1835-47. [PMID: 21188525 DOI: 10.1007/s10620-010-1505-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
329 Valiaeva N, Wyles DL, Schooley RT, Hwu JB, Beadle JR, Prichard MN, Hostetler KY. Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replication. Bioorg Med Chem 2011;19:4616-25. [PMID: 21719300 DOI: 10.1016/j.bmc.2011.06.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
330 Akyüz N, Keskin M, Akyolcu N, Cavdar İ, Özbaş A, Ayoğlu T, Balık E, Bulut T. How and how much do endoscopy professionals protect themselves against infection? Int J Surg 2014;12:720-4. [PMID: 24859352 DOI: 10.1016/j.ijsu.2014.05.065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
331 Dalrymple LS, Koepsell T, Sampson J, Louie T, Dominitz JA, Young B, Kestenbaum B. Hepatitis C virus infection and the prevalence of renal insufficiency. Clin J Am Soc Nephrol. 2007;2:715-721. [PMID: 17699487 DOI: 10.2215/cjn.00470107] [Cited by in Crossref: 66] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
332 Lin ON, Chang C, Lee J, Do A, Martin M, Martin A, Nguyen MH. HCV Prevalence in Asian Americans in California. J Immigr Minor Health 2017;19:91-7. [PMID: 26798070 DOI: 10.1007/s10903-016-0342-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
333 Rongey CA, Kanwal F, Hoang T, Gifford AL, Asch SM. Viral RNA testing in hepatitis C antibody-positive veterans. Am J Prev Med 2009;36:235-8. [PMID: 19162434 DOI: 10.1016/j.amepre.2008.10.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
334 Strauss SM, Astone-Twerell J, Munoz-Plaza CE, Des Jarlais DC, Gwadz M, Hagan H, Osborne A, Rosenblum A. Drug treatment program patients’ hepatitis C virus (HCV) education needs and their use of available HCV education services. BMC Health Serv Res. 2007;7:39. [PMID: 17346346 DOI: 10.1186/1472-6963-7-39] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 2.4] [Reference Citation Analysis]
335 Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of U.S. veterans to treatment for the hepatitis C virus. Hepatology 2007;46:37-47. [DOI: 10.1002/hep.21662] [Cited by in Crossref: 162] [Cited by in F6Publishing: 164] [Article Influence: 10.8] [Reference Citation Analysis]
336 Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, Brown RS, Belle SH, Hoofnagle JH, Kleiner DE. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131:470-477. [PMID: 16890601 DOI: 10.1053/j.gastro.2006.06.008] [Cited by in Crossref: 378] [Cited by in F6Publishing: 334] [Article Influence: 23.6] [Reference Citation Analysis]
337 Yeboah-Korang A, Beig MI, Khan MQ, Goldstein JL, Macapinlac DM, Maurer D, Sonnenberg A, Fimmel CJ. Hepatitis C Screening in Commercially Insured U.S. Birth-cohort Patients: Factors Associated with Testing and Effect of an EMR-based Screening Alert. J Transl Int Med 2018;6:82-9. [PMID: 29984203 DOI: 10.2478/jtim-2018-0012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
338 Fu R, Gutfraind A, Brandeau ML. Modeling a dynamic bi-layer contact network of injection drug users and the spread of blood-borne infections. Math Biosci 2016;273:102-13. [PMID: 26775738 DOI: 10.1016/j.mbs.2016.01.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
339 Lang M, Treister R, Oaklander AL. Diagnostic value of blood tests for occult causes of initially idiopathic small-fiber polyneuropathy. J Neurol 2016;263:2515-27. [PMID: 27730378 DOI: 10.1007/s00415-016-8270-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
340 Gorgos L. Sexual transmission of viral hepatitis. Infect Dis Clin North Am 2013;27:811-36. [PMID: 24275272 DOI: 10.1016/j.idc.2013.08.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
341 Evon DM, Golin CE, Fried MW, Keefe FJ. Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute? J Consult Clin Psychol 2013;81:361-74. [PMID: 22730952 DOI: 10.1037/a0029030] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
342 Stein MD, Herman DS, Kim HN, Howell A, Lambert A, Madden S, Moitra E, Blevins CE, Anderson BJ, Taylor LE, Pinkston MM. A Randomized Trial Comparing Brief Advice and Motivational Interviewing for Persons with HIV-HCV Co-infection Who Drink Alcohol. AIDS Behav 2021;25:1013-25. [PMID: 33047258 DOI: 10.1007/s10461-020-03062-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
343 Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013;19:850-8. [PMID: 23836235 DOI: 10.1038/nm.3184] [Cited by in Crossref: 205] [Cited by in F6Publishing: 199] [Article Influence: 22.8] [Reference Citation Analysis]
344 Ben-Shlomo A, Mirocha J, Gwin SM, Khine AK, Liu NA, Sheinin RC, Melmed S. Clinical factors associated with biochemical adrenal-cortisol insufficiency in hospitalized patients. Am J Med 2014;127:754-62. [PMID: 24632056 DOI: 10.1016/j.amjmed.2014.03.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
345 Drobnik A, Breskin A, Fuld J, Chan C, Hadler J, Tabaei B, Stennis N, Ahuja S, Wu W, Varma JK. Diabetes Among People With Tuberculosis, HIV Infection, Viral Hepatitis B and C, and STDs in New York City, 2006-2010. J Public Health Manag Pract 2017;23:461-7. [PMID: 27997475 DOI: 10.1097/PHH.0000000000000466] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
346 Guglieri-López B, Ventura-Cerdá JM, Gómez-Álvarez S, Climente-Martí M. [Incidence, management and costs of adverse effects in chronic hepatitis C patients on triple therapy with telaprevir or boceprevir: first 12 weeks of treatment]. Enferm Infecc Microbiol Clin 2015;33:331-6. [PMID: 25128462 DOI: 10.1016/j.eimc.2014.05.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
347 Lee SR, Yearwood GD, Guillon GB, Kurtz LA, Fischl M, Friel T, Berne CA, Kardos KW. Evaluation of a rapid, point-of-care test device for the diagnosis of hepatitis C infection. J Clin Virol 2010;48:15-7. [PMID: 20362493 DOI: 10.1016/j.jcv.2010.02.018] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 4.8] [Reference Citation Analysis]
348 Emokpae MA, Adejumol BG, Abdu A, Sadiq NM. Serum alpha-fetoprotein level is higher in hepatitis C than hepatitis B infected chronic liver disease patients. Niger Med J 2013;54:426-9. [PMID: 24665160 DOI: 10.4103/0300-1652.126302] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
349 Myers RP, Fong A, Shaheen AA. Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies. Liver Int. 2008;28:705-712. [PMID: 18433397 DOI: 10.1111/j.1478-3231.2008.01691.x] [Cited by in Crossref: 138] [Cited by in F6Publishing: 142] [Article Influence: 9.9] [Reference Citation Analysis]
350 Zhou K, Terrault NA. Gaps in Viral Hepatitis Awareness in the United States in a Population-based Study. Clin Gastroenterol Hepatol 2020;18:188-195.e4. [PMID: 31173892 DOI: 10.1016/j.cgh.2019.05.047] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
351 Cox DA, Ginde S, Tweddell JS, Earing MG. Outcomes of a Hepatitis C Screening Protocol in At-Risk Adults With Prior Cardiac Surgery. World J Pediatr Congenit Heart Surg 2014;5:503-6. [DOI: 10.1177/2150135114547587] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
352 Darvish Moghaddam S, Zahedi MJ, Dalili M, Shokoohi M. Compliance of healthcare professionals with safety measures for control of hepatitis viruses in hemodialysis centers: an experience from southeast iran. Hepat Res Treat 2012;2012:415841. [PMID: 23198145 DOI: 10.1155/2012/415841] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
353 Gonik B. The role of obstetrician/gynecologists in the management of hepatitis C virus infection. Infect Dis Obstet Gynecol 2008;2008:374517. [PMID: 18818775 DOI: 10.1155/2008/374517] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
354 Korthuis PT, Feaster DJ, Gomez ZL, Das M, Tross S, Wiest K, Douaihy A, Mandler RN, Sorensen JL, Colfax G. Injection behaviors among injection drug users in treatment: the role of hepatitis C awareness. Addict Behav. 2012;37:552-555. [PMID: 22209655 DOI: 10.1016/j.addbeh.2011.12.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
355 Hayashida K, Shoji I, Deng L, Jiang D, Ide Y, Hotta H. 17β-estradiol inhibits the production of infectious particles of hepatitis C virus: 17β-estradiol inhibits HCV virion production. Microbiology and Immunology 2010;54:684-90. [DOI: 10.1111/j.1348-0421.2010.00268.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
356 Kemmer N, Neff G, Secic M, Zacharias V, Kaiser T, Buell J. Ethnic Differences in Hepatocellular Carcinoma: Implications for Liver Transplantation. Dig Dis Sci 2008;53:551-5. [DOI: 10.1007/s10620-007-9872-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
357 Patel PR, Thompson ND, Kallen AJ, Arduino MJ. Epidemiology, surveillance, and prevention of hepatitis C virus infections in hemodialysis patients. Am J Kidney Dis. 2010;56:371-378. [PMID: 20570422 DOI: 10.1053/j.ajkd.2010.01.025] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 4.3] [Reference Citation Analysis]
358 Mencin A, Kluwe J, Schwabe RF. Toll-like receptors as targets in chronic liver diseases. Gut. 2009;58:704-720. [PMID: 19359436 DOI: 10.1136/gut.2008.156307] [Cited by in Crossref: 225] [Cited by in F6Publishing: 226] [Article Influence: 17.3] [Reference Citation Analysis]
359 Baillargeon J, Snyder N, Soloway RD, Paar D, Baillargeon G, Spaulding AC, Pollock BH, Arcari CM, Williams BA, Raimer BG. Hepatocellular carcinoma prevalence and mortality in a male state prison population. Public Health Rep 2009;124:120-6. [PMID: 19413034 DOI: 10.1177/003335490912400115] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
360 Matsushita H, Takaki A. Alcohol and hepatocellular carcinoma. BMJ Open Gastroenterol 2019;6:e000260. [PMID: 31139422 DOI: 10.1136/bmjgast-2018-000260] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
361 Chowdhury JB, Kim H, Ray R, Ray RB. Hepatitis C virus NS5A protein modulates IRF-7-mediated interferon-α signaling. J Interferon Cytokine Res 2014;34:16-21. [PMID: 23962002 DOI: 10.1089/jir.2013.0038] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
362 Wang J, Liu J, Huang Y, Wright DJ, Li J, Zhou Z, He W, Yang T, Yao F, Zhu X, Wen G, Bi X, Tiemuer M, Wen X, Huang M, Cao R, Yun Z, Lü Y, Ma H, Guo N, Yu Q, Ness P, Shan H; NHLBI Retrovirus Epidemiology Donor Study-II (REDS-II) International Component. The persistence of hepatitis C virus transmission risk in China despite serologic screening of blood donations: Hepatitis C in Chinese Blood Donors. Transfusion 2013;53:2489-97. [DOI: 10.1111/trf.12297] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
363 Pandya P, Rzouq F, Oni O. Sustained virologic response and other potential genotype-specific roles of statins among patients with hepatitis C-related chronic liver diseases. Clin Res Hepatol Gastroenterol. 2015;39:555-565. [PMID: 25835493 DOI: 10.1016/j.clinre.2015.02.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
364 Yokoo T, Wolfson T, Iwaisako K, Peterson MR, Mani H, Goodman Z, Changchien C, Middleton MS, Gamst AC, Mazhar SM, Kono Y, Ho SB, Sirlin CB. Evaluation of Liver Fibrosis Using Texture Analysis on Combined-Contrast-Enhanced Magnetic Resonance Images at 3.0T. Biomed Res Int 2015;2015:387653. [PMID: 26421287 DOI: 10.1155/2015/387653] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
365 Ai T, Qiu L, Xie J, Geraghty RJ, Chen L. Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid. Bioorg Med Chem 2016;24:686-92. [PMID: 26753813 DOI: 10.1016/j.bmc.2015.12.035] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
366 Jemal A, Simard EP, Xu J, Ma J, Anderson RN. Selected cancers with increasing mortality rates by educational attainment in 26 states in the United States, 1993–2007. Cancer Causes Control 2013;24:559-65. [DOI: 10.1007/s10552-012-9993-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
367 Sterling RK, Chiu S, Snider K, Nixon D. The prevalence and risk factors for abnormal liver enzymes in HIV-positive patients without hepatitis B or C coinfections. Dig Dis Sci 2008;53:1375-82. [PMID: 17939038 DOI: 10.1007/s10620-007-9999-6] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 3.2] [Reference Citation Analysis]
368 Lynch SM, Wilson SM, DeRycke EC, Driscoll MA, Becker WC, Goulet JL, Kerns RD, Mattocks KM, Brandt CA, Bathulapalli H, Skanderson M, Haskell SG, Bastian LA. Impact of Cigarette Smoking Status on Pain Intensity Among Veterans With and Without Hepatitis C. Pain Med 2018;19:S5-S11. [PMID: 30203017 DOI: 10.1093/pm/pny146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
369 Baeg JY, Kim IH, Seo SY, Kim YS, Jung EU, Cho J, Chung JW, Jang ES, Kim JW, Jeong SH. Prevalence and Incidence of Depression during Interferon-Based Antiviral Therapy in Chronic Hepatitis C Patients in the Republic of Korea. Gut Liver 2017;11:426-33. [PMID: 28335101 DOI: 10.5009/gnl16242] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
370 Putka B, Mullen K, Birdi S, Merheb M. The disposition of hepatitis C antibody-positive patients in an urban hospital. J Viral Hepat 2009;16:814-21. [PMID: 19842281 DOI: 10.1111/j.1365-2893.2009.01137.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
371 Lisker-Melman M, Walewski JL. The impact of ethnicity on hepatitis C virus treatment decisions and outcomes. Dig Dis Sci 2013;58:621-9. [PMID: 23065087 DOI: 10.1007/s10620-012-2392-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
372 Hamburg-Shields E, Prasad M. Infectious Hepatitis in Pregnancy. Clin Obstet Gynecol 2020;63:175-92. [PMID: 31895116 DOI: 10.1097/GRF.0000000000000512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
373 Arora S, Thornton K, Jenkusky SM, Parish B, Scaletti JV. Project ECHO: linking university specialists with rural and prison-based clinicians to improve care for people with chronic hepatitis C in New Mexico. Public Health Rep 2007;122 Suppl 2:74-7. [PMID: 17542458 DOI: 10.1177/00333549071220S214] [Cited by in Crossref: 90] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
374 Kichatova VS, Kyuregyan KK, Soboleva NV, Karlsen AA, Isaeva OV, Isaguliants MG, Mikhailov MI. Frequency of Interferon-Resistance Conferring Substitutions in Amino Acid Positions 70 and 91 of Core Protein of the Russian HCV 1b Isolates Analyzed in the T-Cell Epitopic Context. J Immunol Res 2018;2018:7685371. [PMID: 29577052 DOI: 10.1155/2018/7685371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
375 Burman BE, Bacchetti P, Khalili M. Moderate Alcohol Use and Insulin Action in Chronic Hepatitis C Infection. Dig Dis Sci 2016;61:2417-25. [PMID: 27007134 DOI: 10.1007/s10620-016-4119-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
376 Bader el-Din NG, Abd el-Meguid M, Tabll AA, Anany MA, Esmat G, Zayed N, Helmy A, el-Zayady AR, Barakat A, el-Awady MK. Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy. J Gastroenterol Hepatol. 2011;26:55-62. [PMID: 21175794 DOI: 10.1111/j.1440-1746.2010.06319.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
377 Zhu SS, Zeng QL, Dong Y, Xu ZQ, Wang LM, Chen DW, Gan Y, Wang FC, Yan JG, Cao LL, Wang P, Han J, Zhang XX, Zhang Z, Zhang HF, Wang FS. Interferon-α plus ribavirin yields 98 % sustained virologic response in children aged 1-5 years with iatrogenic chronic hepatitis C. Hepatol Int 2015;9:578-85. [PMID: 26449425 DOI: 10.1007/s12072-015-9671-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
378 Billington S, Ray AS, Salphati L, Xiao G, Chu X, Humphreys WG, Liao M, Lee CA, Mathias A, Hop CECA, Rowbottom C, Evers R, Lai Y, Kelly EJ, Prasad B, Unadkat JD. Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS Proteomics. Drug Metab Dispos 2018;46:189-96. [PMID: 29138286 DOI: 10.1124/dmd.117.077289] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
379 Graham CS, Swan T. A path to eradication of hepatitis C in low- and middle-income countries. Antiviral Res. 2015;119:89-96. [PMID: 25615583 DOI: 10.1016/j.antiviral.2015.01.004] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 9.0] [Reference Citation Analysis]
380 Stephens DB, Havens JR. Predictors of alcohol use among rural drug users after disclosure of hepatitis C virus status. J Stud Alcohol Drugs 2013;74:386-95. [PMID: 23490567 DOI: 10.15288/jsad.2013.74.386] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
381 Smith BD, Jewett A, Drobeniuc J, Kamili S. Rapid diagnostic HCV antibody assays. Antivir Ther 2012;17:1409-13. [PMID: 23322678 DOI: 10.3851/IMP2470] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
382 Cartwright EJ, Miller L. Novel drugs in the management of difficult-to-treat hepatitis C genotypes. Hepatic Medicine: Evidence and Research. 2013;5:53-61. [PMID: 24696624 DOI: 10.2147/hmer.s48545] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
383 Tsioris K, Gupta NT, Ogunniyi AO, Zimnisky RM, Qian F, Yao Y, Wang X, Stern JN, Chari R, Briggs AW, Clouser CR, Vigneault F, Church GM, Garcia MN, Murray KO, Montgomery RR, Kleinstein SH, Love JC. Neutralizing antibodies against West Nile virus identified directly from human B cells by single-cell analysis and next generation sequencing. Integr Biol (Camb) 2015;7:1587-97. [PMID: 26481611 DOI: 10.1039/c5ib00169b] [Cited by in Crossref: 54] [Cited by in F6Publishing: 32] [Article Influence: 7.7] [Reference Citation Analysis]
384 Kuniholm MH, Anastos K, Kovacs A, Gao X, Marti D, Sette A, Greenblatt RM, Peters M, Cohen MH, Minkoff H, Gange SJ, Thio CL, Young MA, Xue X, Carrington M, Strickler HD. Relation of HLA class I and II supertypes with spontaneous clearance of hepatitis C virus. Genes Immun 2013;14:330-5. [PMID: 23636221 DOI: 10.1038/gene.2013.25] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
385 Singal AK, Jampana SC, Anand BS. Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials. Dig Dis Sci. 2011;56:2221-2226. [PMID: 21643737 DOI: 10.1007/s10620-011-1765-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
386 Bonkovsky HL, Tice AD, Yapp RG, Bodenheimer HC, Monto A, Rossi SJ, Sulkowski MS. Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. Am J Gastroenterol. 2008;103:2757-2765. [PMID: 18684176 DOI: 10.1111/j.1572-0241.2008.02065.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
387 Liu S, Schwarzinger M, Carrat F, Goldhaber-Fiebert JD. Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients. PLoS One. 2011;6:e26783. [PMID: 22164204 DOI: 10.1371/journal.pone.0026783] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
388 Mallette C, Flynn MA, Promrat K. Outcome of Screening for Hepatitis C Virus Infection Based on Risk Factors. Am J Gastroenterol 2008;103:131-7. [DOI: 10.1111/j.1572-0241.2007.01522.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
389 Ho EY, Ha NB, Ahmed A, Ayoub W, Daugherty T, Garcia G, Cooper A, Keeffe EB, Nguyen MH. Prospective study of risk factors for hepatitis C virus acquisition by Caucasian, Hispanic, and Asian American patients. J Viral Hepat 2012;19:e105-11. [PMID: 22239506 DOI: 10.1111/j.1365-2893.2011.01513.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
390 Florian J, Mishra P, Arya V, Harrington P, Connelly S, Reynolds K, Sinha V. Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now. Clin Pharmacol Ther 2015;98:394-402. [DOI: 10.1002/cpt.185] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
391 Coyle C, Kwakwa H, Viner K. Integrating Routine HCV Testing in Primary Care: Lessons Learned from Five Federally Qualified Health Centers in Philadelphia, Pennsylvania, 2012-2014. Public Health Rep 2016;131 Suppl 2:65-73. [PMID: 27168664 DOI: 10.1177/00333549161310S211] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 4.6] [Reference Citation Analysis]
392 Tsui JI, Cheng DM, Libman H, Bridden C, Saitz R, Samet JH. Risky alcohol use and serum aminotransferase levels in HIV-infected adults with and without hepatitis C. J Stud Alcohol Drugs 2013;74:266-70. [PMID: 23384374 DOI: 10.15288/jsad.2013.74.266] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
393 Selvarajah S, Keating S, Heitman J, Lu K, Simmons G, Norris PJ, Operskalski E, Mosley JW, Busch MP. Detection of host immune responses in acute phase sera of spontaneous resolution versus persistent hepatitis C virus infection. J Gen Virol 2012;93:1673-9. [PMID: 22535775 DOI: 10.1099/vir.0.041277-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
394 Krajden M, Yu A, Braybrook H, Lai AS, Mak A, Chow R, Cook D, Tellier R, Petric M, Gascoyne RD, Connors JM, Brooks-Wilson AR, Gallagher RP, Spinelli JJ. GBV-C/hepatitis G virus infection and non-Hodgkin lymphoma: a case control study. Int J Cancer 2010;126:2885-92. [PMID: 19904755 DOI: 10.1002/ijc.25035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 20] [Article Influence: 0.4] [Reference Citation Analysis]
395 Everson GT, Martucci MA, Shiffman ML, Sterling RK, Morgan TR, Hoefs JC; HALT-C trial group. Portal-systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shunt. Aliment Pharmacol Ther 2007;26:401-10. [PMID: 17635375 DOI: 10.1111/j.1365-2036.2007.03389.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
396 Kyuregyan KK, Malinnikova EY, Soboleva NV, Isaeva OV, Karlsen AA, Kichatova VS, Potemkin IA, Schibrik EV, Gadjieva OA, Bashiryan BA, Lebedeva NN, Serkov IL, Yankina A, Galli C, Mikhailov MI. Community screening for hepatitis C virus infection in a low-prevalence population. BMC Public Health 2019;19:1038. [PMID: 31375104 DOI: 10.1186/s12889-019-7388-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
397 Golabi P, Otgonsuren M, Suen W, Koenig AB, Noor B, Younossi ZM. Predictors of Inpatient Mortality and Resource Utilization for the Elderly Patients With Chronic Hepatitis C (CH-C) in the United States. Medicine (Baltimore) 2016;95:e2482. [PMID: 26817883 DOI: 10.1097/MD.0000000000002482] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
398 Shen Y, Risch H, Lu L, Ma X, Irwin ML, Lim JK, Taddei T, Pawlish K, Stroup A, Brown R, Wang Z, Jia W, Wong L, Mayne ST, Yu H. Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a case-control study. Cancer Causes Control 2020;31:321-32. [PMID: 32060838 DOI: 10.1007/s10552-020-01277-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
399 Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10:553-562. [PMID: 23817321 DOI: 10.1038/nrgastro.2013.107] [Cited by in Crossref: 625] [Cited by in F6Publishing: 583] [Article Influence: 69.4] [Reference Citation Analysis]
400 Goldberg D, Lewis J, Halpern S, Weiner M, Lo Re V 3rd. Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database. Pharmacoepidemiol Drug Saf 2012;21:765-9. [PMID: 22674685 DOI: 10.1002/pds.3290] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 9.3] [Reference Citation Analysis]
401 Tran HA, Jones TL, Ianna EA, Foy A, Reeves GE. Thyroid disease in chronic hepatitis C infection treated with combination interferon-α and ribavirin: management strategies and future perspective. Endocr Pract 2013;19:292-300. [PMID: 23186968 DOI: 10.4158/EP12195.RA] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
402 Frimpong JA, D'Aunno T, Perlman DC, Strauss SM, Mallow A, Hernandez D, Schackman BR, Feaster DJ, Metsch LR. On-site bundled rapid HIV/HCV testing in substance use disorder treatment programs: study protocol for a hybrid design randomized controlled trial. Trials 2016;17:117. [PMID: 26936623 DOI: 10.1186/s13063-016-1225-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
403 Osinusi A, Naggie S, Poonia S, Trippler M, Hu Z, Funk E, Schlaak J, Fishbein D, Masur H, Polis M. ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV. J Med Virol. 2012;84:1106-1114. [PMID: 22585729 DOI: 10.1002/jmv.23302] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
404 Russell M, Pauly MP, Moore CD, Chia C, Dorrell J, Cunanan RJ, Witt G, Martin S. The impact of lifetime alcohol use on hepatitis C treatment outcomes in privately insured members of an integrated health care plan. Hepatology 2012;56:1223-30. [PMID: 22488513 DOI: 10.1002/hep.25755] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
405 Kemmer N, Neff GW. Liver Transplantation in the Ethnic Minority Population: Challenges and Prospects. Dig Dis Sci 2010;55:883-9. [DOI: 10.1007/s10620-009-0803-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
406 Chen EY, Lee WM, Hynan LS, Singal AG. A survey of hepatitis C treatment clinical practice patterns using the newly approved protease inhibitors. J Clin Gastroenterol 2013;47:800-6. [PMID: 23470640 DOI: 10.1097/MCG.0b013e31828a37c0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
407 Rinella ME. Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease? Hepatology 2011;54:1118-20. [DOI: 10.1002/hep.24634] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
408 Bonner JE, Esserman DA, Golin CE, Evon DM. Self-efficacy and adherence to antiviral treatment for chronic hepatitis C. J Clin Gastroenterol 2015;49:76-83. [PMID: 24356458 DOI: 10.1097/MCG.0000000000000055] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
409 Forde KA, Haynes K, Troxel AB, Trooskin S, Osterman MT, Kimmel SE, Lewis JD, Lo Re V. Risk of myocardial infarction associated with chronic hepatitis C virus infection: a population-based cohort study. J Viral Hepat. 2012;19:271-277. [PMID: 22404725 DOI: 10.1111/j.1365-2893.2011.01545] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
410 Amodio P, Salari L, Montagnese S, Schiff S, Neri D, Bianco T, Minazzato L. Hepatitis C virus infection and health-related quality of life. World J Gastroenterol 2012; 18(19): 2295-2299 [PMID: 22654420 DOI: 10.3748/wjg.v18.i19.2295] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
411 Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, Tanaka J. Long-term prognosis of patients with chronic hepatitis C who did not receive interferon-based therapy: causes of death and analysis based on the FIB-4 index. J Gastroenterol 2016;51:380-9. [DOI: 10.1007/s00535-015-1117-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
412 Luxon BA. Training for a Career in Hepatology: Which Path to Take? Curr Gastroenterol Rep 2010;12:76-81. [DOI: 10.1007/s11894-009-0086-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
413 Carney K, Dhalla S, Aytaman A, Tenner CT, Francois F. Association of tattooing and hepatitis C virus infection: a multicenter case-control study. Hepatology. 2013;57:2117-2123. [PMID: 23315899 DOI: 10.1002/hep.26245] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 4.7] [Reference Citation Analysis]
414 Smith BD, Yartel AK, Krauskopf K, Massoud OI, Brown KA, Fallon MB, Rein DB. Hepatitis C virus antibody positivity and predictors among previously undiagnosed adult primary care outpatients: cross-sectional analysis of a multisite retrospective cohort study. Clin Infect Dis 2015;60:1145-52. [PMID: 25595745 DOI: 10.1093/cid/civ002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
415 Kramer JR, Kanwal F, Richardson P, Mei M, El-serag HB. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. Journal of Hepatology 2012;56:320-5. [DOI: 10.1016/j.jhep.2011.05.032] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 7.3] [Reference Citation Analysis]
416 Gutelius B, Perz JF, Parker MM, Hallack R, Stricof R, Clement EJ, Lin Y, Xia GL, Punsalang A, Eramo A. Multiple clusters of hepatitis virus infections associated with anesthesia for outpatient endoscopy procedures. Gastroenterology. 2010;139:163-170. [PMID: 20353790 DOI: 10.1053/j.gastro.2010.03.053] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
417 Beckwith CG, Larney S, Flanigan TP. Editorial commentary: Hepatitis C virus testing and drug use in north america; is there more than meets the eye? Clin Infect Dis 2014;58:762-4. [PMID: 24363330 DOI: 10.1093/cid/cit941] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
418 Funk E, Kottilil S, Gilliam B, Talwani R. Tickling the TLR7 to cure viral hepatitis. J Transl Med 2014;12:129. [PMID: 24884741 DOI: 10.1186/1479-5876-12-129] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
419 Ilyas JA, Vierling JM. An Overview of Emerging Therapies for the Treatment of Chronic Hepatitis C. Clinics in Liver Disease 2011;15:515-36. [DOI: 10.1016/j.cld.2011.05.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
420 Kumar S, Deo SV, Altarabsheh SE, Dunlay SM, Sarabu N, Sareyyupoglu B, Elgudin Y, Medalion B, Elamm C, Ginwalla M, Zacharias M, Benatti R, Oliveira GH, Kilic A, Fonarow GC, Park SJ. Effect of Hepatitis C Positivity on Survival in Adult Patients Undergoing Heart Transplantation (from the United Network for Organ Sharing Database). The American Journal of Cardiology 2016;118:132-7. [DOI: 10.1016/j.amjcard.2016.04.023] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
421 Liu S, Brandeau ML, Goldhaber-Fiebert JD. Optimizing patient treatment decisions in an era of rapid technological advances: the case of hepatitis C treatment. Health Care Manag Sci 2017;20:16-32. [PMID: 26188961 DOI: 10.1007/s10729-015-9330-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
422 Macías J, Palacios RB, Claro E, Vargas J, Vergara S, Mira JA, Merchante N, Corzo JE, Pineda JA. High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack: HCV infection among noninjecting drug users. Liver International 2008;28:781-6. [DOI: 10.1111/j.1478-3231.2008.01688.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 4.3] [Reference Citation Analysis]
423 Shoreibah M, Orr J, Jones D, Zhang J, Venkata K, Massoud O. Ledipasvir/sofosbuvir without ribavirin is effective in the treatment of recurrent hepatitis C virus infection post-liver transplant. Hepatol Int 2017;11:434-9. [PMID: 28083718 DOI: 10.1007/s12072-016-9778-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
424 Parboosing R, Paruk I, Lalloo UG. Hepatitis C virus seropositivity in a South African Cohort of HIV co-infected, ARV naïve patients is associated with renal insufficiency and increased mortality. J Med Virol 2008;80:1530-6. [DOI: 10.1002/jmv.21262] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
425 Gane E. Future hepatitis C virus treatment: interferon-sparing combinations. Liver Int. 2011;31 Suppl 1:62-67. [PMID: 21205140 DOI: 10.1111/j.1478-3231.2010.02383.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
426 Ray SC, Thomas DL. Hepatitis C. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier; 2010. pp. 2157-85. [DOI: 10.1016/b978-0-443-06839-3.00154-5] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
427 Jonas MC, Rodriguez CV, Redd J, Sloane DA, Winston BJ, Loftus BC. Streamlining Screening to Treatment: The Hepatitis C Cascade of Care at Kaiser Permanente Mid-Atlantic States. Clin Infect Dis 2016;62:1290-6. [PMID: 26908812 DOI: 10.1093/cid/ciw086] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
428 Osna NA, Ganesan M, Donohue TM. Proteasome- and ethanol-dependent regulation of HCV-infection pathogenesis. Biomolecules 2014;4:885-96. [PMID: 25268065 DOI: 10.3390/biom4040885] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
429 Costa ZB, Machado GC, Avelino MM, Gomes Filho C, Macedo Filho JV, Minuzzi AL, Turchi MD, Stefani MM, de Souza WV, Martelli CM. Prevalence and risk factors for Hepatitis C and HIV-1 infections among pregnant women in Central Brazil. BMC Infect Dis 2009;9:116. [PMID: 19635135 DOI: 10.1186/1471-2334-9-116] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
430 Hagan LM, Schinazi RF. Best strategies for global HCV eradication. Liver Int. 2013;33 Suppl 1:68-79. [PMID: 23286849 DOI: 10.1111/liv.12063] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 7.2] [Reference Citation Analysis]
431 Galbraith JW, Donnelly JP, Franco RA, Overton ET, Rodgers JB, Wang HE. National estimates of healthcare utilization by individuals with hepatitis C virus infection in the United States. Clin Infect Dis 2014;59:755-64. [PMID: 24917659 DOI: 10.1093/cid/ciu427] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 6.8] [Reference Citation Analysis]
432 Cook MB, Dawsey SM, Freedman ND, Inskip PD, Wichner SM, Quraishi SM, Devesa SS, McGlynn KA. Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev 2009;18:1174-82. [PMID: 19293308 DOI: 10.1158/1055-9965.EPI-08-1118] [Cited by in Crossref: 230] [Cited by in F6Publishing: 121] [Article Influence: 17.7] [Reference Citation Analysis]
433 Yarbrough ML, Burnham CA. The ABCs of STIs: An Update on Sexually Transmitted Infections. Clin Chem 2016;62:811-23. [PMID: 27076632 DOI: 10.1373/clinchem.2015.240234] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
434 Chowdhury R, Chaudhary MA, Sturgeon DJ, Jiang W, Yau AL, Koehlmoos TP, Haider AH, Schoenfeld AJ. The impact of hepatitis C virus infection on 90-day outcomes following major orthopaedic surgery: a propensity-matched analysis. Arch Orthop Trauma Surg 2017;137:1181-6. [PMID: 28674736 DOI: 10.1007/s00402-017-2742-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
435 Chhatwal J, Chen Q, Ayer T, Bethea ED, Kanwal F, Kowdley KV, Wang X, Roberts MS, Gordon SC. Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA. Aliment Pharmacol Ther 2018;47:1023-31. [PMID: 29377245 DOI: 10.1111/apt.14527] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
436 Ambrose P, Zepf R, Parrott AH, Dawson-Rose C. Prevalence of Hepatitis C Screening in an HIV Primary Care Clinic. J Assoc Nurses AIDS Care 2017;28:422-7. [PMID: 27939429 DOI: 10.1016/j.jana.2016.10.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
437 Russell M, Chen MJ, Nochajski TH, Testa M, Zimmerman SJ, Hughes PS. Risky sexual behavior, bleeding caused by intimate partner violence, and hepatitis C virus infection in patients of a sexually transmitted disease clinic. Am J Public Health 2009;99 Suppl 1:S173-9. [PMID: 19218181 DOI: 10.2105/AJPH.2007.126383] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
438 Hashimoto S, Yatsuhashi H, Abiru S, Yamasaki K, Komori A, Nagaoka S, Saeki A, Uchida S, Bekki S, Kugiyama Y, Nagata K, Nakamura M, Migita K, Nakao K. Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment. PLoS One. 2016;11:e0163644. [PMID: 27680885 DOI: 10.1371/journal.pone.0163644] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 8.7] [Reference Citation Analysis]
439 Kamal SM, Ghoraba D. Epidemiology and Modes of Transmission of HCV in Developing Countries. Hepatitis C in Developing Countries. Elsevier; 2018. pp. 13-22. [DOI: 10.1016/b978-0-12-803233-6.00002-3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
440 Kim DY, Kim IH, Jeong SH, Cho YK, Lee JH, Jin YJ, Lee D, Suh DJ, Han KH, Park NH, Kang HY, Jung YK, Kim YS, Kim KA, Lee YJ, Lee BS, Yim HJ, Lee HJ, Baik SK, Tak WY, Lee SJ, Chung WJ, Choi SK, Cho EY, Heo J, Kim DJ, Song BC, Kim MW, Lee J, Chae HB, Choi DH, Choi HY, Ki M. A nationwide seroepidemiology of hepatitis C virus infection in South Korea. Liver Int 2013;33:586-94. [PMID: 23356674 DOI: 10.1111/liv.12108] [Cited by in Crossref: 69] [Cited by in F6Publishing: 61] [Article Influence: 7.7] [Reference Citation Analysis]
441 Daw MA, El-Bouzedi A, Dau AA. Geographic distribution of HCV genotypes in Libya and analysis of risk factors involved in their transmission. BMC Res Notes. 2015;8:367. [PMID: 26293137 DOI: 10.1186/s13104-015-1310-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
442 El-Kamary SS, Hashem M, Saleh DA, Ehab M, Sharaf SA, El-Mougy F, Abdelsalam L, Jhaveri R, Aboulnasr A, El-Ghazaly H. Reliability of risk-based screening for hepatitis C virus infection among pregnant women in Egypt. J Infect. 2015;70:512-519. [PMID: 25623176 DOI: 10.1016/j.jinf.2015.01.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
443 Gale HB, Dufour DR, Qazi NN, Kan VL. Comparison of serial Hepatitis C virus detection in samples submitted through serology for reflex confirmation versus samples directly submitted for quantitation. J Clin Microbiol 2011;49:3036-9. [PMID: 21653774 DOI: 10.1128/JCM.00577-11] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
444 Prussing C, Bornschlegel K, Balter S. Hepatitis C surveillance among youth and young adults in New York City, 2009-2013. J Urban Health 2015;92:387-99. [PMID: 25450518 DOI: 10.1007/s11524-014-9920-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
445 Assoumou SA, Huang W, Horsburgh CR, Mus, Linas BP. Quality of hepatitis C care at an urban tertiary care medical center. J Health Care Poor Underserved 2014;25:705-16. [PMID: 24858880 DOI: 10.1353/hpu.2014.0093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
446 Rhodes AG, Taxman FS, Friedmann PD, Cropsey KL. HCV in incarcerated populations: an analysis of gender and criminality on risk. J Psychoactive Drugs 2008;40:493-501. [PMID: 19283953 DOI: 10.1080/02791072.2008.10400655] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
447 Echevarria D, Gutfraind A, Boodram B, Layden J, Ozik J, Page K, Cotler SJ, Major M, Dahari H. Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago. Vaccine 2019;37:2608-16. [PMID: 30962092 DOI: 10.1016/j.vaccine.2019.02.081] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
448 Muir AJ. The rapid evolution of treatment strategies for hepatitis C. Am J Gastroenterol. 2014;109:628-635; quiz 636. [PMID: 24732866 DOI: 10.1038/ajg.2014.66] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 7.4] [Reference Citation Analysis]
449 Dahal S, Upadhyay S, Banjade R, Dhakal P, Khanal N, Bhatt VR. Thrombocytopenia in Patients with Chronic Hepatitis C Virus Infection. Mediterr J Hematol Infect Dis. 2017;9:e2017019. [PMID: 28293407 DOI: 10.4084/mjhid.2017.019] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
450 Cannon NA, Donlin MJ, Fan X, Aurora R, Tavis JE; Virahep-C Study Group. Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy. PLoS One 2008;3:e2123. [PMID: 18463735 DOI: 10.1371/journal.pone.0002123] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
451 Dehesa-Violante M, Nuñez-Nateras R. Epidemiology of hepatitis virus B and C. Arch Med Res 2007;38:606-11. [PMID: 17613351 DOI: 10.1016/j.arcmed.2007.03.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
452 Luo R, Greenberg A, Stone CD. Increasing Volume but Decreasing Mortality of Hospitalized Hepatitis C Patients in the United States, 2005 to 2011. J Clin Gastroenterol 2015;49:620-7. [PMID: 25203363 DOI: 10.1097/MCG.0000000000000216] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
453 Van der Poorten D, Kenny DT, Butler T, George J. Liver disease in adolescents: A cohort study of high-risk individuals. Hepatology 2007;46:1750-8. [DOI: 10.1002/hep.21918] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
454 Gupta S, Singh R. Analysis of the virus dynamics model reveals that early treatment of HCV infection may lead to the sustained virological response. PLoS One 2012;7:e41209. [PMID: 22911761 DOI: 10.1371/journal.pone.0041209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
455 Harzke AJ, Baillargeon JG, Kelley MF, Diamond PM, Goodman KJ, Paar DP. HCV-related mortality among male prison inmates in Texas, 1994-2003. Ann Epidemiol 2009;19:582-9. [PMID: 19443239 DOI: 10.1016/j.annepidem.2009.03.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
456 Oster AM, Sternberg M, Nebenzahl S, Broz D, Xu F, Hariri S, Miles I, Paz-bailey G. Prevalence of HIV, Sexually Transmitted Infections, and Viral Hepatitis by Urbanicity, Among Men Who Have Sex With Men, Injection Drug Users, and Heterosexuals in the United States. Sexually Transmitted Diseases 2014;41:272-9. [DOI: 10.1097/olq.0000000000000110] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
457 Stasi R, Willis F, Shannon MS, Gordon-Smith EC. Infectious causes of chronic immune thrombocytopenia. Hematol Oncol Clin North Am. 2009;23:1275-1297. [PMID: 19932434 DOI: 10.1016/j.hoc.2009.08.009] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
458 Tran HA. Hepatitis C Infection, Treatment Regimens, and Thyroid Function Abnormalities: . The Endocrinologist 2007;17:231-5. [DOI: 10.1097/ten.0b013e3180dc91d3] [Cited by in Crossref: 10] [Article Influence: 0.7] [Reference Citation Analysis]
459 Lagios K, Deane FP. Severe mental illness is a new risk marker for blood-borne viruses and sexually transmitted infections. Australian and New Zealand Journal of Public Health 2007;31:562-6. [DOI: 10.1111/j.1753-6405.2007.00144.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
460 Vezali E, Aghemo A, Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther. 2010;32:2117-2138. [PMID: 21316532 DOI: 10.1016/s0149-2918(11)00022-1] [Cited by in Crossref: 75] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
461 Rodrigo C, Eltahla AA, Bull RA, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Morris MD, Cox AL, Osburn W, Kim AY, Schinkel J, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Estes C, Razavi H, Lloyd AR, Luciani F; International Collaborative of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study Group. Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia. J Infect Dis 2016;214:1383-9. [PMID: 27571901 DOI: 10.1093/infdis/jiw389] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
462 El-amine H, Bish EK, Bish DR. Robust Postdonation Blood Screening Under Prevalence Rate Uncertainty. Operations Research 2018;66:1-17. [DOI: 10.1287/opre.2017.1658] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.8] [Reference Citation Analysis]
463 Currie SL, Ryan JC, Tracy D, Wright TL, George S, McQuaid R, Kim M, Shen H, Monto A. A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. Drug Alcohol Depend 2008;93:148-54. [PMID: 17977668 DOI: 10.1016/j.drugalcdep.2007.09.011] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.2] [Reference Citation Analysis]
464 Schaeffer S, Khalili M. Reasons for HCV non-treatment in underserved African Americans: Implications for treatment with new therapeutics. Annals of Hepatology 2015;14:234-42. [DOI: 10.1016/s1665-2681(19)30786-0] [Cited by in Crossref: 13] [Article Influence: 1.9] [Reference Citation Analysis]
465 O'connell RJ, Gates RG, Bautista CT, Imbach M, Eggleston JC, Beardsley SG, Manak MM, Gonzales R, Rentas FJ, Macdonald VW, Cardo LJ, Reiber DT, Stramer SL, Michael NL, Peel SA. Laboratory evaluation of rapid test kits to detect hepatitis C antibody for use in predonation screening in emergency settings: HCV RAPID TESTS FOR PREDONATION SCREEN. Transfusion 2013;53:505-17. [DOI: 10.1111/j.1537-2995.2012.03770.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
466 Mostafa A, Taylor SM, El-daly M, El Hoseiny M, Bakr I, Arafa N, Thiers V, Rimlinger F, Abdel-hamid M, Fontanet A, Mohamed MK. Is the hepatitis C virus epidemic over in Egypt? Incidence and risk factors of new hepatitis C virus infections. Liver International 2010;30:560-6. [DOI: 10.1111/j.1478-3231.2009.02204.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 3.7] [Reference Citation Analysis]
467 Bialek SR, Terrault NA. The Changing Epidemiology and Natural History of Hepatitis C Virus Infection. Clinics in Liver Disease 2006;10:697-715. [DOI: 10.1016/j.cld.2006.08.003] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 4.6] [Reference Citation Analysis]
468 Heslin KC, Guerrero EG, Mitchell MN, Afable MK, Dobalian A. Explaining Differences in Hepatitis C Between U.S. Veterans and Nonveterans in Treatment for Substance Abuse: Results From a Regression Decomposition. Substance Use & Misuse 2013;48:854-62. [DOI: 10.3109/10826084.2013.808222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
469 Coffin PO, Stevens AM, Scott JD, Stekler JD, Golden MR. Patient acceptance of universal screening for hepatitis C virus infection. BMC Infect Dis 2011;11:160. [PMID: 21645388 DOI: 10.1186/1471-2334-11-160] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
470 Rose L, Bias TE, Mathias CB, Trooskin SB, Fong JJ. Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C Infection. Ann Pharmacother. 2014;48:1019-1029. [PMID: 24811396 DOI: 10.1177/1060028014534194] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
471 Liang TJ. Current progress in development of hepatitis C virus vaccines. Nat Med. 2013;19:869-878. [PMID: 23836237 DOI: 10.1038/nm.3183] [Cited by in Crossref: 115] [Cited by in F6Publishing: 109] [Article Influence: 12.8] [Reference Citation Analysis]
472 Tomaszewski KJ, Deniz B, Tomanovich P, Graham CS. Comparison of current US risk strategy to screen for hepatitis C virus with a hypothetical targeted birth cohort strategy. Am J Public Health 2012;102:e101-6. [PMID: 22813094 DOI: 10.2105/AJPH.2011.300488] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
473 Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice. Aliment Pharmacol Ther 2016;44:400-10. [DOI: 10.1111/apt.13696] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 9.0] [Reference Citation Analysis]
474 Horowitz JM, Kamel IR, Arif-tiwari H, Asrani SK, Hindman NM, Kaur H, Mcnamara MM, Noto RB, Qayyum A, Lalani T. ACR Appropriateness Criteria ® Chronic Liver Disease. Journal of the American College of Radiology 2017;14:S391-405. [DOI: 10.1016/j.jacr.2017.08.045] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
475 Aldawood A, Arabi Y, Aljumah A, Alsaadi A, Rishu A, Aldorzi H, Alqahtani S, Alsultan M, Felemban A. The incidence of venous thromboembolism and practice of deep venous thrombosis prophylaxis in hospitalized cirrhotic patients. Thromb J. 2011;9:1. [PMID: 21244669 DOI: 10.1186/1477-9560-9-1] [Cited by in Crossref: 68] [Cited by in F6Publishing: 53] [Article Influence: 6.2] [Reference Citation Analysis]
476 Tsui JI, Whooley MA, Monto A, Seal K, Tien PC, Shlipak M. Association of hepatitis C virus seropositivity with inflammatory markers and heart failure in persons with coronary heart disease: data from the Heart and Soul study. J Card Fail. 2009;15:451-456. [PMID: 19477406 DOI: 10.1016/j.cardfail.2008.12.003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 2.9] [Reference Citation Analysis]
477 Reid M, Price JC, Tien PC. Hepatitis C Virus Infection in the Older Patient. Infect Dis Clin North Am 2017;31:827-38. [PMID: 29079161 DOI: 10.1016/j.idc.2017.07.014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
478 Stoller EP, Webster NJ, Blixen CE, McCormick RA, Perzynski AT, Kanuch SW, Dawson NV. Lay management of chronic disease: a qualitative study of living with hepatitis C infection. Am J Health Behav 2009;33:376-90. [PMID: 19182983 DOI: 10.5993/ajhb.33.4.4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
479 Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology. 2008;47:1128-1135. [PMID: 18318441 DOI: 10.1002/hep.22165] [Cited by in Crossref: 150] [Cited by in F6Publishing: 144] [Article Influence: 10.7] [Reference Citation Analysis]
480 Rajasekaran A, Franco RA, Overton ET, McGuire BM, Towns GC, Locke JE, Sawinski DL, Bell EK. Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population. Kidney Int Rep 2021;6:1788-98. [PMID: 34307975 DOI: 10.1016/j.ekir.2021.04.015] [Reference Citation Analysis]
481 Xiang X, Lu J, Dong Z, Zhou H, Tao W, Guo Q, Zhou X, Bao S, Xie Q, Zhong J. Viral sequence evolution in Chinese genotype 1b chronic hepatitis C patients experiencing unsuccessful interferon treatment. Infect Genet Evol 2011;11:382-90. [PMID: 21147266 DOI: 10.1016/j.meegid.2010.11.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
482 Kapadia SN, Marks KM. Hepatitis C Management Simplification From Test to Cure: A Framework for Primary Care Providers. Clin Ther 2018;40:1234-45. [PMID: 29983266 DOI: 10.1016/j.clinthera.2018.05.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
483 Holmberg SD, Lu M, Rupp LB, Lamerato LE, Moorman AC, Vijayadeva V, Boscarino JA, Henkle EM, Gordon SC. Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort. Clin Infect Dis. 2013;57:240-246. [PMID: 23592832 DOI: 10.1093/cid/cit245] [Cited by in Crossref: 89] [Cited by in F6Publishing: 93] [Article Influence: 9.9] [Reference Citation Analysis]
484 Rahman S, Wathington D, Waterboer T, Pawlita M, Villa LL, Lazcano-Ponce E, Willhauck-Fleckenstein M, Brenner N, Giuliano AR. Seroprevalence of Chlamydia trachomatis, herpes simplex 2, Epstein-Barr virus, hepatitis C and associated factors among a cohort of men ages 18-70 years from three countries. PLoS One 2021;16:e0253005. [PMID: 34157055 DOI: 10.1371/journal.pone.0253005] [Reference Citation Analysis]
485 Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, Eheman C, Saraiya M, Bandi P, Saslow D. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013;105:175-201. [PMID: 23297039 DOI: 10.1093/jnci/djs491] [Cited by in Crossref: 670] [Cited by in F6Publishing: 609] [Article Influence: 74.4] [Reference Citation Analysis]
486 Angulo P. Noninvasive assessment of fibrosis and steatosis in NASH and ASH. Gastroentérologie Clinique et Biologique 2009;33:940-8. [DOI: 10.1016/j.gcb.2009.08.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
487 Hotho DM, Kreefft K, Groothuismink ZM, Janssen HL, de Knegt RJ, Boonstra A. Natural killer cell activity and function in chronic HCV-infected patients during peg interferon and ribavirin: early effects of active substance use. Antiviral Res 2013;97:347-55. [PMID: 23291200 DOI: 10.1016/j.antiviral.2012.12.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
488 Sautto G, Mancini N, Diotti RA, Solforosi L, Clementi M, Burioni R. Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference. Antiviral Res 2012;96:82-9. [PMID: 22898087 DOI: 10.1016/j.antiviral.2012.07.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
489 Takashima T, Enomoto H, Ninomiya T, Kim SR, Okushin H, Sugano M, Imoto S, Yano Y, Ooka T, Seo Y, Kasugai H, Muramatsu A, Jomura H, Shimomura S, Shindo M, Nakamura H, Aizawa N, Iwata Y, Saito M, Imanishi H, Iijma H, Nishiguchi S. Hepatitis C virus relapse was suppressed by long-term self-injection of low-dose interferon in patients with chronic hepatitis C after pegylated interferon plus ribavirin treatment. Hepatol Res 2014;44:597-607. [PMID: 23639109 DOI: 10.1111/hepr.12153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
490 Adla M, Downey KK, Ahmad J. Hepatic sarcoidosis associated with pegylated interferon alfa therapy for chronic hepatitis C: case report and review of literature. Dig Dis Sci. 2008;53:2810-2812. [PMID: 18320314 DOI: 10.1007/s10620-008-0209-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
491 Tyler D, Nyamathi A, Stein JA, Koniak-Griffin D, Hodge F, Gelberg L. Increasing hepatitis C knowledge among homeless adults: results of a community-based, interdisciplinary intervention. J Behav Health Serv Res 2014;41:37-49. [PMID: 23616250 DOI: 10.1007/s11414-013-9333-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
492 Yu SC, Lin CW. Early-stage splenic diffuse large B-cell lymphoma is highly associated with hepatitis C virus infection. Kaohsiung J Med Sci. 2013;29:150-156. [PMID: 23465418 DOI: 10.1016/j.kjms.2012.08.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
493 Lopata SM, McNeer E, Dudley JA, Wester C, Cooper WO, Carlucci JG, Espinosa CM, Dupont W, Patrick SW. Hepatitis C Testing Among Perinatally Exposed Infants. Pediatrics. 2020;145. [PMID: 32060140 DOI: 10.1542/peds.2019-2482] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
494 Shiina M, Kobayashi K, Hiroishi K, Imawari M. Hepatitis C Patients on Maintenance Hemodialysis Show Complex Immune Disturbances in the Peripheral Blood. Viral Immunology 2013;26:351-6. [DOI: 10.1089/vim.2013.0026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
495 Henderson DK. Does a little bit really go a long way? Infection prevention in ambulatory healthcare facilities. Infect Control Hosp Epidemiol 2011;32:425-7. [PMID: 21515971 DOI: 10.1086/659402] [Reference Citation Analysis]
496 Smith GP. Animal models of cutaneous and hepatic fibrosis. Prog Mol Biol Transl Sci 2012;105:371-409. [PMID: 22137437 DOI: 10.1016/B978-0-12-394596-9.00011-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
497 Hopkins S, Bobardt M, Chatterji U, Garcia-Rivera JA, Lim P, Gallay PA. The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes. Antimicrob Agents Chemother. 2012;56:3888-3897. [PMID: 22585215 DOI: 10.1128/aac.00693-12] [Cited by in Crossref: 40] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
498 Taylor-Young P, Hildebrandt E. The multidimensional burden of hepatitis C and its treatment: a case study. Gastroenterol Nurs 2009;32:180-7. [PMID: 19506434 DOI: 10.1097/SGA.0b013e3181a80655] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
499 Sims OT, Hong BA, Ji S, Pollio DE, North CS. A Systematic Comparison of African American and Non-African American Patients on Psychosocial Aspects of Hepatitis C Infection. J Relig Health 2018;57:1764-70. [PMID: 29411232 DOI: 10.1007/s10943-018-0565-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
500 Bihl F, Bruggmann P, Castro Batänjer E, Dufour JF, Lavanchy D, Müllhaupt B, Negro F, Razavi H, Scheidegger C, Semela D, Semmo N, Blach S. HCV disease burden and population segments in Switzerland. Liver Int 2021. [PMID: 34839578 DOI: 10.1111/liv.15111] [Reference Citation Analysis]
501 Haley SJ, Kreek MJ. A window of opportunity: maximizing the effectiveness of new HCV regimens in the United States with the expansion of the Affordable Care Act. Am J Public Health 2015;105:457-63. [PMID: 25602859 DOI: 10.2105/AJPH.2014.302327] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
502 Le TK, Macaulay D, Kalsekar A, Yuan Y, Sorg RA, Wei J, Wu EQ. Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States. Clin Ther 2015;37:1713-25.e3. [PMID: 26111918 DOI: 10.1016/j.clinthera.2015.05.503] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
503 Mathur AK, Sonnenday CJ, Merion RM. Race and ethnicity in access to and outcomes of liver transplantation: a critical literature review. Am J Transplant 2009;9:2662-8. [PMID: 20021478 DOI: 10.1111/j.1600-6143.2009.02857.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
504 Tyson GL, Kramer JR, Duan Z, Davila JA, Richardson PA, El-Serag HB. Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2013;58:538-545. [PMID: 23505059 DOI: 10.1002/hep.26400] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 5.2] [Reference Citation Analysis]
505 Shrivastava S, Raychoudhuri A, Steele R, Ray R, Ray RB. Knockdown of autophagy enhances the innate immune response in hepatitis C virus-infected hepatocytes. Hepatology. 2011;53:406-414. [PMID: 21274862 DOI: 10.1002/hep.24073] [Cited by in Crossref: 150] [Cited by in F6Publishing: 149] [Article Influence: 13.6] [Reference Citation Analysis]
506 Gish RG, Arora S, Rajender Reddy K, Nelson DR, O’brien C, Xu Y, Murphy B. Virological response and safety outcomes in therapy–naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: A randomized, phase 2 study. Journal of Hepatology 2007;47:51-9. [DOI: 10.1016/j.jhep.2007.02.018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 38] [Article Influence: 2.1] [Reference Citation Analysis]
507 Ward JW. The epidemiology of chronic hepatitis C and one-time hepatitis C virus testing of persons born during 1945 to 1965 in the United States. Clin Liver Dis. 2013;17:1-11. [PMID: 23177279 DOI: 10.1016/j.cld.2012.09.011] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
508 Alpers CE, Smith KD. Cryoglobulinemia and renal disease. Curr Opin Nephrol Hypertens 2008;17:243-9. [PMID: 18408474 DOI: 10.1097/MNH.0b013e3282f8afe2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
509 Forman MS, Valsamakis A. Hepatitis C Virus. In: Jorgensen JH, Carroll KC, Funke G, Pfaller MA, Landry ML, Richter SS, Warnock DW, editors. Manual of Clinical Microbiology. Washington: ASM Press; 2015. pp. 1599-616. [DOI: 10.1128/9781555817381.ch92] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
510 Jung J, Feldman R, Kalidindi Y, Riley T 3rd. Association of Direct-Acting Antiviral Therapy for Hepatitis C With After-Treatment Costs Among Medicare Beneficiaries. JAMA Netw Open 2020;3:e208081. [PMID: 32602909 DOI: 10.1001/jamanetworkopen.2020.8081] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
511 Drainoni ML, Litwin AH, Smith BD, Koppelman EA, McKee MD, Christiansen CL, Gifford AL, Weinbaum CM, Southern WN. Effectiveness of a risk screener in identifying hepatitis C virus in a primary care setting. Am J Public Health 2012;102:e115-21. [PMID: 22994166 DOI: 10.2105/AJPH.2012.300659] [Cited by in Crossref: 38] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
512 deLemos AS, Chung RT. Hepatitis C treatment: an incipient therapeutic revolution. Trends Mol Med. 2014;20:315-321. [PMID: 24636306 DOI: 10.1016/j.molmed.2014.02.002] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 4.5] [Reference Citation Analysis]
513 Njouom R, Lavoie M, Foupouapouognigni Y, Frost E, Deslandes S, Mamadou-yaya F, Mbélesso P, Mbadingai S, Pépin J. Transmission of Hepatitis C virus among spouses in Cameroon and the Central African Republic. J Med Virol 2011;83:2113-8. [DOI: 10.1002/jmv.22225] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
514 Rodrigues Neto J, Cubas MR, Kusma SZ, Olandoski M. Prevalence of hepatitis C in adult users of the public health service of São José dos Pinhais--Paraná. Rev Bras Epidemiol 2012;15:627-38. [PMID: 23090309 DOI: 10.1590/s1415-790x2012000300016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
515 Barton JC, Barton JC, Acton RT. Insulin Resistance and Metabolic Syndrome: Clinical and Laboratory Associations in African Americans Without Diabetes in the Hemochromatosis and Iron Overload Screening Study. Metab Syndr Relat Disord 2018;16:267-73. [PMID: 29851359 DOI: 10.1089/met.2018.0036] [Reference Citation Analysis]
516 Klibanov OM, Williams SH, Smith LS, Olin JL, Vickery SB. Telaprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C. Pharmacotherapy 2011;31:951-74. [DOI: 10.1592/phco.31.10.951] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
517 Tamura S, Sugawara Y, Yamashiki N, Kaneko J, Kokudo N, Makuuchi M. Pre-emptive antiviral therapy in living donor liver transplantation for hepatitis C: observation based on a single-center experience. Transpl Int. 2010;23:580-588. [PMID: 20028490 DOI: 10.1111/j.1432-2277.2009.01023.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
518 Vanatta JM, Modanlou KA, Dean AG, Nezakatgoo N, Campos L, Nair S, Eason JD. Outcomes of orthotopic liver transplantation for hepatic sarcoidosis: an analysis of the United Network for Organ Sharing/Organ Procurement and Transplantation Network data files for a comparative study with cholestatic liver diseases. Liver Transpl 2011;17:1027-34. [PMID: 21594966 DOI: 10.1002/lt.22339] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
519 Proeschold-Bell RJ, Patkar AA, Naggie S, Coward L, Mannelli P, Yao J, Bixby P, Muir AJ. An integrated alcohol abuse and medical treatment model for patients with hepatitis C. Dig Dis Sci. 2012;57:1083-1091. [PMID: 22134784 DOI: 10.1007/s10620-011-1976-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
520 Loftis JM, Taylor J, Raué HP, Slifka MK, Huang E. Alcohol intake alters immune responses and promotes CNS viral persistence in mice. Behav Brain Res 2016;312:1-8. [PMID: 27269869 DOI: 10.1016/j.bbr.2016.06.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
521 Sood A, Sarin SK, Midha V, Hissar S, Sood N, Bansal P, Bansal M. Prevalence of hepatitis C virus in a selected geographical area of northern India: a population based survey. Indian J Gastroenterol 2012;31:232-6. [PMID: 23073754 DOI: 10.1007/s12664-012-0251-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
522 Strauss SM, Munoz-Plaza C, Rosedale MT, Rindskopf DM, Lunievicz J. Enhancing Drug Treatment Program Staff's Self-Efficacy to Support Patients' HCV Needs. J Soc Work Pract Addict 2011;11:254-69. [PMID: 22102796 DOI: 10.1080/1533256X.2011.596458] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
523 Singal AG, Thomassen LV, Gretch DR, Shuhart MC. Use of the AST to platelet ratio index in HCV/HIV co-infected patients. Aliment Pharmacol Ther. 2011;33:566-577. [PMID: 21205257 DOI: 10.1111/j.1365-2036.2010.04560.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
524 Mariano A, Scalia Tomba G, Tosti ME, Spada E, Mele A. Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy. Scand J Infect Dis. 2009;41:689-699. [PMID: 19579149 DOI: 10.1080/00365540903095358] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
525 Conjeevaram HS, Wahed AS, Afdhal N, Howell CD, Everhart JE, Hoofnagle JH;  Virahep-C Study Group. Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology. 2011;140:469-477. [PMID: 21070775 DOI: 10.1053/j.gastro.2010.11.002] [Cited by in Crossref: 55] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
526 El Khoury AC, Vietri J, Prajapati G. The Burden of Untreated Hepatitis C Virus Infection: A US Patients’ Perspective. Dig Dis Sci 2012;57:2995-3003. [DOI: 10.1007/s10620-012-2233-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
527 Torres DM, Harrison SA. Hepatitis C, insulin resistance, and steatosis. Curr hepatitis rep 2007;6:129-37. [DOI: 10.1007/s11901-007-0015-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
528 Tamura S, Sugawara Y. Treatment strategy for hepatitis C after liver transplantation. J Hepatobiliary Pancreat Surg 2008;15:111-23. [DOI: 10.1007/s00534-007-1295-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
529 Christian WJ, Hopenhayn C, Christian A, McIntosh D, Koch A. Viral hepatitis and injection drug use in Appalachian Kentucky: a survey of rural health department clients. Public Health Rep 2010;125:121-8. [PMID: 20402204 DOI: 10.1177/003335491012500116] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
530 Pan JJ, Qu HQ, Rentfro A, McCormick JB, Fisher-Hoch SP, Fallon MB. Prevalence of metabolic syndrome and risks of abnormal serum alanine aminotransferase in Hispanics: a population-based study. PLoS One. 2011;6:e21515. [PMID: 21720553 DOI: 10.1371/journal.pone.0021515] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
531 Coppola N, Pisaturo M, Zampino R, Macera M, Sagnelli C, Sagnelli E. Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals. World J Gastroenterol 2015; 21(38): 10749-10759 [PMID: 26478667 DOI: 10.3748/wjg.v21.i38.10749] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
532 Chen CM, Yoon YH, Yi HY, Lucas DL. Alcohol and hepatitis C mortality among males and females in the United States: a life table analysis. Alcohol Clin Exp Res 2007;31:285-92. [PMID: 17250621 DOI: 10.1111/j.1530-0277.2006.00304.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
533 Harris KA, Arnsten JH, Litwin AH. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med. 2010;4:20-26. [PMID: 20485532 DOI: 10.1097/adm.0b013e3181add3de] [Cited by in Crossref: 51] [Cited by in F6Publishing: 23] [Article Influence: 5.7] [Reference Citation Analysis]
534 Cheng KC, Gupta S, Wang H, Uss AS, Njoroge GF, Hughes E. Current drug discovery strategies for treatment of hepatitis C virus infection. J Pharm Pharmacol 2011;63:883-92. [PMID: 21635253 DOI: 10.1111/j.2042-7158.2011.01267.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
535 Adams S, Ostermeier M. Retinopathy associated with pegylated interferon and ribavirin treatment for chronic hepatitis C. Optometry - Journal of the American Optometric Association 2010;81:580-6. [DOI: 10.1016/j.optm.2010.04.094] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
536 Mustian MN, Shelton BA, MacLennan PA, Reed RD, White JA, Eckhoff DE, Locke JE, Allman RM, Gray SH. Ethnic and Age Disparities in Outcomes Among Liver Transplant Waitlist Candidates. Transplantation 2019;103:1425-32. [PMID: 30418427 DOI: 10.1097/TP.0000000000002523] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
537 Carey KJ, Huang W, Linas BP, Tsui JI. Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders. J Subst Abuse Treat 2016;66:54-9. [PMID: 26988423 DOI: 10.1016/j.jsat.2016.01.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
538 Ho SB, Groessl E, Dollarhide A, Robinson S, Kravetz D, Dieperink E. Management of chronic hepatitis C in veterans: the potential of integrated care models. Am J Gastroenterol 2008;103:1810-23. [PMID: 18564122 DOI: 10.1111/j.1572-0241.2008.01877.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 2.9] [Reference Citation Analysis]
539 Ruta S, Cernescu C. Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes. World J Gastroenterol 2015; 21(38): 10811-10823 [PMID: 26478672 DOI: 10.3748/wjg.v21.i38.10811] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
540 Sung H, Chang M, Saab S. Management of Hepatitis C Antiviral Therapy Adverse Effects. Curr Hepat Rep. 2011;10:33-40. [PMID: 21423320 DOI: 10.1007/s11901-010-0078-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
541 Sebhatu P, Martin MT. Genotype 1 hepatitis C virus and the pharmacist's role in treatment. Am J Health Syst Pharm 2016;73:764-74. [PMID: 27126832 DOI: 10.2146/ajhp150704] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
542 Zeremski M, Zibbell JE, Martinez AD, Kritz S, Smith BD, Talal AH. Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. World J Gastroenterol 2013; 19(44): 7846-7851 [PMID: 24307778 DOI: 10.3748/wjg.v19.i44.7846] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 56] [Article Influence: 6.6] [Reference Citation Analysis]
543 Rustgi VK. The epidemiology of hepatitis C infection in the United States. J Gastroenterol. 2007;42:513-521. [PMID: 17653645 DOI: 10.1007/s00535-007-2064-6] [Cited by in Crossref: 127] [Cited by in F6Publishing: 110] [Article Influence: 8.5] [Reference Citation Analysis]
544 Visconti AJ, Doyle JS, Weir A, Shiell AM, Hellard ME. Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia: Hepatitis C treatment cost-effectiveness. J Gastroenterol Hepatol 2013;28:707-16. [DOI: 10.1111/jgh.12041] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
545 Liapakis A, Lim JK. Impact of rapid point-of-care screening tests for the identification of chronic hepatitis C infection: Hepatology Elsewhere. Hepatology 2013;58:822-6. [DOI: 10.1002/hep.26552] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
546 Rzouq F, Olyaee M, Alahdab F. Statins and Hepatitis C Virus Infection: An Old Therapy With New Scope. The American Journal of the Medical Sciences 2014;348:426-30. [DOI: 10.1097/maj.0000000000000291] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
547 Mohammed DY, Martin E, Sadashige C, Jaker M, Paul S. An anonymous unlinked sero-prevalence survey of HIVHCV in an urban Emergency Department. Journal of Clinical Virology 2013;58:e19-23. [DOI: 10.1016/j.jcv.2013.08.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
548 Oliveira CP, Kappel CR, Siqueira ER, Lima VM, Stefano JT, Michalczuk MT, Marini SS, Barbeiro HV, Soriano FG, Carrilho FJ. Effects of hepatitis C virus on cardiovascular risk in infected patients: a comparative study. Int J Cardiol. 2013;164:221-226. [PMID: 21784542 DOI: 10.1016/j.ijcard.2011.07.016] [Cited by in Crossref: 47] [Cited by in F6Publishing: 55] [Article Influence: 4.3] [Reference Citation Analysis]
549 Chaabna K, Kouyoumjian SP, Abu-Raddad LJ. Hepatitis C Virus Epidemiology in Djibouti, Somalia, Sudan, and Yemen: Systematic Review and Meta-Analysis. PLoS One. 2016;11:e0149966. [PMID: 26900839 DOI: 10.1371/journal.pone.0149966] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
550 Wilder JM, Jeffers LJ, Ravendhran N, Shiffman ML, Poulos J, Sulkowski MS, Gitlin N, Workowski K, Zhu Y, Yang JC. Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data. Hepatology. 2016;63:437-444. [PMID: 26547499 DOI: 10.1002/hep.28334] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 6.4] [Reference Citation Analysis]
551 Fusco M, Girardi E, Piselli P, Palombino R, Polesel J, Maione C, Scognamiglio P, Pisanti FA, Solmone M, Di Cicco P. Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancer. Eur J Cancer. 2008;44:847-853. [PMID: 18313290 DOI: 10.1016/j.ejca.2008.01.025] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
552 Ferguson MC. Current therapies for chronic hepatitis C. Pharmacotherapy 2011;31:92-111. [PMID: 21182362 DOI: 10.1592/phco.31.1.92] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
553 Balter S, Stark JH, Kennedy J, Bornschlegel K, Konty K. Estimating the prevalence of hepatitis C infection in New York City using surveillance data. Epidemiol Infect 2014;142:262-9. [PMID: 23657093 DOI: 10.1017/S0950268813000952] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
554 Tran HA, Jones TL, Gibson R, Reeves GE. Thyroid disease is a favorable prognostic factor in achieving sustained virologic response in chronic hepatitis C undergoing combination therapy: A nested case control study. BMC Endocr Disord 2011;11:10. [PMID: 21605462 DOI: 10.1186/1472-6823-11-10] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
555 Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, Henley SJ, Holtzman D, Lake A, Noone AM, Anderson RN, Ma J, Ly KN, Cronin KA, Penberthy L, Kohler BA. Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122:1312-1337. [PMID: 26959385 DOI: 10.1002/cncr.29936] [Cited by in Crossref: 512] [Cited by in F6Publishing: 505] [Article Influence: 85.3] [Reference Citation Analysis]
556 Busch MP, Kleinman SH. Hepatitis C infection: recent insights relevant to transfusion safety. ISBT Science Series 2009;4:72-9. [DOI: 10.1111/j.1751-2824.2009.01214.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
557 Ford MM, Desai PS, Maduro G, Laraque F. Neighborhood Inequalities in Hepatitis C Mortality: Spatial and Temporal Patterns and Associated Factors. J Urban Health 2017;94:746-55. [PMID: 28623451 DOI: 10.1007/s11524-017-0174-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
558 Terrault NA, Dodge JL, Murphy EL, Tavis JE, Kiss A, Levin TR, Gish RG, Busch MP, Reingold AL, Alter MJ. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology. 2013;57:881-889. [PMID: 23175457 DOI: 10.1002/hep.26164] [Cited by in Crossref: 150] [Cited by in F6Publishing: 125] [Article Influence: 16.7] [Reference Citation Analysis]
559 Davis DR, Seth PP. Therapeutic targeting of HCV internal ribosomal entry site RNA. Antivir Chem Chemother 2011;21:117-28. [PMID: 21233533 DOI: 10.3851/IMP1693] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
560 Nel E, Sokol RJ, Comparcola D, Nobili V, Hardikar W, Gana JC, Abarca K, Wu JF, Chang MH, Renner JK. Viral hepatitis in children. J Pediatr Gastroenterol Nutr 2012;55:500-5. [PMID: 22983372 DOI: 10.1097/MPG.0b013e318272aee7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
561 Garcia-Rivera JA, Bobardt M, Chatterji U, Hopkins S, Gregory MA, Wilkinson B, Lin K, Gallay PA. Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir. Antimicrob Agents Chemother. 2012;56:5113-5121. [PMID: 22802259 DOI: 10.1128/aac.00919-12] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
562 Rubin LH, Cook JA, Weber KM, Cohen MH, Martin E, Valcour V, Milam J, Anastos K, Young MA, Alden C, Gustafson DR, Maki PM. The association of perceived stress and verbal memory is greater in HIV-infected versus HIV-uninfected women. J Neurovirol 2015;21:422-32. [PMID: 25791344 DOI: 10.1007/s13365-015-0331-5] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
563 Acharya JN, Pacheco VH. Neurologic Complications of Hepatitis C. The Neurologist 2008;14:151-6. [DOI: 10.1097/nrl.0b013e31815fa594] [Cited by in Crossref: 41] [Cited by in F6Publishing: 6] [Article Influence: 2.9] [Reference Citation Analysis]
564 Barritt AS, Jiang Y, Schmidt M, Hayashi PH, Bataller R. Charges for Alcoholic Cirrhosis Exceed All Other Etiologies of Cirrhosis Combined: A National and State Inpatient Survey Analysis. Dig Dis Sci 2019;64:1460-9. [DOI: 10.1007/s10620-019-5471-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
565 Al Kanaani Z, Mahmud S, Kouyoumjian SP, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Pakistan: systematic review and meta-analyses. R Soc Open Sci. 2018;5:180257. [PMID: 29765698 DOI: 10.1098/rsos.180257] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 9.3] [Reference Citation Analysis]
566 Navinés R, Castellví P, Moreno-España J, Gimenez D, Udina M, Cañizares S, Diez-Quevedo C, Valdés M, Solà R, Martín-Santos R. Depressive and anxiety disorders in chronic hepatitis C patients: reliability and validity of the Patient Health Questionnaire. J Affect Disord 2012;138:343-51. [PMID: 22326842 DOI: 10.1016/j.jad.2012.01.018] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
567 Ngo BV, James JR, Blalock KL, Jackson SL, Chew LD, Tsui JI. Hepatitis C treatment outcomes among patients treated in co-located primary care and addiction treatment settings. J Subst Abuse Treat 2021;131:108438. [PMID: 34098298 DOI: 10.1016/j.jsat.2021.108438] [Reference Citation Analysis]
568 Spaulding AC, Sharma A, Messina LC, Zlotorzynska M, Miller L, Binswanger IA. A comparison of liver disease mortality with HIV and overdose mortality among Georgia prisoners and releasees: a 2-decade cohort study of prisoners incarcerated in 1991. Am J Public Health 2015;105:e51-7. [PMID: 25790417 DOI: 10.2105/AJPH.2014.302546] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
569 Khaderi S, Shepherd R, Goss JA, Leung DH. Hepatitis C in the pediatric population: Transmission, natural history, treatment and liver transplantation. World J Gastroenterol 2014; 20(32): 11281-11286 [PMID: 25170212 DOI: 10.3748/wjg.v20.i32.11281] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
570 Fuster D, Gelberg L. Community Screening, Identification, and Referral to Primary Care, for Hepatitis C, B, and HIV Among Homeless Persons in Los Angeles. J Community Health 2019;44:1044-54. [PMID: 31127412 DOI: 10.1007/s10900-019-00679-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
571 Huang CF, Yu ML. Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments. Expert Opin Pharmacother 2017;18:1867-74. [PMID: 29086615 DOI: 10.1080/14656566.2017.1400010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
572 Lubega S, Agbim U, Surjadi M, Mahoney M, Khalili M. Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response. Liver Int. 2013;33:999-1007. [PMID: 23509897 DOI: 10.1111/liv.12150] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
573 Snyder N, Martinez JG, Xiao SY. Chronic hepatitis C is a common associated with hepatic granulomas. World J Gastroenterol 2008; 14(41): 6366-6369 [PMID: 19009653 DOI: 10.3748/wjg.14.6366] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
574 Hampton MD, Chafetz L, Portillo C. Differences in substance-related risk behavior between dual and triple diagnosed severely mentally ill adults. Ment Health Subst Use 2012;5:52-63. [PMID: 22582086 DOI: 10.1080/17523281.2011.608374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
575 Jepsen P, Vilstrup H, Tarone RE, Friis S, Sørensen HT. Incidence rates of hepatocellular carcinoma in the U.S. and Denmark: recent trends. Int J Cancer 2007;121:1624-6. [PMID: 17557292 DOI: 10.1002/ijc.22860] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
576 Chhatwal J, Wang X, Ayer T, Kabiri M, Chung RT, Hur C, Donohue JM, Roberts MS, Kanwal F. Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals. Hepatology. 2016;64:1442-1450. [PMID: 27015107 DOI: 10.1002/hep.28571] [Cited by in Crossref: 102] [Cited by in F6Publishing: 89] [Article Influence: 17.0] [Reference Citation Analysis]
577 Radziewicz H, Ibegbu CC, Hon H, Osborn MK, Obideen K, Wehbi M, Freeman GJ, Lennox JL, Workowski KA, Hanson HL, Grakoui A. Impaired hepatitis C virus (HCV)-specific effector CD8+ T cells undergo massive apoptosis in the peripheral blood during acute HCV infection and in the liver during the chronic phase of infection. J Virol. 2008;82:9808-9822. [PMID: 18667503 DOI: 10.1128/jvi.01075-08] [Cited by in Crossref: 73] [Cited by in F6Publishing: 48] [Article Influence: 5.2] [Reference Citation Analysis]
578 Evans AT, Loeb KR, Shulman HM, Hassan S, Qiu WC, Hockenbery DM, Ioannou GN, Chauncey TR, Gretch DR, McDonald GB. Fibrosing cholestatic hepatitis C after hematopoietic cell transplantation: report of 3 fatal cases. Am J Surg Pathol 2015;39:212-20. [PMID: 25517948 DOI: 10.1097/PAS.0000000000000345] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
579 Kenyon CR, Colebunders R. The Association between Female Genital Cutting and Spousal HCV Infection in Egypt. Int J Hepatol 2014;2014:164357. [PMID: 24778883 DOI: 10.1155/2014/164357] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
580 Morasco BJ, Loftis JM, Indest DW, Ruimy S, Davison JW, Felker B, Hauser P. Prophylactic Antidepressant Treatment in Patients With Hepatitis C on Antiviral Therapy: A Double-Blind, Placebo-Controlled Trial. Psychosomatics 2010;51:401-8. [DOI: 10.1016/s0033-3182(10)70722-2] [Cited by in Crossref: 23] [Article Influence: 1.9] [Reference Citation Analysis]
581 Tenner CT, Herzog K, Chaudhari S, Bini EJ, Weinshel EH. Knowledge, attitudes and barriers regarding vaccination against hepatitis A and B in patients with chronic hepatitis C virus infection: a survey of family medicine and internal medicine physicians in the United States: Knowledge, attitudes and barriers regarding vaccination against hepatitis A and B in patients with chronic hepatitis C virus infection. International Journal of Clinical Practice 2012;66:1009-13. [DOI: 10.1111/ijcp.12013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
582 Vera-llonch M, Martin M, Aggarwal J, Donepudi M, Bayliss M, Goss T, Younossi Z. Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. Aliment Pharmacol Ther 2013;38:124-33. [DOI: 10.1111/apt.12354] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
583 Kuncio DE, Newbern EC, Fernandez-Viña MH, Herdman B, Johnson CC, Viner KM. Comparison of risk-based hepatitis C screening and the true seroprevalence in an urban prison system. J Urban Health 2015;92:379-86. [PMID: 25795212 DOI: 10.1007/s11524-015-9945-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
584 Longmire AG, Sims S, Rytsareva I, Campo DS, Skums P, Dimitrova Z, Ramachandran S, Medrzycki M, Thai H, Ganova-Raeva L, Lin Y, Punkova LT, Sue A, Mirabito M, Wang S, Tracy R, Bolet V, Sukalac T, Lynberg C, Khudyakov Y. GHOST: global hepatitis outbreak and surveillance technology. BMC Genomics 2017;18:916. [PMID: 29244005 DOI: 10.1186/s12864-017-4268-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
585 Huang J, Zhang X, Tong J, Du J, Duan R, Yang L, Moore JH, Tao C, Chen Y. Comparing drug safety of hepatitis C therapies using post-market data. BMC Med Inform Decis Mak 2019;19:147. [PMID: 31391106 DOI: 10.1186/s12911-019-0860-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
586 Cozen ML, Ryan JC, Shen H, Lerrigo R, Yee RM, Sheen E, Wu R, Monto A. Nonresponse to interferon-α based treatment for chronic hepatitis C infection is associated with increased hazard of cirrhosis. PLoS One 2013;8:e61568. [PMID: 23637856 DOI: 10.1371/journal.pone.0061568] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
587 Eze JC, Ibeziako NS, Ikefuna AN, Nwokoye IC, Uleanya ND, Ilechukwu GC. Prevalence and risk factors for hepatitis C and human immunodeficiency virus coinfection among children in enugu, Nigeria. Afr J Infect Dis 2014;8:5-8. [PMID: 24653810 DOI: 10.4314/ajid.v8i1.2] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
588 Hirsch AA, Lawrence RH, Kern E, Falck-Ytter Y, Shumaker DT, Watts B. Implementation and evaluation of a multicomponent quality improvement intervention to improve efficiency of hepatitis C screening and diagnosis. Jt Comm J Qual Patient Saf 2014;40:351-7. [PMID: 25208440 DOI: 10.1016/s1553-7250(14)40046-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
589 M Tawfik N, A Hegazy M, A Abdel Maksoud I, S Nasr A. Iron Load and Serum Hepcidin in Hepatitis C Virus-Related Hepatocellular Carcinoma. Euroasian Journal of Hepato-Gastroenterology 2012;2:24-7. [DOI: 10.5005/jp-journals-10018-1026] [Reference Citation Analysis]
590 Chappell CA, Hillier SL, Crowe D, Meyn LA, Bogen DL, Krans EE. Hepatitis C Virus Screening Among Children Exposed During Pregnancy. Pediatrics. 2018;141. [PMID: 29720535 DOI: 10.1542/peds.2017-3273] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 11.5] [Reference Citation Analysis]
591 Southern WN, Drainoni ML, Smith BD, Koppelman E, McKee MD, Christiansen CL, Gifford AL, Weinbaum CM, Litwin AH. Physician nonadherence with a hepatitis C screening program. Qual Manag Health Care 2014;23:1-9. [PMID: 24368717 DOI: 10.1097/QMH.0000000000000007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
592 Linas BP, Wang B, Smurzynski M, Losina E, Bosch RJ, Schackman BR, Rong J, Sax PE, Walensky RP, Schouten J. The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. J Viral Hepat. 2011;18:506-512. [PMID: 20546501 DOI: 10.1111/j.1365-2893.2010.01325.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
593 Liu G, Holmberg SD, Kamili S, Xu F. Racial disparities in the proportion of current, unresolved hepatitis C virus infections in the United States, 2003-2010. Dig Dis Sci 2014;59:1950-7. [PMID: 24573716 DOI: 10.1007/s10620-014-3059-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
594 Buffington J, Jones TS. Integrating viral hepatitis prevention into public health programs serving people at high risk for infection: good public health. Public Health Rep 2007;122 Suppl 2:1-5. [PMID: 17542445 DOI: 10.1177/00333549071220S201] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
595 Halegoua-De Marzio DL, Herrine SK. Training the next generation of hepatologist: What will they need to know? Clin Liver Dis (Hoboken) 2015;5:129-31. [PMID: 31040968 DOI: 10.1002/cld.461] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
596 Melis R, Fauron C, McMillin G, Lyon E, Shirts B, Hubley LM, Slev PR. Simultaneous genotyping of rs12979860 and rs8099917 variants near the IL28B locus associated with HCV clearance and treatment response. J Mol Diagn 2011;13:446-51. [PMID: 21704279 DOI: 10.1016/j.jmoldx.2011.03.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
597 Kanwal F, Hoang T, Chrusciel T, Kramer JR, El-Serag HB, Dominitz JA, Asch SM. Process of care for hepatitis C infection is linked to treatment outcome and virologic response. Clin Gastroenterol Hepatol 2012;10:1270-1277.e3. [PMID: 22841970 DOI: 10.1016/j.cgh.2012.07.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
598 Desai AP, Reau N. Naives, Nonresponders, Relapsers: Who Is There Left to Treat? Clinics in Liver Disease 2011;15:483-95. [DOI: 10.1016/j.cld.2011.05.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
599 Stoller EP, Webster NJ, Blixen CE, McCormick RA, Hund AJ, Perzynski AT, Kanuch SW, Thomas CL, Kercher K, Dawson NV. Alcohol Consumption Decisions among Nonabusing Drinkers Diagnosed with Hepatitis C: An Exploratory Sequential Mixed Methods Study. J Mix Methods Res 2009;3:65-86. [PMID: 20046861 DOI: 10.1177/1558689808326119] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
600 Subbarao I, Steinbrecher R, Tan L, Peleg K, Zeiger J, James JJ. Postexposure Immunization and Prophylaxis of Bloodborne Pathogens Following a Traumatic Explosive Event: Preliminary Recommendations. Disaster med public health prep 2007;1:106-9. [DOI: 10.1097/dmp.0b013e3181590736] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
601 Alavian SM, Mirahmadizadeh A, Javanbakht M, Keshtkaran A, Heidari A, Mashayekhi A, Salimi S, Hadian M. Effectiveness of Methadone Maintenance Treatment in Prevention of Hepatitis C Virus Transmission among Injecting Drug Users. Hepat Mon 2013;13:e12411. [PMID: 24069039 DOI: 10.5812/hepatmon.12411] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
602 Kershenobich D, Razavi HA, Sánchez-Avila JF, Bessone F, Coelho HS, Dagher L, Gonçales FL, Quiroz JF, Rodriguez-Perez F, Rosado B. Trends and projections of hepatitis C virus epidemiology in Latin America. Liver Int. 2011;31 Suppl 2:18-29. [PMID: 21651701 DOI: 10.1111/j.1478-3231.2011.02538.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 86] [Article Influence: 8.5] [Reference Citation Analysis]
603 Latka MH, Hagan H, Kapadia F, Golub ET, Bonner S, Campbell JV, Coady MH, Garfein RS, Pu M, Thomas DL. A randomized intervention trial to reduce the lending of used injection equipment among injection drug users infected with hepatitis C. Am J Public Health. 2008;98:853-861. [PMID: 18382005 DOI: 10.2105/ajph.2007.113415] [Cited by in Crossref: 35] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
604 Torres DM, Harrison SA. Editorial : Killing Two Birds With One Stone: Screening for Chronic Hepatitis C at the Time of Colonoscopy in the Baby Boomer Cohort. American Journal of Gastroenterology 2013;108:990-2. [DOI: 10.1038/ajg.2013.54] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
605 Chemaitelly H, Mahmud S, Rahmani AM, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Afghanistan: systematic review and meta-analysis. Int J Infect Dis 2015;40:54-63. [PMID: 26417880 DOI: 10.1016/j.ijid.2015.09.011] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
606 Backus LI, Belperio PS, Shahoumian TA, Cheung R, Mole LA. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol Ther. 2014;39:93-103. [PMID: 24206566 DOI: 10.1111/apt.12546] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
607 Gane EJ, Agarwal K. Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: “a flood of opportunity”. Am J Transplant. 2014;14:994-1002. [PMID: 24730431 DOI: 10.1111/ajt.12714] [Cited by in Crossref: 69] [Cited by in F6Publishing: 55] [Article Influence: 8.6] [Reference Citation Analysis]
608 Kamal SM. Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents. Hepat Med. 2014;6:61-77. [PMID: 25114601 DOI: 10.2147/hmer.s41127] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 3.1] [Reference Citation Analysis]
609 Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl. 2008;14 Suppl 2:S36-S44. [PMID: 18825724 DOI: 10.1002/lt.21646] [Cited by in Crossref: 203] [Cited by in F6Publishing: 172] [Article Influence: 15.6] [Reference Citation Analysis]
610 Sheikh MY, Atla PR, Ameer A, Sadiq H, Sadler PC. Seroprevalence of Hepatitis B and C Infections among Healthy Volunteer Blood Donors in the Central California Valley. Gut Liver 2013;7:66-73. [PMID: 23423771 DOI: 10.5009/gnl.2013.7.1.66] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
611 Khullar V, Firpi RJ. Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. World J Hepatol 2015; 7(14): 1843-1855 [PMID: 26207166 DOI: 10.4254/wjh.v7.i14.1843] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
612 Lu L, Wang M, Xia W, Tian L, Xu R, Li C, Wang J, Rong X, Xiong H, Huang K, Huang J, Nakano T, Bennett P, Zhang Y, Zhang L, Fu Y. Migration patterns of hepatitis C virus in China characterized for five major subtypes based on samples from 411 volunteer blood donors from 17 provinces and municipalities. J Virol 2014;88:7120-9. [PMID: 24719413 DOI: 10.1128/JVI.00414-14] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
613 Greenaway C, Thu Ma A, Kloda LA, Klein M, Cnossen S, Schwarzer G, Shrier I. The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis. PLoS One. 2015;10:e0141715. [PMID: 26558905 DOI: 10.1371/journal.pone.0141715] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 6.7] [Reference Citation Analysis]
614 Heil EL, Hynicka LM, Kottilil S, Tang L. What does the pharmacological future of treating chronic hepatitis C look like? Expert Rev Clin Pharmacol 2015;8:605-22. [PMID: 26289223 DOI: 10.1586/17512433.2015.1074859] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
615 Provazzi PJ, Mukherjee S, Hanson AM, Nogueira ML, Carneiro BM, Frick DN, Rahal P. Analysis of the Enzymatic Activity of an NS3 Helicase Genotype 3a Variant Sequence Obtained from a Relapse Patient. PLoS One 2015;10:e0144638. [PMID: 26658750 DOI: 10.1371/journal.pone.0144638] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
616 Hatzakis A, Van Damme P, Alcorn K, Gore C, Benazzouz M, Berkane S, Buti M, Carballo M, Cortes Martins H, Deuffic-Burban S. The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conference. J Viral Hepat. 2013;20 Suppl 2:1-20. [PMID: 23827008 DOI: 10.1111/jvh.12120] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.1] [Reference Citation Analysis]
617 Chang ET, Yang J, Alfaro-Velcamp T, So SK, Glaser SL, Gomez SL. Disparities in liver cancer incidence by nativity, acculturation, and socioeconomic status in California Hispanics and Asians. Cancer Epidemiol Biomarkers Prev. 2010;19:3106-3118. [PMID: 20940276 DOI: 10.1158/1055-9965.epi-10-0863] [Cited by in Crossref: 59] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
618 Porter JC, Lusk HM, Katz AR. Prevalence of HCV infection among clients in community-based health settings in Hawaii, 2002-2010: assessing risk factors. Am J Public Health 2014;104:1534-9. [PMID: 24028267 DOI: 10.2105/AJPH.2013.301282] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
619 Zhou Y, Lukes Y, Anderson J, Fileta B, Reinhardt B, Sjogren M. Hepatitis C virus E2 envelope protein induces dendritic cell maturation. J Viral Hepat 2007;14:849-58. [PMID: 18070288 DOI: 10.1111/j.1365-2893.2007.00879.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.1] [Reference Citation Analysis]
620 Esmaeili A, Yu W, Cucciare MA, Combs AS, Joshi G, Humphreys K. Budget Impact Analysis of a Computer-Delivered Brief Alcohol Intervention in Veterans Affairs (VA) Liver Clinics: A Randomized Controlled Trial. Alcoholism Treatment Quarterly 2020;38:515-31. [DOI: 10.1080/07347324.2020.1760755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
621 Gayam V, Tiongson B, Khalid M, Mandal AK, Mukhtar O, Gill A, Garlapati P, Shrestha B, Khalid M, Chakraborty S, Guss D, Sherigar J, Mansour M, Mohanty S. Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study. Eur J Gastroenterol Hepatol 2018;30:1200-7. [PMID: 30096090 DOI: 10.1097/MEG.0000000000001233] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
622 Nurutdinova D, Abdallah AB, Bradford S, O'Leary CC, Cottler LB. Risk factors associated with Hepatitis C among female substance users enrolled in community-based HIV prevention studies. BMC Res Notes 2011;4:126. [PMID: 21492467 DOI: 10.1186/1756-0500-4-126] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
623 Hackl NJ, Bersch C, Feick P, Antoni C, Franke A, Singer MV, Nakchbandi IA. Circulating fibronectin isoforms predict the degree of fibrosis in chronic hepatitis C. Scand J Gastroenterol. 2010;45:349-356. [PMID: 20017652 DOI: 10.3109/00365520903490606] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
624 Lee SJ, Shin JW, Park BR, Kim CJ, Jung SW, Kim B, Jeong ID, Bang SJ, Park NH. The expression kinetics of CD137 in chronic hepatitis C patients treated with pegylated-interferon and ribavirin. Scand J Gastroenterol 2012;47:601-6. [PMID: 22416920 DOI: 10.3109/00365521.2012.668929] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
625 Thitinan S, McConville JT. Interferon alpha delivery systems for the treatment of hepatitis C. Int J Pharm 2009;369:121-35. [PMID: 19103271 DOI: 10.1016/j.ijpharm.2008.11.027] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
626 Sood A, Suryaprasad A, Trickey A, Kanchi S, Midha V, Foster MA, Bennett E, Kamili S, Alvarez-Bognar F, Shadaker S, Surlikar V, Garg R, Mittal P, Sharma S, May MT, Vickerman P, Averhoff F. The burden of hepatitis C virus infection in Punjab, India: A population-based serosurvey. PLoS One 2018;13:e0200461. [PMID: 30048454 DOI: 10.1371/journal.pone.0200461] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
627 Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatology. 2007;45:806-816. [PMID: 17326207 DOI: 10.1002/hep.21565] [Cited by in Crossref: 128] [Cited by in F6Publishing: 130] [Article Influence: 8.5] [Reference Citation Analysis]
628 Chandriani S, Skewes-Cox P, Zhong W, Ganem DE, Divers TJ, Van Blaricum AJ, Tennant BC, Kistler AL. Identification of a previously undescribed divergent virus from the Flaviviridae family in an outbreak of equine serum hepatitis. Proc Natl Acad Sci U S A 2013;110:E1407-15. [PMID: 23509292 DOI: 10.1073/pnas.1219217110] [Cited by in Crossref: 113] [Cited by in F6Publishing: 96] [Article Influence: 12.6] [Reference Citation Analysis]
629 Rodart IF, Pares MM, Mendes A, Accardo CM, Martins JRM, Silva CB, Carvalho FO, Barreto JA, Reis MG, Tersariol ILS, Nader HB. Diagnostic Accuracy of Serum Hyaluronan for Detecting HCV Infection and Liver Fibrosis in Asymptomatic Blood Donors. Molecules 2021;26:3892. [PMID: 34202190 DOI: 10.3390/molecules26133892] [Reference Citation Analysis]
630 Tsai HH, Liou HH, Muo CH, Lee CZ, Yen RF, Kao CH. Hepatitis C virus infection as a risk factor for Parkinson disease: A nationwide cohort study. Neurology 2016;86:840-6. [PMID: 26701382 DOI: 10.1212/WNL.0000000000002307] [Cited by in Crossref: 35] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
631 Clark BT, Garcia-Tsao G, Fraenkel L. Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection. Patient Prefer Adherence 2012;6:285-95. [PMID: 22536063 DOI: 10.2147/PPA.S30111] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
632 Parikh N, Ahmad J. Nonalcoholic fatty liver disease: pharmacologic and surgical options. Gastroenterol Clin North Am 2011;40:541-59. [PMID: 21893273 DOI: 10.1016/j.gtc.2011.06.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
633 Wong R, Corley DA. Racial and ethnic variations in hepatocellular carcinoma incidence within the United States. Am J Med. 2008;121:525-531. [PMID: 18501235 DOI: 10.1016/j.amjmed.2008.03.005] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
634 Benjamin RM. Raising awareness of viral hepatitis: National Hepatitis Testing Day, May 19. Public Health Rep 2012;127:244-5. [PMID: 22547853 DOI: 10.1177/003335491212700302] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
635 Munshaw S, Hwang HS, Torbenson M, Quinn J, Hansen KD, Astemborski J, Mehta SH, Ray SC, Thomas DL, Balagopal A. Laser captured hepatocytes show association of butyrylcholinesterase gene loss and fibrosis progression in hepatitis C-infected drug users. Hepatology. 2012;56:544-554. [PMID: 22331678 DOI: 10.1002/hep.25655] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
636 Page-Shafer K, Pappalardo BL, Tobler LH, Phelps BH, Edlin BR, Moss AR, Wright TL, Wright DJ, O'Brien TR, Caglioti S, Busch MP. Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. J Clin Microbiol 2008;46:499-506. [PMID: 18032621 DOI: 10.1128/JCM.01229-07] [Cited by in Crossref: 70] [Cited by in F6Publishing: 45] [Article Influence: 4.7] [Reference Citation Analysis]
637 El-Serag HB, Engels EA, Landgren O, Chiao E, Henderson L, Amaratunge HC, Giordano TP. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology. 2009;49:116-123. [PMID: 19085911 DOI: 10.1002/hep.22606] [Cited by in Crossref: 182] [Cited by in F6Publishing: 176] [Article Influence: 14.0] [Reference Citation Analysis]
638 Rashrash M, Maneno M, Wutoh A, Ettienne E, Daftary M. Predictors of hepatitis C testing intention among African American Baby Boomers. J Epidemiol Glob Health 2017;7:119-22. [PMID: 28215491 DOI: 10.1016/j.jegh.2016.12.005] [Reference Citation Analysis]
639 Lodato F, Mazzella G, Festi D, Azzaroli F, Colecchia A, Roda E. Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J Gastroenterol 2006; 12(45): 7239-7249 [PMID: 17143937 DOI: 10.3748/wjg.v12.i45.7239] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 53] [Article Influence: 3.7] [Reference Citation Analysis]
640 Frimpong JA, D'Aunno T, Jiang L. Determinants of the availability of hepatitis C testing services in opioid treatment programs: results from a national study. Am J Public Health 2014;104:e75-82. [PMID: 24825236 DOI: 10.2105/AJPH.2013.301827] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
641 Wang CC, Cook L, Tapia KA, Holte S, Krows M, Bagabag A, Santos A, Corey L, Jerome KR. Cervicovaginal shedding of hepatitis C viral RNA is associated with the presence of menstrual or other blood in cervicovaginal fluids. Journal of Clinical Virology 2011;50:4-7. [DOI: 10.1016/j.jcv.2010.09.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
642 Moore ZS, Schaefer MK, Hoffmann KK, Thompson SC, Xia GL, Lin Y, Khudyakov Y, Maillard JM, Engel JP, Perz JF. Transmission of hepatitis C virus during myocardial perfusion imaging in an outpatient clinic. Am J Cardiol. 2011;108:126-132. [PMID: 21529725 DOI: 10.1016/j.amjcard.2011.03.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
643 Dokubo EK, Evans J, Winkelman V, Cyrus S, Tobler LH, Asher A, Briceno A, Page K. Comparison of Hepatitis C Virus RNA and antibody detection in dried blood spots and plasma specimens. J Clin Virol. 2014;59:223-227. [PMID: 24529844 DOI: 10.1016/j.jcv.2014.01.014] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
644 Eckman MH, Ward JW, Sherman KE. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens. Clin Gastroenterol Hepatol 2019;17:930-939.e9. [PMID: 30201597 DOI: 10.1016/j.cgh.2018.08.080] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 9.5] [Reference Citation Analysis]
645 Johnson S, Aluzaite K, Taar A, Schultz M. Identifying barriers to treatment of HCV in the primary care setting. Hepatol Int 2019;13:58-65. [DOI: 10.1007/s12072-018-9902-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
646 Kaushik-Basu N, Bopda-Waffo A, Talele TT, Basu A, Costa PR, da Silva AJ, Sarafianos SG, Noël F. Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors. Nucleic Acids Res 2008;36:1482-96. [PMID: 18203743 DOI: 10.1093/nar/gkm1178] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 4.6] [Reference Citation Analysis]
647 Shah H, Kuehl K, Sherker AH. Liver disease after the Fontan procedure: what the hepatologist needs to know. J Clin Gastroenterol 2010;44:428-31. [PMID: 20216078 DOI: 10.1097/MCG.0b013e3181d476fc] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
648 Mathias S, Crosby RD, Bayliss MS, L'Italien G, Sapra S. Measurement properties of the flu-like symptom index from the hepatitis physical symptom severity diary. Qual Life Res 2014;23:1489-96. [PMID: 24379136 DOI: 10.1007/s11136-013-0609-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
649 Allyn PR, O'Malley SM, Ferguson J, Tseng CH, Chew KW, Bhattacharya D. Attitudes and potential barriers towards hepatitis C treatment in patients with and without HIV coinfection. Int J STD AIDS 2018;29:334-40. [PMID: 28820346 DOI: 10.1177/0956462417725462] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
650 Nicasio M, Sautto G, Clementi N, Diotti RA, Criscuolo E, Castelli M, Solforosi L, Clementi M, Burioni R. Neutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape? Viruses 2012;4:1731-52. [PMID: 23170181 DOI: 10.3390/v4091731] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
651 Shankar H, Bichoupan K, Dieterich DT. The pharmacokinetic evaluation of boceprevir for treatment of hepatitis C virus. Expert Opin Drug Metab Toxicol 2013;9:1647-57. [PMID: 24079600 DOI: 10.1517/17425255.2013.840290] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
652 Salvatore M, Jeon J, Meza R. Changing trends in liver cancer incidence by race/ethnicity and sex in the US: 1992-2016. Cancer Causes Control 2019;30:1377-88. [PMID: 31606852 DOI: 10.1007/s10552-019-01237-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
653 Prieto Ortíz JE, Sánchez Pardo S, Rojas Díaz EL, Huertas Pacheco SJ. Hepatitis C crónica: aspectos clínicos, serológicos y de tratamiento en dos centros de atención en Bogotá, Colombia. Rev Colomb Gastroenterol 2014;29:424-32. [DOI: 10.22516/25007440.440] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
654 Guiltinan AM, Kaidarova Z, Custer B, Orland J, Strollo A, Cyrus S, Busch MP, Murphy EL. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol. 2008;167:743-750. [PMID: 18203734 DOI: 10.1093/aje/kwm370] [Cited by in Crossref: 94] [Cited by in F6Publishing: 97] [Article Influence: 6.7] [Reference Citation Analysis]
655 Congiu M, Slavin JL, Desmond PV. Expression of common housekeeping genes is affected by disease in human hepatitis C virus-infected liver. Liver Int. 2011;31:386-390. [PMID: 21073651 DOI: 10.1111/j.1478-3231.2010.02374.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
656 Mack CL, Gonzalez-Peralta RP, Gupta N, Leung D, Narkewicz MR, Roberts EA, Rosenthal P, Schwarz KB;  North American Society for Pediatric Gastroenterology; Hepatology, and Nutrition. NASPGHAN practice guidelines: Diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr. 2012;54:838-855. [PMID: 22487950 DOI: 10.1097/mpg.0b013e318258328d] [Cited by in Crossref: 134] [Cited by in F6Publishing: 46] [Article Influence: 13.4] [Reference Citation Analysis]
657 Vedham V, Divi RL, Starks VL, Verma M. Multiple infections and cancer: implications in epidemiology. Technol Cancer Res Treat 2014;13:177-94. [PMID: 23919392 DOI: 10.7785/tcrt.2012.500366] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
658 Altamirano J, Michelena J. Alcohol consumption as a cofactor for other liver diseases. Clin Liver Dis (Hoboken) 2013;2:72-5. [PMID: 30992828 DOI: 10.1002/cld.197] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
659 Hennessey KA, Kim AA, Griffin V, Collins NT, Weinbaum CM, Sabin K. Prevalence of infection with hepatitis B and C viruses and co-infection with HIV in three jails: a case for viral hepatitis prevention in jails in the United States. J Urban Health 2009;86:93-105. [PMID: 18622707 DOI: 10.1007/s11524-008-9305-8] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 3.3] [Reference Citation Analysis]
660 Wenger PJ, Rottnek F, Parker T, Crippin JS. Assessment of hepatitis C risk factors and infection prevalence in a jail population. Am J Public Health 2014;104:1722-7. [PMID: 25033142 DOI: 10.2105/AJPH.2014.301996] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
661 Stopka TJ, Goulart MA, Meyers DJ, Hutcheson M, Barton K, Onofrey S, Church D, Donahue A, Chui KKH. Identifying and characterizing hepatitis C virus hotspots in Massachusetts: a spatial epidemiological approach. BMC Infect Dis 2017;17:294. [PMID: 28427355 DOI: 10.1186/s12879-017-2400-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
662 Hartleb M, Gutkowski K, Zejda JE, Chudek J, Więcek A. Serological prevalence of hepatitis B virus and hepatitis C virus infection in the elderly population: Polish nationwide survey--PolSenior. Eur J Gastroenterol Hepatol 2012;24:1288-95. [PMID: 22864260 DOI: 10.1097/MEG.0b013e328357632a] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
663 Deyessa N, Senbete B, Abdo A, Mundia BM. Population estimation and harm reduction among people who inject drugs in Addis Ababa, Ethiopia. Harm Reduct J 2020;17:61. [PMID: 32894153 DOI: 10.1186/s12954-020-00407-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
664 Wilson SR, Knowles SB, Huang Q, Fink A. The prevalence of harmful and hazardous alcohol consumption in older U.S. adults: data from the 2005-2008 National Health and Nutrition Examination Survey (NHANES). J Gen Intern Med 2014;29:312-9. [PMID: 24101531 DOI: 10.1007/s11606-013-2577-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
665 Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, Holmberg SD. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160:293-300. [PMID: 24737271 DOI: 10.7326/m13-1133] [Cited by in Crossref: 492] [Cited by in F6Publishing: 264] [Article Influence: 61.5] [Reference Citation Analysis]
666 Almario CV, Vega M, Trooskin SB, Navarro VJ. Examining hepatitis C virus testing practices in primary care clinics. J Viral Hepat 2012;19:e163-9. [PMID: 22239514 DOI: 10.1111/j.1365-2893.2011.01539.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
667 Nápoles TM, Batchelder AW, Lin A, Moran L, Johnson MO, Shumway M, Luetkemeyer AF, Peters MG, Eagen KV, Riley ED. HCV treatment barriers among HIV/HCV co-infected patients in the US: a qualitative study to understand low uptake among marginalized populations in the DAA era. J Public Health (Oxf) 2019;41:e283-9. [PMID: 31044248 DOI: 10.1093/pubmed/fdz045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
668 Moon C, Jung KS, Kim DY, Baatarkhuu O, Park JY, Kim BK, Kim SU, Ahn SH, Han KH. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin. Dig Dis Sci. 2015;60:573-581. [PMID: 25236421 DOI: 10.1007/s10620-014-3361-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
669 Tohme RA, Holmberg SD. Transmission of hepatitis C virus infection through tattooing and piercing: a critical review. Clin Infect Dis. 2012;54:1167-1178. [PMID: 22291098 DOI: 10.1093/cid/cir991] [Cited by in Crossref: 67] [Cited by in F6Publishing: 54] [Article Influence: 6.7] [Reference Citation Analysis]
670 Yang CHT, Yoo ER, Ahmed A. The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C. J Clin Transl Hepatol. 2017;5:59-66. [PMID: 28507928 DOI: 10.14218/jcth.2016.00053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
671 Donlin MJ, Cannon NA, Aurora R, Li J, Wahed AS, Di Bisceglie AM, Tavis JE; Virahep-C Study Group. Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients. PLoS One 2010;5:e9032. [PMID: 20140258 DOI: 10.1371/journal.pone.0009032] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
672 Wang P, Jing Z, Liu C, Xu M, Wang P, Wang X, Yin Y, Cui Y, Ren D, Rao X. Hepatitis C virus infection and risk of thyroid cancer: A systematic review and meta-analysis. Arab J Gastroenterol 2017;18:1-5. [PMID: 28223105 DOI: 10.1016/j.ajg.2017.01.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
673 Baden R, Rockstroh JK, Buti M. Natural history and management of hepatitis C: does se